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Abstract
Introduction: Respiratory syncytial virus (RSV) is the most important
viral cause for lower respiratory infection and respiratory failure leading to
paediatric intensive care unit (PICU) admission in infants and young children
throughout the world.
Setting: 20-bed PICU in tertiary university-affiliated, multi-disciplinary,
regional referral children’s hospital with an annual admission rate of
approximately 1100 children.
Study patients: All children with confirmed RSV infection that required
PICU admission between June 1999 and May 2009 (i.e. ten consecutive RSV
seasons).
Aim: To investigate the clinical impact of severe RSV disease onchildren,
with admission to PICU being the marker of severe RSV disease.
Results: During the ten-year study period 491 RSV-positive patients were
admitted to PICU. Elevation of hepatic transaminase levels was common
(46% of those studied). Disease severity as judged by duration of ventilation,
inotrope use and mortality was greater in children with elevated transaminase
levels. Myocardial damageorinjury as indicated by elevated cardiac troponin
levels were found in 35-40% of infants with structurally normal hearts and
severe RSV lung disease. Significantly reduced right ventricular function was
found in 20% of infants without congenital heart disease ventilated for RSV
bronchiolitis, but the degree of dysfunction was not related to the levels of
respiratory support or biochemical markers of inflammation.
Up to 40% of patients admitted with severe RSV bronchiolitis were infected
with bacteria in their lower airways and had a longer duration of ventilation
(p<0.001). Overall PICU mortality of RSV-positive patients was 8.6%, with a
standardised mortality ratio (SMR) 0.76, PICU RSV-attributable mortality 4.4%
and hospital RS\V-attributable mortality 0.9%. Pre-existing disease/co-
morbidity, namely congenital heart disease, chronic lung disease, large airway
abnormality, immunodeficiency, neuromuscular disease (Relative Risk/RR
2.4), and in particular multiple pre-existing diseases (RR 4.4) and cardiac
anomaly (RR 3.0), was associated with a significantly higher risk of death.
Nosocomial RSVinfection rates were: PICU-acquired 8.1% and hospital ward-
acquired 7.8%. Mortality, 25% in PICU-acquired (RR 4.3) and 21% in hospital-
acquired (RR 3.6), was increased, but principally by its association with pre-
existing conditions/comorbidity. Nosocomial RSV infection was the strongest
predictor of duration of ventilation and length of stay on PICU.
Conclusions: Myocardial and hepatocellular damage can occur in
infants with severe RSV bronchiolitis with structurally normal hearts and
normal ventricular function. Reduced right ventricular function occurs in infants
without congenital heart disease ventilated for RSV bronchiolitis. This may
explain the increased morbidity and mortality associated with RSV bronchiolitis
in children with significant congenital heart disease. Pre-existing disease/co-
morbidity and nosocomialinfection is associated with a significantly higherrisk
of death from severe RSVinfection.
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4 Introduction
1.1 Respiratory Syncytial Virus (RSV)
Although outbreaks of pyrexial respiratory illnesses have been described for
many centuries, probably the first description of an outbreak of respiratory
syncytial virus (RSV) was reported 1941 (Adams 1941). Adams described an
outbreak of nosocomial chest infections in thirty-two infants in a neonatalunit
that resulted in 9 deaths, with cytoplasmic inclusions identified in the lungs at
autopsy. RSV wasfirst identified in 1956 from a colony of chimpanzees with
coryza and designated “chimpanzee coryzal agent” (Blount, Morris and
Savage 1956). Subsequently a yearlater in 1957 it was isolated from children
with lung disease in Baltimore, USA (Chanock and Finberg 1957; Chanock,
Roizman and Myers 1957). Since then RSV has been recognised as the
single most important virus causing acute respiratory tract infections in children
(Howardet al. 2000; Hall 2001; Crowe, Collins and Knipe 2007; Hall 2009).
Because of its characteristic cytopathologic findings in tissue culture where
RSV-infected epithelial cells clump together forming syncytia (giant
multinucleated cells), the virus was named respiratory syncytial virus, as
suggested by Chanock and colleagues (Chanocket al. 1961; Chanock etal.
1962). Syncytium formation has been found to be both anin vitro and an in
vivo phenomenon.
Respiratory syncytial virus (RSV) is the most important viral cause for lower
respiratory infection in infants and young children throughout the world
(Howard et al. 2000). RSV bronchiolitis is one of the commonest causes of
respiratory tract infection leading to respiratory failure (Howard etal. 2000)].
Annually RSV bronchiolitis accounts for 20 000 admissions to hospital in the
UK and 90 000 hospitalisations in the USA with associated costs of $300
million per year (Deshpande and Northern 2003; Handforth, Friedland and
Sharland 2000). Although primarily a respiratory pathogen of young children,
-1-
RSV infects and re-infects adults causing disease in predominatly the elderly,
chronic lung disease and immunocompromised patients (Hall 2001). It has
been estimated that each year 600,000 deaths occur world-wide that are
directly or indirectly attributable to RSV (Howardet al. 2000).
 
Figure 1.1 A high resolution histology slide of lung tissue showing clumping
of RSV-infected host respiratory epithelial cells to form a large multinucleated
cell or syncytium, from where respiratory syncytial virus (RSV) acquired its
name. (from web.uct.ac.za/depts/mmi/stannard/rsv-cpe2.gif - prepared by Linda M Stannard from
photographs taken by Diana Hardie, Dept of Medical Microbiology, University of Cape Town)
1.2 Classification and Structure
RSV is a pleomorphic (spherical or filamentous form) enveloped RNA virus
120 - 300nm in size of the order Mononegavirales, family Paramyxoviridae and
genus Pneumovirus. RSV contains a non-segmented single-strand negative-
sense RNA genome, 15 222 nucleotides in length, that encodesfor 9 structural
and 2 non-structural proteins.
Respirovirus Morbilivirus [ Pneumovirus | metapnoumovius |
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Figure 1.2: Viral taxomony for respiratory syncytial virus (RSV) in the order of
   Paramyxivirinae Pneumovirinae
 
 
 
family, subfamily, genus and species.
Parainflu = Parainfluenza virus HMPV = Human Metapeumonvirus
Figure 1.3. An electron micrograph of the respiratory syncytial virus (RSV).
Thevirion is variable in shape and size (average diameter between 120-300nm).
(from the Centers for Disease Control and Prevention, part of the United States Department of Health
and HumanServices, the imageis in the public domain.)
Twolarge surface glycoproteins, fusion protein (F) and attachmentprotein (G),
are the major antigenic determinants. Other structural proteins are associated
with the viral envelope — matrix proteins, transcription antiterminator protein,
small hydrophobic protein (SH), 22 kDa protein; or are found in the nuclear
capsule — nucleoprotein (N), large nucleoprotein/polymerase complex (L),
phosphoprotein (P), M2-1 and M2-2 matrix proteins. There are 2 non-
structural proteins (NS1, NS2) that are unique to pneumoviruses.
Thereis a lipid bilayer membrane enveloping the matrix protein layer.
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Figure 1.4: Animated diagram ofthe viral structure of RSV
(from http://www.kuleuven.be/rega/mvr/research. html)
There are two major groups of RSV strains, A and B,that are distinguished by
antigenic characteristics, mainly in variations in the G (attachment) protein, as
there are few differences in the F (fusion) protein between the strains (Hall
2001; Openshaw 2005; Openshaw and Tregoning 2005; Crowe, Collins and
Knipe 2007).
1.3 Pathogenesis and Pathophysiology
Viral transmission is by direct inoculation of contagious secretions from hands
and self-inoculation of eyes and nose. Transmission requires close or direct
contact with large droplets or fomites residing on skin, cloth or clinical surfaces.
RSV’s incubation period can be 2 - 8 days, usually 2 - 5 days (Hall, Douglas
and Geiman 1980; Hall 1980; Hall et al. 1981; Hall and Douglas 1981; Hall
2001; Simoes 1999; Crowe, Collins and Knipe 2007). The virus replicates in
nasopharyngeal epithelium and then spreads to lower respiratory tract 1 - 3
days later. RSV infects respiratory epithelial cells by attaching itself to the cell
surface by meansof a capsular glycoprotein, the G (attachment) protein. A
second capsular glycoprotein, the F (fusion) protein, mediates fusion with the
epithelial cell membrane along with adjacentcells, resulting in the formation of
multinucleated cells — syncytia — for which the virus is named, respiratory
syncytial virus (RSV). It is suggested that the small hydrophobic protein (SH)
plays a role in both syncytial formation and blocking of cell death / apoptosis.
RSV virion assembly occurs at the plasma membrane ofinfected cells and are
released by budding, taking a lipid bilayer membrane derived from the infected
host cell with them. Infectious RSV is probablyin the filamentous form (Crowe,
Collins and Knipe 2007).
RSV has a direct cytopathic effect on respiratory epithelial cells. The
characteristic inflammatory process of RSV bronchiolitis leads to loss ofcilial
motility, submucosal oedema, increased mucus secretion, infiltration by
leucocytes, necrosis and sloughing of the respiratory epithelial cells of the
small airways, all of which obstructs airflow through the smalli/distal airways.
During expiration this enhances dynamic smalli/distal airways narrowing
producing disproportionate turbulence and decreased airflow causing
airtrapping. Further airtrapping can caused by a ball-valve mechanism of
airway obstruction due to intraluminal plugging by mucus andcellular debris.
Clinically the inflammatory processin the small/distal airways(i.e. bronchiolitis)
results in pulmonary hyperinflation, areas of atelectasis, and wheezing due to
small/distal airways obstruction.
 
Figure 1.5: Histology slide of human lung tissue demonstrating inflammatory
debris (A) obstructing the lumen of a bronchiole (B) with an inflammatory
macrophagicinfiltrates (C) in the surrounding bronchiolartissue.
(from www1.imperial.ac.uk/.../respinfect/viralimm/ - Group Leader: Prof Peter Openshaw © Copyright
2009 Imperial College London)
Theviral strain (A or B) appears not to be an important factor as studies have
failed to show significant differences in virulence and severity of disease
between A and strains (Hall et al. 1990; Kneyber et al. 1996; Hall 2001).
The effect of viral load on disease severity is also unclear. Reported data
(from the same research team) is conflicting when comparing viral loads in
nasals washings between ventilated and non-ventilated children. An initial
study (Buckingham, Bush and Devincenzo 2000) demonstrated a higher nasal
viral load in the ventilated group, however, a subsequent larger study
(Devincenzo, El Saleeby and Bush 2005)failed to find a significant difference.
Van Woenselet al found a higherviral load in tracheal aspirates of ventilated
infants with “severe RSV LRTI” compared to “mild disease” (differentiaited on
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mean airways pressure and oxygenation indices) (van Woenselet al. 2003a).
Since viral strain and viral load cannot fully account for variations in disease
severity, it is likely that variations in pre-existing structural elements of the
distal respiratory tree and the inherent immune response play major roles
(Welliver 2003).
The impact of the structural/anatomical factor on the degree of distal airways
obstruction is governed by vector properties (for example Pouiseille’s Law
dictating that the turbulencein the airflow in a cylinder increases to the power
of 4 with each decrease in radius), and the physical size/absolute diameter of
the distal airway presposing it to intraluminal plugging. Whereas inherent
variations in the infected individual’s inflammatory response influence the
degree of submucosal oedema, increased mucus secretion, and sloughing of
epithelial cells. The former factor, anatomical and physical aspects, most
probably accounts for the high incidence of respiratory disease in younger
smaller individuals with their smaller distal airways (e.g. premature infants)
(Simoes 1999; Smyth and Openshaw 2006; Crowe, Collins and Knipe 2007;
Simoes 2008). The latter factor, individualistic inflammatory response,
continues to fuel much research worldwide.
Clinically airtrapping and atelectasis will increase work of breathing due to
increased end expiratory lung volume and decreased lung compliance (Crowe,
Collins and Knipe 2007). Respiratory failure is usually the result of worsening
lung compliance and fatigue of respiratory muscle. Apnoea, which is common
in infants with RSV bronchiolitis, can be secondary to severe lung disease or
central in origin. The reported frequency varies from 8% (Vogelet al. 2003) to
21% (Kneyber et al. 1998) of those children admitted to hospital, and up to
20% of those admitted to PICU (Khoetal. 2004).
The respiratory epithelial cells usually recover within 2 — 4 days, but
histologically the ciliated epithelial cells take two weeks to regenerate (Hall
2001; Crowe,Collins and Knipe 2007).
7's
1.4 Immune Responseto RSVinfection
Protection against upper (URTI) and lowerrespiratory tract infections (LRT])
requires a balance between humoral and cellular immunity. Local secretory
IgA is the prominent humoral mediator of resistance in the upper respiratory
tract, whereas serum IgG provides additional protection in the lowerrespiratoty
tract. The F and G surface glycoproteins are the only RSV proteins to induce
protective neutralising antibodies (mainly of the IgG1 subclass) in children
(Simoes 1999; Hall 2001; Crowe, Collins and Knipe 2007). In neonates and
infants high levels of maternally-derived neutralising antibodies confer some
protection (Anderson and Heilman 1995; Hall 2001; Crowe, Collins and Knipe
2007).
Cellular immunity plays the predominantrole in combating and recovering from
RSVinfection, with T-lymphocytic stimulation and response playing an integral
function. The antiviral and cell-mediated immune reaction to RSVinfection is
primarily orchestrated by RSV-infected respiratory epithelial cells and by
alveolar macrophages. T helper 1-type cytokines — interferon y (IFNy),
interleukin type 2 (IL-2), IL-12; T helper 2-type cytokines — IL-4, IL-5, IL-6, IL-
10; antiviral interferons — IFNa, IFN; and chemokines — C, CC, CXC and
CX3C subgroups, attract and activate leucocytes, especially alveolar
macrophages, to the RSV-infected respiratory tract. These cytokines and
chemokines may enter the systemic circulation and impact on outlying cells in
extrapulmonary sites (Openshaw, Culley and Olszewska 2001; Tripp 2004;
Openshaw 2005; Tripp, Oshansky and Alvarez 2005; Culley et al. 2006).
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Figure 1.6: Animated diagram of the inflammatory pathways and resultant
clinical impact triggered by infection with RSV (adapted, with permission, from a diagram
constructed by Dr Steve Brearey,Institute of Child Heath, University of Liverpool)
Much of our understanding of the immune response to RSV infection comes
from animal models or studies in children with severe disease(i.e. intubated
and mechanically ventilated children from whom respiratory samples can be
obtained). Therefore the immunopathogenesis of RSV disease in the great
majority of children who develop mild respiratory symptoms, and may not see
a doctor or attend hospital, is largely inferred (Tripp 2004; Openshaw 2005;
Tripp, Oshansky and Alvarez 2005; Crowe, Collins and Knipe 2007). Severe
RSV disease is probably associated with a misdirected immune cascade,
characterised by an overexuberant release of inflammatory mediators
(‘cytokine storm”) and infiltration of a range of monocytes and
polymorphonuclear cells. Host genetic and acquired factors will manipulate
the extent and severity of the immune-augmented response within the
respiratory tree, as well as at distant extrapulmonarysites.
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In a trial of a formalin-inactivated vaccine in the late 1960’s, immunised
children suffered more severe disease than controls when they subsequent
contracted natural RSV (re)infection (80% required hospitalisation compared to
5% of controls) (Kim et al. 1969). Vaccinated children lacked specific mucosal
antibodies; their serum antibodies were deficient in fusion-inhibiting and
neutralising activity; some had increased lymphocytic and/or eosinophilic
proliferation (Kim et al. 1976; Murphy et al. 1986; Hall 2001; Belshe et al.
2004). These findings suggested that protection against RSV infection
necessitates a balance between humoral and cellular immunity. However, the
relative contributions of the humoral and cellular immune components in RSV
infection and immunity to subsequent RSV infection is still debated (Hall 2001;
Openshaw, Culley and Olsewska 2001; Schwarze et al. 2004; Openshaw
2005; Crowe, Collins and Knipe 2007). Effective and appropriately-restrained
protection from RSV LRTI most probably requires a viral neutralising response
(humoral/antibody + cellular) without an excessive RSV-specific cytotoxic T-
lymphocyte response (Simoes 1999; Openshaw, Culley and Olsewska 2001;
Schwarze et al. 2004; Openshaw 2005; Crowe,Collins and Knipe 2007).
Primary infection with RSV doesnot lead to acquired immunity against future
infections. Although naturally acquired immunity is neither durable nor
complete, it does appear to provide someprotection as subsequentinfections
are less severe (Hall 2001; Openshaw and Tregoning 2005; Crowe, Collins
and Knipe 2007). Despite extensive study of the major surface glycoprotein
(G), the fusion protein (F), and even the transcription antiterminator matrix
protein, the reasons for this lack of acquired immunity remain unclear
(Openshaw and Tregoning 2005).
Both laboratory and human studies have demonstrated that immune
competent hosts clear the virus following natural RSV infection within 3 weeks,
whereas immunocompromised hosts with deficiencies of cellular immunity tend
to suffer more severe disease and have prolonged viral shedding (Hall,
Douglas and Geiman 1975; Hall 1977; Hall et al. 1986; Wendt and Hertz 1995;
Hall 2001; Madhiet al. 2001).
-10-
1.5 Diagnosis
1.5.1 Clinical diagnosis
The diagnosis of RSV infection for the vast majority of children around the
world is made onclinical grounds in diagnosing (RSV) bronchiolitis — coryza,
fever, increase respiratory effort, hyperinflation of the chest, wheezing, fine
crackles on auscultation, poor feeding and dehydration; which may be backed
up by non-specific chest radiographic findings of hyperinflation and patchy
atelectasis, and/or below normal oxygen saturations on pulse oximetry
(Mulholland, Olinsky and Shann 1990; Mallory et al. 2003; Bordley et al. 2004;
Smyth and Openshaw 2006; Bush and Thomson 2007; Yanney and Vyas
2008). Chest radiography (chest xrays) does not differentiate RSV from other
viral causes of bronchiolitis or even viral bronchiolitis from bacterial LRTI (Friis
et al. 1990; Perlstein et al. 1999; Perlstein et al. 2000; Farah et al. 2002).
Additionally, clinical severity and chest radiography changes do notcorrelate
well (Friis et al. 1990; Perlstein et al. 1999; Perlstein et al. 2000; Farah etal.
2002). Although oxygen saturation measurements mayinfluence clinicians in
admitting infants with bronchiolitis, the benefits of pulse oximetry in this group
have not been proven (Mai et al. 1995; Mallory et al. 2003; Smyth and
Openshaw 2006; Bush and Thomson 2007; Yanney and Vyas 2008). Some
authors have suggested that certain clinical features like cyanosis and crackles
were related to disease severity in bronchiolitis (Mulholland et al. 1990), but
others have questioned the validity and reliability of auscultatory findings due
to variations in inter-observer agreement (Elphick et al. 2001; Elphick etal.
2004).
1.5.2 Laboratory confirmation of RSV infection
Diagnostic methods for confirming RSV infection in resource-rich countries
include viral isolation and culture; direct immunofluorescence and enzyme-
linked immunosorbent assays (ELISA) that detect antigen; reverse-
transcriptase polymerase chain reaction (RT-PCR) that detect nucleic acid.
Seriological testing (acute and convalescent antibody viral titires) is usually
clinically unhelpful as seroconversion may take weeks and have a poor
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response (Crowe, Collins and Knipe 2007). Rapid antigen detection tests
(immunofluorescence and enzyme-linked immunoassays) generally have
overall sensitivity and specificity of 80-90% [range 60-95%] (Bordley et al.
2004). RT-PCRis reported to offer greater sensitivity (Fan, Henrickson and
Savatski 1998) and multiplex PCR kits that detect several viruses
simultaneously are have been developed (Kehlet al. 2001; Kumaret al. 2008).
Most commonly nasopharyngealaspirates are tested, but in intubated patients
an endotracheal aspirate or broncho-alveolar lavage can be utilised. The
quality of the sample, largely dependent on the sampler’s technique and
expertise, govern the accuracy of diagnostic testing rather than the site
sampled (Bordley et al. 2004; Crowe, Collins and Knipe 2007).
1.5.3 Clinical phenotype
RSV bronchiolitis is the common term for lower respiratory tract disease
caused by RSV. Typically the resultant airtrapping will lead to increased end
expiratory lung volume and decreased lung compliance compatible with an
obstructive lung disease pattern (Simoes 1999, Hall 2001, Bush and Thomson
2007). However, it is appreciated that RSV bronchiolitis/LRTI is a
heterogenous disease with some patients having a significant consolidation
element and morerestrictive lung disease than an obstructive pattern (Isaacs
1998; Frankel and Derish 1999). Some authors have discriminated restrictive
from obstructive RSV lung disease on pulmonary function tests (decrease
respiratory compliance) (Hammer and Newth 1995, Hammer, Numa and
Newth 1997, Newth and Hammer 1998) or ventilatory indices (oxygen index,
alveolar-arterial oxygen gradient, mean airways pressure) (Tasker, Gordon
and Kiff 2000), in addition to four-quadrant alveolar consolidation on chest
radiograph in mechanically ventilated children. In everyday practice (PICU
practice included) clinicians cannot strictly dichotomise this heterogeneous
lung diseaseinto restrictive and obstructive forms (Isaacs 1998; Frankel and
Derish 1999; van Woenseland van Aalderen 2002).
In some European countries and in the USA “RSV bronchiolitis” and “RSV
pneumonia” are differentiated clinically by the presence of localised crackles
and consolidation on chest radiograph (van Woensel, Kimpen and Brand 2001;
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van Woensel and van Aalderen 2002). “RSV pneumonia” is not commonly
recognised as a separate clinical entity in the UK (Smyth and Openshaw
2006). Informed clinicians generally appreciate the pneumonic aspects of
severe bronchiolitis. In this thesis “RSV bronchiolitis” is not differentiated from
“RSV pneumonia”, and “RSV bronchiolitis” is synonymous with “RSV LRTI”,
“RSV lung disease” and “RSV pneumonia”.
1.6 Epidemiology
RSV affects about 60-70% of infants by the age of 1 year and 90% of children
by the age of 2 years, most commonly as bronchiolitis. Peak infection rates
occur in infants 6 weeks to 6 months of age. Re-infection occurs frequently
(throughout life), but illness tends to be milder (Henderson et al. 1979).
Virtually all children have developed antibodies to RSV by 3 years of age
(Simoes 1999; Smyth and Openshaw 2006; Crowe, Collins and Knipe 2007).
RSV infection can occur throughout the year, but RSV epidemics occur at
predictable annual intervals during the winter months in moderate climates,
and during hottest and rainy seasonin tropical climates (Simoes 1999; Crowe,
Collins and Knipe). During their first RSV infection, between 25-40% of infants
have bronchiolitic (or pneumonic) signs and symptoms, and 0.5-2.5% require
hospitalisation (in developed/resource-rich nations) (Shay et al. 1999;
Handforth, Friedland and Sharland 2000; Hall 2009). In the Netherlands RSV
bronchiolitis accounts for 3 000 hospitalisations annually, 20 000 in the UK,
and 90 000 in the USA (Handforth, Friedland and Sharland 2000; Hall 2001;
Deshpande and Northern 2003). Generally the reported hospital admission
rates for children under 1 year of age in Europe and the USAis around 30 per
1000 infants (Deshpande and Northern 2003; Dayan et al 2004; Levineetal.
2004; Smyth and Openshaw 2006). Incidence and hospitalisation rates for
RSV bronchiolitis in resource-limited areas are lacking owing to the paucity of
epidemiological studies and cost-saving restrictions in laboratory confirmation
of RSV infection (Hussey et al. 2000; Madhi et al 2006; Morrow et al. 2006;
Smyth and Openshaw 2006; Argent 2008).
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Approximately 3-10% of hospitalised RSV-infected infants (and about 1% ofall
RSV bronchiolitics) develop respiratory failure and require admission to PICU
(Navas et al. 1992; Brooks et al. 1999; Buckingham etal. 2001; Smyth and
Openshaw 2006). Amongstthe children from resource-rich countries admitted
to PICU with RSV infection, the reported incidence of those requiring
mechanical or non-invasive ventilation varies from 50-100% depending more
on the country, than the region or unit (Navas et al. 1992; Buckingham etal.
2001; Leclerc et al. 2001; Duttweiler, Nadal and Frey 2004; Randolph, Reder
and Englund 2004; Kneyber et al. 2005; Kneyber, Plétz and Vincent 2007;
Thorburn et al 2006).
The mortality rate for those hospitalised with RSV infection is usually low at 1 —
3%, but the mortality rate increases in children with severe bronchiolitis
requiring intensive care management (Buckingham et al. 2001; Shayet al.
2001; Holman et al. 2003; Thompsonetal. 2003; Thorburn 2009). It has been
estimated that annually in the USA up to 2700 deaths are caused by RSV
(Thompsonetal. 2003; Handforth, Friedland and Sharland 2000). RSV is the
most common viral cause of death in children below 5 years of age and
especially in infants less than 1 year old (Thompsonetal. 2003). World-wide
each year 600,000 deaths occur that are directly or indirectly attributable to
RSV (Thompsonet al. 2003; Fleming, Pannell and Cross 2005)).
Both A and strains circulate concurrently within a RSV season. There are
distinct genotypes within the strains which vary in dominance within a
community from year to year (Hall et al. 1990; Peret at al. 1998; Peret et al.
2000). This may accountfor the frequency of re-infection as any immunity to
previous genotypes is evaded (Hall et al. 1990; Peret at al. 1998; Peret et al.
2000). Convincing differences in virulence and severity of clinical disease
between A and strains have not been demonstrated (Hall et al. 1990;
Kneyberet al. 1996; Hall 2001).
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1.7 Severity of Disease and Risk factors
The vast majority of children with RSV bronchiolitis will be treated in the
community, with only up to 3% requiring admission to hospital (Shay etal.
1999: Handforth, Friedland and Sharland 2000; Deshpande and Northern
2003; Bush and Thomson 2007). Most studies therefore define severe
disease by the requirement for hospitalisation (Navas et al. 1992; Langley et
al. 1997b; Handforth, Friedland and Sharland 2000; Howard et al. 2000;
Deshpande and Northern 2003; Holman et al. 2003; Purcell and Fergie 2004;
Bush and Thomson 2007; Jansen et al. 2007). Although a numberofclinical
scoring systems have been proposed (and frequently utilised in bronchiolitis
studies), none have proved better than clinical judgement (Fitzgerald and
Kilham 2004; Plint et al. 2004; Bush and Thomson 2007). Even national
guidelines on indications for hospital referral, for example those produced by
the Scottish Intercollegiate Guidelines Network or the American Academy of
Pediatrics, still rely on clinical judgement in interpreting clinical features and
recognition of risk factors that predispose to severe disease (Baumer 2007,
Carraro, Zanconato and Baraldi 2009).
Risk factors that are associated with increased severity of disease can be
divided into host and environmental risk factors. Host factors include
chronological age less than 6 weeks, prematurity, chronic lung disease,
congenital heart disease, neurological disease, and immunodeficiency (Navas
et al. 1992: Arnold et al. 1999; Shay et al. 1999; Simoes 1999; Handforth,
Friedland and Sharland 2000; Hall 2001; Law, Carbonell-Estrany and Simoes
2002; Nielsen et al. 2003; Purcell and Fergie 2004a; Smyth and Openshaw
2006; Wilkesmann et al. 2007). Additionally there are someindicators (for
example surfactant protein D gene polymorphism) to suggest host genetic
predisposition to severe RSV infection (Lahti et al. 2002; Goetghebueretal.
2004; Smyth and Openshaw 2006). Dual respiratory viral infections (RSV in
addition to other respiratory viruses) have also been shown to increase
disease severity as indicated by the need for PICU admission and mechanical
ventilation (Semple et al. 2005; Richard et al. 2008). Environmental factors
include poverty, overcrowding, malnutrition, and exposure to postnatal tobacco
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smoke,oldersiblings, nursery attendance (Gurkanet al. 2000; Law et al. 2002;
Smyth and Openshaw 2006; Yanney and Vyas 2008).
RSV infection of the respiratory tree can lead to respiratory failure due to
deteriorating lung compliance and increasing fatigue of respiratory muscles,
resulting in the need for respiratory support. Apnoea, secondary to severe
lung disease or central in origin, occurs in 8% to 21% of infants admitted to
hospital with RSV bronchiolitis (Kneyber et al. 1998; Vogel et al. 2003).
Frequently it is an indication for PICU admission and is reported in up to 20%
of those admitted to PICU (Kho etal. 2004).
Within the large group of children hospitalised with RSV infection there is a
smaller subgroup (3 — 10%) which require intensive care treatment. It is
recognised that this group has more severe RSV disease (Navaset al. 1992;
Brooks et al. 1999; Frankel and Derish 1999; Simoes 1999; Smyth and
Openshaw 2006). Manyclinicians and researchers, and certainly the critical
care community, regard this group as truly reflecting severe RSV disease
(Tasker et al. 2000; Buckingham et al 2001; Leclerc et al. 2001; Bont and
Kimpen 2002; Kneyberet al. 2002; Davison et al. 2004; Duttweiler et al. 2004;
Randolph et al. 2004; Kneyberet al. 2005, Kneyberet al. 2007; Argent 2008;
Richard et al. 2008; Tasker 2008).
> For this thesis, PICU admission has been used as the marker of severe
RSV disease.
1.8 Therapeutic Options in PICU
“Oxygenis vitally important in bronchiolitis and thereislittle evidence that any
other treatment is useful” — Reynolds and Cook (Reynolds and Cook 1963).
It is 45 years since this statement by Reynolds and Cook and theclinical
situation essentially remains the same. Maintaining adequate oxygenation and
hydration is the mainstay of largely supportive treatment in RSV bronchiolitis
(Cooper, Banasiak and Allen 2003; Bordley et al. 2004; King et al. 2004;
Scarfone 2005; Checchia 2008).
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1.8.1 Oxygen
There are no randomised controlled trials or systematic reviews investigating
the use of oxygen in LRTI, let alone RSV bronchiolitis. Evidence for the use of
oxygen supplementation is extrapolated from case-control studies that show
hypoxaemia as a risk factor for near-fatal asthma (Turner et al. 1998). It is
generally recommended that oxygen saturation levels are maintained above
92% (Fitzgerald and Kilham 2004; Baumer 2007; Bush and Thomson 2007;
Carraro et al. 2009; Rojas, Granados and Charry-Anzola 2009).
1.8.2 Bronchodilators
Bronchodilators, generally &2 agonists, are commonly prescribed in children
with bronchiolitis in Europe and North America (Plint et al. 2004; Scarfone
2005). Heterogenicity in study design and the bronchodilator used complicate
comparisons between studies (King et al. 2004). Systematic reviews
demonstrated modest improvementin clinical scores following bronchodilator
therapy in mild to moderate bronchiolitis, but no improvement in oxygenation
and hospital admission rate (Flores and Horwitz 1997; King et al. 2004;
Gadomski and Bhasale 2006). There are few studies investigating the benefit
of bronchodilators in children with RSV bronchiolitis requiring mechanical
ventilation (Mallory et al. 1989; Hammer and Newth 1995; Derish et al. 1998;
Levin et al. 2008). Any transient improvement in measured lung functions did
not translate to significant and sustained clinical benefit or decrease in length
of ventilation (Argent 2008). Their routine use in ventilated patients, as with
non-ventilated patients, remains unsupported (Argent 2008; American
Academyof Pediatrics 2006).
1.8.3 Adrenaline (Epinephrine)
Nebulised adrenaline with its 8 adrenergic bronchodilator effect, along with the
a adrenergic effect of pulmonary vasoconstriction and reduction in oedema,
has been considered useful and used in the treatment of bronchiolitis.
Although studies on nebulised adrenaline in bronchiolitis show it to have a
good safety profile, short-term improvementin clinical scores when compared
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to both placebo and salbutamol failed to translate into clinically significant
improvement in oxygenation or hospital admission rates (Lowell et al. 1987;
Sanchez et al. 1993; Menon, Sutcliffe and Klassen 1995; Reijonen et al. 1995;
Lodrup Carlsen and Carlsen 2000; Bertrand et al 2001; Numa, Williams and
Dakin 2001; Patel et al. 2002; Ray and Singh 2002; Hariprakash et al. 2003;
Hartling et al. 2003; Wainwright et al. 2003; Mull et al. 2004; Langley et al
2005; Plint et al. 2009). A Cochrane review of this treatment confirmed these
findings (Hartling et al. 2004). Routine use is generally not recommended
(Fitzgerald and Kilham 2004; Scarfone 2005).
1.8.4 Corticosteroids
The rationale for the use of corticosteroids (inhaled, oral or intravenous) comes
from their acknowledged benefit in other obstructive airways disease, such as
asthma,andtheir ability to inhibit the immune response which contributes to
the pathogenesis of RSV disease (Openshaw, Dean and Culley 2003; van
Woensel et al. 2003a; Openshaw and Tregoning 2005; Hall 2007).
Heterogenicity in study design and the corticosteroid administered make
comparisons betweenstudiesdifficult. A systematic review of 13 trials (1198
patients) failed to demonstrate benefit in outcome (usually requirement for
hospital admission, requirement for respiratory support, or length of stay in
hospital) from systemic corticosteroids (Patel et al. 2004). A systematic review
of 5 studies (374 patients) failed to show benefit in outcome (hospital
(re)admission) from inhaled corticosteroids (Blom et al. 2007). A recent
randomised controlled trial examined whether dexamethasone treatment to
previously healthy infants presenting with moderate to severe bronchiolitis for
the first time reduced the need for hospitalisation (Corneli et al. 2007). No
significant difference was found between the corticosteroid and placebo
groups. Likewise a randomised placebo-controlled trial in 2009 examining
whethertreatment with dexamethasonefor children ventilated with severe RSV
disease impacted on cytokine concentrations in tracheal aspirates and disease
severity (days of ventilation, PICU and hospitalisation) failed to demonstrate a
difference between the dexamethasone and placebo groups (Somers et al.
2009).
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Three studies investigated the the role of corticosteroids in ventilated children
with RSV bronchiolitis (van Woenselet al. 1997; Buckingham et al 2002; van
Woensel et al. 2003b). Different corticosteroid and treatment durations were
used. Nosignificant difference in duration of mechanical ventilation between
the treatment and placebo arms were found in any of the 3 trials. A meta-
analysis combining these 3 trials (66 patients) showed no overall effect on
duration of mechanical ventilation or on duration of hospitalisation (Davison et
al. 2004).
Currently van Woensel et al. are performing a third multicentre randomised
controlled trial (the Steroid Treatmentin Artificially ventilated children with RSV
infection [STAR]trial) investigating the potential benefit of corticosteroids in
ventilated children with RSV bronchiolitis (personal communication). Its results
are awaited, but | am sceptical as to whether they will impact on future PICU
managementof severe RSV bronchiolitis.
1.8.5 Methylxanthines
Data from uncontrolled trials suggest that there may be some benefit in using
methylxanthines, such as theophylline and caffeine,in infants with
bronchiolitis-associated apnoeas (Ramesh and Samuels 2005). A
randomised, double blind, placebo controlled trial to determine whether
treatment with aminophylline will reduce the need for ventilatory support in
infants with bronchiolitis is currently in progress in Melbourne, Australia (Royal
Children’s Hospital Melbourne 2007).
1.8.6 Chest physiotherapy, nebulised hypertonic saline
Three trials have failed to demonstrate compelling evidence of the benefit of
chest physiotherapy in bronchiolitis, as borne out by a systematic review
(Perrotta, Ortiz and Roque 2007).
A recent meta-analysis of 4 trials investigating the effect of nebulisation with
hypertonic 3% saline solutions vs. 0.9% saline solutions suggested that
nebulised 3% saline solutions may hold some benefit - reduced length of
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hospital stay and a decreased clinical severity score. However, none of the
studies included mechanically ventilated children (Zhang et al. 2008).
1.8.7 Ribavirin
Ribavirin is a purine nucleoside analoguethat is believed to interfere with viral
nucleic acid function. Ribavirin has activity against RSV, influenza, and
hepatitis C (Hall 1983; Hall et al. 1986; Crowe, Collins and Knipe 2007).
Ribavirin is expensive, difficult to deliver as the nebulised droplets adhere to
the ventilatory circuit, and teratogenic (therefore potentially toxic to both the
patient and the treating team) (Fitzgerald and Kilham 2004). Systematic
reviews have failed to show any convincing effect in the acute setting (Ventre
and Randolph 2007).
Three trials have studied ribavirin in ventilated patients (Smith et al. 1991;
Meert et al 1994; Guerguerian et al. 1999). Meta-Analysis in a Cochrane
review of the 104 patients that were mechanically ventilated in these 3 trials
showedthat aerosolised ribavirin was associated with a significant decrease in
the duration of mechanical ventilation of 1.2 days (95%CI -0.2 to -3.4, p = 0.03)
(Randolph and Wang 2000). However, saline was utilised as the placebo in
two studies (Meert et al. 1994; Guerguerian et al. 1999) and sterile water in the
third (Smith et al. 1991). Sterile water has the serious potential side-effect of
induction of bronchospasm which potentially confounds interpretation of data
from this study. When the 28 patients from this study were excluded from the
meta-analysis, the difference in duration of mechanical ventilation became
insignificant (1.08 days, 95%Cl 0.67 to — 2.83, p = 0.2) (Davison et al. 2004).
Additionally, in the three trials the between-study variation in length of
mechanical ventilation of the control groups ranged from 5.3 days
(Guerguerian et al. 1999) to 9.9 days (Smith et al. 1991) confounds
interpretation.
Because of high cost, safety concerns, challenges in delivery, and weakness
with trial data, ribavirin is usually only considered in immunocompromised
children in the PICU setting in Europe (Kneyber, Moll and de Groot 2000).
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1.8.8 Surfactant
Endogenous surfactant lowers the surface tension within the alveoli at the
alveolar-capillary membrane level. The rationale for exogenous surfactant
comesfrom the findings of low levels of surfactant phopholipids and proteins,
along with reduced surfactant function, in children with severe bronchiolitis
(Tibby et al. 2000; Leclerc 2001; Ventre, Haroon and Davison 2006; Kneyber
and Plétz 2007). Due to its endotracheal route of administration exogenous
surfactant can only be considered in intubated children. Three randomised
controlled trials, (79 patients in total) investigating its efficacy have been
published. Two used porcine surfactant and no placebo [Luchetti et al. 1998;
Luchetti et al. 2002), and the other bovine surfactant and an air placebo (Tibby
et al. 2000). A meta-analysis of the 3 studies showed a nonsignificant
reduction in duration of mechanical ventilation by 2.6 days (95%Cl -5.34 to
0.18 days; p = 0.07) and significant reduction in PICU days bi 3.3 days (95%Cl
-6.38 to -0.23 days; p = 0.04). However, between-study variation in length of
mechanical ventilation of the control groups in the three trials of 5.8 days
(Luchetti et al. 2002), 7.1 days (Tibby et al. 2000) and 8.9 days (Luchetti et al.
1998), along with variation in study design, confounds effective interpretation.
A systematic review highlighted the inadequacy of available data (Ventre,
Haroon and Davison 2006). Any future large randomised controlledtrial will be
hampered by the need for multiple centres to obtain adequate numbers and
the expense of exogenous surfactant.
1.8.9 Heliox (helium / oxygen mixture)
The pathophysiological rationale for heliox is that with a density one-seventh
that of air it would result in decreased resistance to airflow (Gupta and Cheifetz
2005). A prospective, randomised, double-blind study in 20 infants with
bronchiolitis found a significant improvement in a modified clinical asthma
score after 1 hour of heliox use (Cambonie et al. 2006). A single randomised
controlled trial in 18 PICU patients (though only 13 were randomise d) reported
improvement in a clinical asthma score during heliox delivery, but did not
report length of PICU stay (Hollman et al. 1998). Only 7 children received
ventilatory support — mechanical ventilation 1, continuous positive airways
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pressure (CPAP)6,soit is difficult to glean any relevant PICU interpretation
from this data. Onetrial investigating the effect of various concentrations of
heliox on mechanical ventilation in 10 infants with RSV_ bronchiolitis
demonstrated no beneficial effect (Gross, Spear and Peterson 2000). A
multicentre, randomised, double-blind placebo-controlled study in 39 infants
with bronchiolitis found no difference in the need for intubation between
controls and the study group following 24 hours of heliox use (Liet et al. 2005).
A recent Dutch study of 9 infants with RSV bronchiolitis reported reduced
“respiratory system resistance”, but failed to address benefits in clinical terms
(i.e. need for intubation, duration of ventilation, length of stay) (Kneyberet al.
2009).
1.8.10 Inhaled Nitric Oxide (iNO)
Inhaled nitric oxide (INO) by nature of its route of administration produces
vasodilation in the bronchial tree, thereby enhancing the blood flow and the
ventilation-perfusion quotient. There is a single study examining the effect of
inhaled nitric oxide on respiratory mechanicsin 12 ventilated infants with RSV
bronchiolitis (Patel et al. 1999). It concluded that iNO had no apparent
bronchodilator effect in the majority of acutely ill infants with RSV bronchiolitis
and did not appear to provide any additional benefit over the use of
salbutamol.
A Cochranereview of randomised controlled trials (535 ventilated children and
adults) analysed the effect of iNO in acute hypoxemic respiratory failure
(Sokol, Jacobs and Bohn 2004). It found that iNO did not demonstrate any
Statistically significant effect on mortality or ventilator-free days, and only
transiently improved oxygenation in patients with hypoxemic respiratory failure.
1.8.11 Recombinant human DNAse (rhDNAse)
Intraluminal mucus plugsin the distal airways is an important pathophysiologic
feature in RSV bronchiolitis. DNA released by degenerating leucocytes is
present in these mucus plugs and contributes to their increased viscocity and
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adhersiveness (Nasr et al. 2001). By cleaving this released DNA, rhnDNAse
can help liquify the mucus. Anecdotal data suggested that rhnDNAse was
effective in infants with severe RSV bronchiolitis (Merkus et al. 2001; Nasr et
al. 2001). A multicentre, randomised, double-blind placebo-controlled study in
224 infants with RSV bronchiolitis found that administration of rnDNAsedid not
reduce the length of hospital stay, duration of supplemental oxygen, and
number requiring intensive care or mechanical ventilation (Boogard et al.
2007).
1.8.12 Interferon, Erythropoietin, Vitamin A
There are 2 studies assessing the efficacy of vitamin A (Neuzil et al. 1994:
Quinlan and Hayani 1996), and single studies each of interferon (Chipps,
Sullivan and Portnoy 1993) and erythropoietin (Jacobs, Lyons andBrilli 2003)
in RSV infection. None of the studies showed significant difference between
the study groups andcontrols.
1.8.13 Respiratory support
If despite oxygen supplementation children develop respiratory failure artificial
respiratory support (non-invasive or mechanical ventilation) may become
necessary. The application of continuous positive airway pressure (CPAP)
keeps the airways open and thereby facilitates expiratory flow, improves
compliance, reduces work of breathing and enhances gas exchange. Thereis
supportive evidence that delivery of CPAP via a mask or nasal prongs may
reverse impending respiratory failure and avoid intubation (Beasley and Jones
1981; Soong, Hwang and Tang 1993; Larrar et al. 2006; Thia et al. 2007;
Cambonie et al. 2008; Shah, Ohlsson and Shah 2008). Intubation and
mechanical ventilation (positive pressure ventilatory support) is the mainstay of
supportive therapy for children with RSV-induced respiratory failure due to
worsening lung compliance, imminent respiratory collapse secondary to
exhaustion, or apnoea and respiratory arrest (Yanney and Vyas 2008).
Already in the 1980s, retrospective studies confirmed the effectiveness of
mechanicalventilation in bronchiolitis-associated respiratory failure (Outwater
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and Crone 1984; Lebel et al. 1989). Unfortunately there are no randomised
controlled trials on the level of positive end-expiratory pressure (PEEP) or
ventilatory strategies (for example, volume-controlled vs pressure controlled, or
high frequency vs conventional ventilation) for ventilated children with RSV-
induced respiratory failure (Leclerc et al. 2001; Kneyber and Plétz 2007:
Greenough 2009). Perhaps this is because RSV bronchiolitis is a
heterogeneous lung disease with varying obstructive and restrictive elements,
rather than a homogemousclinical entity (Isaacs 1998; Frankel and Derish
1999; van Woenseland van Aalderen 2002; Kneyber and Plétz 2007). When
maximum conventional mechanical ventilation or high frequency oscillatory
ventilation (HFOV) fail to stabilise or reverse deteriorating oxygenation (and
ventilation), extracorporeal life support (ECLS) / extracorporeal membrane
oxygenation (ECMO)is the last port of call for these refractory cases. Survival
rates of ECLS/ECMOfor RSV bronchiolitis are better than other indications for
ECLS/ECMO and range from 71% (Flamant et al. 2005) to as high as 96%
(Khan et al. 1995), with a low rate of neurological sequelae (Steinhorn and
Green 1990).
1.9 Preventive Treatments
1.9.1 RSV Immunoglobulin
Hyperimmune RSV immunoglobulin (RSVIG) and monoclonal RSV
immunoglobulin augment neutralising antibodies and are used for
immunoprophylaxis in high risk patients (Hall 2001; Meissner and Long 2003;
American Academy of Pediatrics 2003; Meissner et al. 2004; Smyth and
Openshaw 2006; Bush and Thomson 2007). They have been shown to
reduce hospital admissions from RSV bronchiolitis (Impact-RSV Study Group
1998; Wang and Tang 2000; Fuller and Del 2006). Both are expensive,offer
partial protection, and require monthly intravenous (RSVIG) or intramuscular
(monoclonal RSV immunoglobulin) injections (Fuller and Del 2006). Their
prohibitive expense has lead to many cost-effectiveness analyses and the
restriction of use to targeted high risk groups (Kamal-Bahl, Doshi and
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Campbell 2002; American Academy of Pediatrics 2003; Rackham, Thorburn
and Kerr 2005; Fuller and Del 2006).
The use of hyperimmune RSV (polyclonal) immunoglobulin has fallen out of
favour due to its intravenous route, the intravenous volume required, an
increased risk of adverse outcomesin infants with cyanotic heart disease, and
possible inactivation of live vaccines (for example measles-mumps-rubella)
(American Academy of Pediatrics 2003). RSVIG is not licensed for treatment
in the UK.
Palivizumab, the first humanised monoclonal antibody against the surface F
glycoprotein in RSV,is the immunoprophylactic agent generally favoured and
has been studied extensively (Wang and Tang 2000; Fuller and Del 2006).
Palivizumab has been shown to reduce RS\V-related hospital admission by
55% in preterm infants born at less than 32 weeks gestation (1002 palivizumab
recipients vs 500 controls) (Impact-RSV Study Group 1998) and by 45% in
infants born with significant congenital heart disease (639 palivizumab
recipients vs 648 controls) (Feltes et al. 2003). Despite this reduction in
hospital admission for serious RSV disease, the cost-benefit balance for
infants born at more than 32 weeks gestation or with congenital heart disease
is still debated intensely (Joffe et al. 1999; Clark et al. 2000; Kamal-Bahl,
Doshi and Campbell 2002; American Academy of Pediatrics 2003; Prais,
Schonfeld and Amir 2003; Wegneret al. 2004; Yount and Mahle 2004; Bala,
Ryan and Murphy 2005; Embleton, Harkensee and McKean 2005; Heikkinen
et al. 2005; Prais et al. 2005; Meberg and Bruu 2006; Sunnegardh 2006;
Geskey, Thomas and Brummel2007; Nuijten, Wittenberg and Lebmeier 2007).
Although the RSV-IMpacttrial examining the efficacy of palivizumab in preterm
infants demonstrated an overall reduction in hospitalisation of 55% compared
to controls, it did not impact on the number requiring PICU admission (1.3% vs
3%) or the numberrequiring mechanical ventilation (0.2% vs 0.7%) (Impact-
RSV Study Group 1998). Similarly, despite an overall reduction in
hospitalisation of 45% compared to controls in the trial examining the efficacy
of palivizumab in children with congenital heart disease, the numberrequiring
PICU admission (2% vs 3.7%) or the number requiring mechanical ventilation
(1.3% vs 2.2%) was not signiciantly different (Feltes et al. 2003). Post
-25-
palivizumab licensure studies comparing the number of children requiring
PICU admission and mechanical ventilation in the RSV seasons prior to
palivizumab to those in the RSV seasonsfollowing its prophylactic use have
found no significant reductions following the introduction of palivizumab
(Pedraz et al. 2003; Prais et al. 2005).
Three trials have examined the use of RSVIG (Rodriguez et al. 1997) or
palivizumab (Malley et al. 1998) in infants admitted to PICU with RSV infection
— 125 children; 103 mechanically ventilated. There was no difference in
ventilator days, length of PICU stay, length of hospital stay, adverse reactions
or mortality comparedto controls in any of the studies.
The Joint Committee on Vaccination and Immunization (a UK Department of
Health advisory body) made the following recommendations regarding
indications for palivizumab prophylaxis (June 2005):
1. Children under 2 years of age with chronic lung disease (oxygen
dependencyfor at least 28 days from birth), on home oxygen or who
have had prolonged useof oxygen.
2. Infants less than 6 months of age whohaveleft to right shunt
haemodynamically significant congenital heart disease and/or
pulmonary hypertension.
3. Children under 2 years of age with severe congenital immuno-
deficiency.
The indications for the use of palivizumab at the Royal Liverpool Children’s
Hospital - Alder Hey are displayed in Table 2.2. They reflect widely accepted
high risk subgroups and other guidelines internationally (Meissner and Long
2003; Yount and Mahle 2004; Embleton, Harkensee and McKean 2005).
1.9.2 Vaccination
The first RSV vaccine produced in the 1960’s was a formalin-inactivated
vaccine. Even though it produced high serum antibody levels it resulted in
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worse bronchiolitis following RSV infection in the vaccinated group than the
control non-vacinated children (Simoes 1999; Handforth, Friedland and
Sharland 2000; Bush and Thomson 2007). Developmentof an effective RSV
vaccine is being actively explored and is a high research priority (Hall 2001;
Smyth and Openshaw 2006: Bush and Thomson 2007). A RSV vaccine needs
to offer better protection than that from natural infection and be effective in the
first weeks of life when maternally-acquired anti-RSV antibodies are still
present. Live attenuated vaccines have the potential advantages of being
delivered intranasally and inducing both a local mucosal and a systemic
immune response. However, they tend to be unstable, too virulent and revert
back to wild-type virus (Handforth, Friedland and Sharland 2000; Hall 2001;
Smyth and Openshaw 2006). Vaccines produced from purified viruses,
recombinantvectors, and plasmids containing complementary DNAoftheviral
genome that generally target the F (fusion) and G (attachment)
transmembrane glycoproteins are being trialled (Simoes 1999; Handforth,
Friedland and Sharland 2000; Hall 2001; Kneyber and Kimpen 2004; Smyth
and Openshaw 2006: Bush and Thomson 2007).
1.10 Current Research
1.10.1 Overall aims of Current Research
The initial trigger for the current research was an anecdotal observation that a
number of the children ventilated with RSV bronchiolitis appeared to have
raised liver enzymes / hepatic transaminases. This led to a 2 year
retrospective study of 55 children (52 mechanically ventilated) admitted to
PICU with severe RSV bronchiolitis in which it was found that hepatitis, as
reflected by raised alanine transaminase (ALT) and asparate transaminase
(AST) levels, was a common extrapulmonary manifestation associated with
severe RSV disease (Eisenhut and Thorburn 2002). The hypotheses for many
of the subsequent studies evolved from the findings of the prior studies.
. 9F
The overall aim of this thesis is to investigate the clinical impact of severe RSV
disease on children, with the need for admission to PICU being the marker of
severe RSV disease.
1.10.2
1.10.1.1
1.10.1.2
1.10.1.3
1.10.1.4
1.10.1.5
1.10.1.6
Specific aims of separate parts of the study
To determine the relationship between hepatic transaminase
levels and disease severity, and the aetiology of the elevated
transaminaselevels in children with severe RSV disease.
To determine the prevalence of myocardial involvement andits
relationship with disease severity in children with severe RSV
bronchiolitis.
To investigate whether severe RSV bronchiolitis is associated
with reduced right ventricular function in infants without
congenital heart disease, and to determine whether reducedright
ventricular function is associated with myocardial damage,
elevated transaminaselevels, and disease severity.
To determine the incidence of pulmonary bacterial co-infection
andits impact on mortality and morbidity in children with severe
RSVbronchiolitis.
To determine the mortality rate and the risk factors for death in
children admitted to PICU with RSV infection.
To determine the incidence of nosocomial (acquired) RSV
infection in critically ill children, and the impact of nosocomial
RSVinfection on mortality and morbidity.
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2 Patients and Methods
2.1 Patients
2.1.1 Setting
Children admitted to the PICU at the Royal Liverpool Children’s Hospital -
Alder Hey, a tertiary university-affiliated, multi-disciplinary, regional referral
centre, were studied. The PICUis a 20-bed facility with an annual admission
rate of approximately 1100 children. Cardiac and medical patients each
account for 40% of the PICU admissions and 20% are surgical (all
subspecialities represented). The overall mortality rate is 4.5%, with a
predicted mortality of 6.25% using Paediatric Index of Mortality (PIM) (Shann
et al 1997) and a standardized mortality rate of 0.72.
2.1.2 Inclusion criteria
All children with RSV_ infection, confirmed on RSV antigen testing,
immunofluorescence and/or culture that required PICU admission between
June 1999 and May 2009(i.e. encompassing ten consecutive RSV seasons —
Octoberto March) were studied.
2.1.3 Study design
The data were collected prospectively from June 2001 onwards (the most
recent eight RSV / winter seasons studied) and retrospectively from June 1999
— June 2001 (the first two RSV seasonsstudied).
PICU admission wasutilised as the markerof severity of disease.
2.1.4 Study population
The PICU at the Royal Liverpool Children’s Hospital is a multidisciplinary
tertiary and regional referral centre. The referral/catchment area (North West
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England + North Wales) has a paediatric population (0 - 16 years age) of 1 474
900 (Office for National Statistics (England & Wales) Census 2001).
Annually usually between 220 and 380 children are admitted to the Royal
Liverpool Children’s Hospital with confirmed RSV bronchiolitis (Figure 2.1).
Annually approximately 50 RSV-infected children are admitted to the PICU at
Royal Liverpool Children’s Hospital (Figure 2.2 and Table 2.1).
Children admitted to PICU may have been admitted via the Accident &
Emergency (A&E) Department in the Royal Liverpool Children’s Hospital, from
one of our children’s wards, or may originally have presented to another
hospital (usually a district general / secondary level hospital) prior to transfer to
the regional PICU.
Children were referred to PICUat the clinical discretion of the primary medical
team responsible for the care of the child. Children for whom intensive care
was requested were usually in respiratory failure or impending respiratory
collapse and required respiratory support (most often mechanical ventilation).
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Figure 2.1: The number of RSV bronchiolitis children admitted each month
andin total to the Royal Liverpool Children’s Hospital: 1993 - 2009.
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Figure 2.2: The number of RSV-infected patients admitted each month andin
total to PICU during the ten RSV seasons: 1999 - 2009.
Table 2.1: RSV-infected patients admitted each season to PICU during the
ten RSV seasons: 1999 — 2009. median (interquartile range)
 
 
 
RSV seasons Number Age Length of Stay Deaths
1999 - 2000 28 1.6 (1.1 : 5.8) 8 (6: 9) 1
2000 - 2001 39 3.8 (1.7 : 5.8) 6 (3:7) 7
2001 - 2002 54 1.5 (0.9: 7.4) 7 (5: 13.5) 8
2002 - 2003 50 2.0 (0.9: 5.4) 6 (4:8) 3
2003 - 2004 94 3.6 (1.2: 16.1) 6 (4.5: 9) 9
2004 - 2005 55 4.6 (1.8: 17.8) 6 (4: 12.5) 4
2005 - 2006 37 2.4 (1.3: 6.4) 5 (4:9) 3
2006 - 2007 49 2.4 (1.3: 6.5) 4 (3:7) 0
2007 - 2008 34 2.6 (1.4: 8.0) 4 (3:7) 5
2008 - 2009 50 3.1 (1.5: 14.4) 5 (3: 8) 2  
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2.1.5 Research & Ethics
All studies had been approved by the Royal Liverpool Children’s Hospital NHS
Trust Research and Development Directorate — as required, following full
processing, approval wasgranted bythe Liverpool Children’s Research Ethics
Committee, or the Liverpool Children’s Research Ethics Committee waived the
need for formal ethical approval for those studies that in their opinion fell into
the realms of audit. The latter were registered with the Clinical Audit
Department, a division of the Directorate of Research and Developmentat the
Royal Liverpool Children’s Hospital NHS Trust.
2.2 Clinical Management
2.2.1 Medical management
Following PICU admission the child was reviewed promptly, by one of the six
PICU consultants who are responsible for the managementof critically ill
children in the Royal Liverpool Children’s Hospital. Subsequent management
depended on the condition and clinical progress of the child. The PICU
consultants work closely as a team, patients are discussed regularly and
similar managementstrategies are used.
2.2.2 Therapeutics
Adequate hydration and oxygenation is the mainstay of medical management
in (RSV) bronchiolitis. No specific RSV treatments (for example
bronchodilators, corticosteroids, surfactant, ribavirin, etc.) were employed in
our PICU in the RSV infected patients. All the study patients received
standard PICU managementwhich included early enteral feeding.
2.2.3 Respiratory support
It is national policy that all children who require intensive care and mechanical
respiratory support are transferred to the regional PICU. Intubation was
performed by our PICU retrieval team at the referring hospital, in our A&E
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department, or in one of the hospital wards prior to PICU admission.
Alternatively, the anaesthetic team of the referring hospital intubated some of
the patients preceding the arrival of our PICU retrieval team.
All forms of mechanical ventilation (conventional and high frequency) and
continuous positive airways pressure (CPAP) support are carried out on the
PICU at the Royal Liverpool Children’s Hospital. Patients were given sufficient
oxygen to maintain oxygen saturation at a minimum of 93% when measured
by continuous pulse oximetry. Ventilation strategies were tailored to the
individual's evolving respiratory disease and not protocolised indescriminantly.
Permissive hypercapnia was tolerated in order to minimise barotrauma and
volume trauma to the lungs. Muscle relaxants were not routinely used.
Non-invasive CPAP support wasinfrequently employed on our PICU because
it is usually performed on our 14-bed high dependency unit (HDU) which is
separate from the PICU. More recently someof the regional secondary-level
hospitals have been performing non-invasive CPAP support within their own
paediatric HDU/wards.
Children requiring extracorporeal life support (ECLS) / extracorporeal
membrane oxygenation (ECMO) becauseof deteriorating oxygenation despite
maximal ventilatory support were transferred to one of four national centres.
The timing of extubation was judged clinically and not influenced at all by any
of the studies.
2.2.4 Antimicrobial policy
The empiric use of antibiotics in children with severe bronchiolitis was at the
discretion of the attending consultant. Patients with signs of infection received
intravenous cefotaxime (50 mg/kg/dose 4 times daily) as first line therapy for
48 hours whilst awaiting culture results. Clinical status on presentation
governed whether supplementary intravenous cover with an aminoglycoside,
gentamicin (7 mg/kg/day - single daily dose) was added. Antibiotics were
rationalised or stopped onceculture and sensitivity results became available.
Ribavirin therapy is only considered in immunocompromisedchildren.
«@F«.
RSV immunoprophylaxis with the humanised monoclonal antibody,
palivizumabis used at the Royal Liverpool Children’s Hospital - Alder Hey on a
very selective basis. The indications for the use of palivizumabare displayedin
Table 2.2. They reflect widely accepted high risk subgroups and other
guidelines internationally (Meissner and Long 2003; Meissner et al. 2004;
Yount and Mahle 2004; Embleton, Harkensee and McKean 2005).
Table 2.2: Indications for palivizumab treatment / immunoprophylaxis at the
Royal Liverpool Children’s Hospital - Alder Hey, Liverpool, UK .
The following high risk patient groups can be considered for palivizumab treatmentif the
consultant considers them to be at particular risk should they get RSV infection.
1. Long term ventilated (LTV) patients (UK LTV working party 1998)
* All children on LTV aged less than 12 months at the start of the RSV
season
¢ Children on LTV aged less than 24 monthswith additional co-pathology:
a. Heart disease/pulmonary hypertension
b. Intrinsic lung disease (as reflected by oxygen dependency)
2. Congenital heart disease in children under 6 months with either
a. A haemodynamically significant left-to-right shunt
b. Pulmonary hypertension
3. Children under 24 monthswith either
° Severe congenital immunodefiency
° Chronic Lung Disease (CLD) using oxygen at home
4. Children in the first 6-12 monthsoflife born at under 35 weeks gestation
Only if there are other factors considered by the consultant specialist to
significantly increase the risk of hospitalisation
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2.3 Diagnosis
2.3.1 Microbiologic sampling
Diagnostic samples of nasopharyngeal aspirates (for RSV detection) and lower
airway secretions (for bacterial culture and viral detection) were taken through
the endotracheal tube using sterile precautions (de Blic et al. 2000) on
admission to PICU and thereafter whenclinically indicated.
From January 2002 onwards RSV surveillance samples (nasopharyngeal or
endotracheal aspirates) were taken on all children during the RSV season
(October — March) on admission and twice a week while on PICU.
Nasopharyngeal and endotracheal aspirate samples were collected by
specialist respiratory physiotherapists or PICU staff members.
Broncho-alveolar lavage (BAL) sampling was performed by specialist PICU
respiratory physiotherapists. Prior to routine bronchial toilet a sterile suction
catheter was passed down the endotracheal tube. Two 1ml/kg aliquots of
sterile 0.9% saline were instilled through the suction catheter, immediately
followed by aspiration with constant pressure into a mucus trap. BAL was
performed immediately after endotracheal intubation in children intubated in
our hospital and on arrival in the PICU - generally within three hours of
endotrachealintubation for those retrieved from other hospitals.
Surveillance samples of throat and rectum were obtained on admission and
then twice weekly, in keeping with the routine surveillance practice in our unit.
2.3.2 Laboratory procedures
2.3.2.1 Viral
Respiratory tract secretions were tested by the Directigen™ RSV test [Becton
Dickinson microbiology systems, Maryland, USA] (1999 — 2004) or NOW™
RSV test [Binax Inc., Maine, USA] (2005 - 2009). These are in vitro
immunochromatographic assays for the rapid and qualitative detection of RSV
fusion protein antigen directly from nasopharyngeal and tracheal specimens.
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The specimenis applied directly to the RSV test kits (Binax) and following 15
minutes incubation, the test window is assessed for reactivity. RSV antigen
present in the sample reacts to bind anti-RSV conjugate antibody. The
resulting antigen-conjugate complexes are captured by immobilised anti-RSV
antibody in the sample line of the test strip. Immobilsed anti-RSV antibody in
the control line captures a visualising conjugate, allowing reading of a positive
result as both a pink-to-purple sample line and control line. Commercially
available rapid antigen tests are designed to detect the most commonly
occurring RSVstrains, but may not detect all RSVstrains.
Samples negative for RSV using the rapid antigen tests were cultured using
Rmix shell vial culture techniques at the Pu.'ic Health Laboratory (Aintree,
Liverpool, UK).
Immunofluorescence for RSV was performed using SimulFluor™ reagents
(Chemicon/Millipore, Massachusetts, USA) at the Public Health Laboratory
(Standards Unit HPA UK 2007).
2.3.2.2 Bacterial/Yeast
Diagnostic or clinical samples were processed immediately in a qualitative and
semi-quantitative way using standard microbiological methods. Broncho-
alveolar lavages were centrifuged at 1200xg for 10 minutes. All but 0.5ml of
the supernatant was removed andthe centrifuged deposit re-suspendedin the
remaining fluid. A sterile calibrated loop was usedto plate out 0.01ml of the
BAL sample. Thereafter the agar plates were incubated. Less than 10
colonies on the agar plate equated to <10° CFU/ml; between 10-100 colonies
equated to 10°-10* CFU/ml; >100 colonies to >10* CFU/ml; and >1000
colonies to > 10° CFU/ml of BAL. Chocolate, MacConkey, Staph 110, and
blood agars were used for bacterial isolation; and Sabuoraud agar for fungi.
Standard methodsforidentification, typing, and sensitivity patterns were used
for all micro-organisms (Brook 1979, Baselski and Wunderlink 1994, Standards
Unit HPA UK 2009).
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2.3.200 Biochemistry
Arterial blood gases were measured whenclinically relevant from indwelling
arterial lines (as is standard in PICU management) on blood gas analysers
within the PICU — Rapidlab 1265, Bayer Diagnostics Limited, Sudbury, UK.
Urea and creatinine levels, transaminase levels (alanine and aspartate
aminotransferase levels), and C-reactive protein (CRP) levels were determined
daily by photometric analysis using the Abbott Architect c8000 routine
biochemistry analyser in the Department of Clinical Biochemistry at the Royal
Liverpool Children’s Hospital. Normal ranges for urea was 2.3 - 6.4 mmol/I and
for creatinine 24 - 52 umol/l. Normal rangesfor alanine aminotransferase was
9 - 36 IU/I and for aspartate aminotransferase 15 - 58 IU/I. Elevated C-reactive
protein level was defined as a level of > 10mg/I (Hicks and Soldin 1995).
Cardiac troponin T (cTnT)levels, as a marker of myocardial damage (Immeret
al 1997), were determined on the day of echocardiographic assessmentwith a
one-step monoclonal sandwich immunoassay (Roche Diagnostics Ltd) in the
Departmentof Clinical Biochemistry at the Royal Liverpool Children’s Hospital.
The cTnT immunoassayhasa lowerlimit of detection of 10 pg/ml, with minimal
cross reactivity with cardiac troponin | of 0.002%, and skeletal troponin T of
0.001% (Roche Diagnostics GmbH: TroponinT STAT data sheet Mannheim,
Germany 1999). Elevated levels were defined as values of >10 pg/ml.
2.3.2.4 Cardiac assessments
Pulse wave Doppler echocardiographic assessment (using Vivid 5 or Vivid 7,
General Electric Healthcare, Milwaukee, USA) was performed by Paediatric
Cardiologists on admission in enrolled patients - measurements included:
pulmonary valve ejection time, tricuspid valve closure time, left ventricular end
diastolic and systolic dimension, left ventricular fractional shortening, and Tei
index. Measurements were repeated three times per patient and average
values calculated. The two cardiologists reviewed and analysed the
recordings independently. The average of their calculated values wasutilized.
Electrocardiography (ECG) monitoring was routinely undertaken throughout
the admission with any abnormalities leading to formal tracing and analysis.
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2.4 Definitions and Formulae
RSV infection — any child admitted to the PICU that tested positive for RSV on
RSV antigen testing, immunofluorescence and/or culture from respiratory
secretions.
RSV disease — any child that tested positive for RSV on RSV antigentesting,
immunofluorescence and/orculture from respiratory secretions that had either
clinical bronchiolitis or apnoeas related to RSV infection.
Community-acquired RSV infection - Children with RSV_ bronchiolitis
confirmed on RSV antigen testing, immunofluorescence or viral culture from
respiratory tract secretions on admission to hospital.
Hospital ward-acquired RSV infection - Children who were RSV negative (or
from whom no samples were taken as they had nosigns of bronchiolitis) on
admission to hospital and who then became RSVpositive five or more days
after admission to hospital (Hall et al. 1978; Raymond and Aujard 2000;
Thorburn et al. 2004).
PICU-acquired RSV infection - Children who were RSV negative (or from
whom no samples were taken as they had no signs of bronchiolitis) on
admission to PICU and who then became RSVpositive five or more days after
admission to PICU (Hall et al. 1978; Raymond and Aujard 2000; Thorburn et
al. 2004).
RSV-attributable deaths — deaths were considered directly attributable to
RSVif the patients werestill RSV positive when they died or when the RSV
infection contributed to the adverseclinical course leading to death (Simonet
al. 2008, von Renesseetal. 2009).
PIM-predicted mortality — the paediatric index of mortality (PIM) predicted
mortality was calculated according to the original description (Shann et al.
1997). The clinical and physiological features are scored at the time offirst
contact with the intensive carestaff (if children are retrieved to the unit, at the
referring hospital).
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Standardised mortality ratio (SMR) — the ratio of actual deaths compared to
the numberpredicted (in this thesis derived from PIM-prediced mortality).
Oxygen Index (Ol) — meanairways pressure (MAP) x Fi02/PaO2
Ventilation Index (VI) — respiratory rate x PaCOz x peakinspiratory pressure /
1000.
CFU/ml — colony forming units of a single bacterial species per ml of
diagnostic sample.
2.5 Analytic Methods
Results were expressed as a percentageof the total study population; median
and inter-quartile ranges (IQR) were used to describe the demographic
distributions. Prediction of mortality using paediatric index of mortality (PIM)
was obtained on the patient’s first contact with the PICU team (Shannetal.
1997). Standardised mortality ratio (SMR) is the ratio of actual deaths
compared to the numberpredicted (in this study derived from PIM score).
Continuous data were analysed using the Wilcoxon-Mann-Whitney (W-M-VV)
test. Categorical data were analysed using Fisher’s exact or McNemar’stest.
Multivariate analysis was performed using linear and logistic regression
analysis. Statistical calculations were performed with the Statistical Program
for Social Science (SPSS) version 11.0, 13.0 or 15.0 (Chicago,Illinois) and
Epi-Info version 6.04 (CDC, Atlanta). A p value < 0.05 was considered
statistically significant. All p-values were twotailed. Relative Risk (RR) with
95% confidence intervals (95% Cl) calculations was performed with
Confidence Interval Analysis software (CIA 2.1.2) from Statistics with
Confidence, editors: DG Altman, D Machin, TN Bryant, MJ Gardner; BMJ
Books, London (2000).
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3 Hepatic transaminase levels and
disease severity in children with severe
RSV disease
3.1 Introduction
Previously in our PICU we had noted anecdotally that a numberof the children
ventilated with RSV bronchiolitis appeared to have raised liver enzymes /
hepatic transaminases. This led to an earlier 2 year retrospective study of 55
children (52 mechanically ventilated) admitted to PICU with severe RSV
bronchiolitis in which it was found that hepatitis, as reflected by raised alanine
transaminase (ALT) and asparate transaminase (AST) levels, was a common
extrapulmonary manifestation associated with severe RSV disease (Eisenhut
and Thorburn 2002). Transaminaselevels were elevated in 49% (27 of 55) of
these children. The duration of ventilation was significantly longer in the
children with elevated transaminase levels compared to those with normal
transaminase levels (p = 0.02, 2-sample t-test for unequal variance). This
association was independent of potentially confounding factors such as
medication administered, hypoxic event before admission, chronic lung
disease and congenital heart disease.
Those children with elevated transaminases appeared to have more severe
disease as reflected by their longer duration of ventilation. A possible
explanation was that they were co-infected with a second pathogen (most
likely viral) that resulted in more severe respiratory disease and caused
hepatitis. An alternative explanation was the possibility that RSV itself held the
potential to cause hepatitis. There are few reports in the medicalliterature of
hepatic involvement in RSV disease. There is a report of RSV being isolated
from the liver tissue of a 7-month old infant with bronchiolitis and extrahepatic
biliary atresia (Nadal et al. 1990). The only other report was that of hepatitis in
3 children with severe bronchiolitis (Tristam et al. 1988). However, in all these
described cases there was dual infection with RSV and cytomegalovirus
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(CMV)or adenovirus.
It was proposed that coincidental infection with other viruses as described
previously (Tristam et al. 1988) may have caused the hepatitis or myocarditis
which led to an increase in transaminase levels and more severe disease. A
prospective cohort study in patients admitted to the PICU with RSV
bronchiolitis was therefore conducted to investigate hepatic transaminase
levels and their relationship with disease severity, and whether there was
evidence on concomitantviral hepatitis.
3.2 Patients and Methods
3.2.1 Setting:
20-bed regional multidisciplinary tertiary paediatric intensive care unit (PICU)in
university-affiliated children’s hospital.
3.2.2 Objectives:
1) To investigate the origin of transaminase level elevation by
looking at ALT/ ASTratios in patients with and without congenital
heart disease, and cardiac Troponin T (cTnT) levels in patients
with a ratio of ALT to AST < 1 indicative of a possible cardiac
origin of the transaminase elevation. Cardiac troponin T has been
shown to be a more sensitive marker of myocyte injury in
myocarditis than conventional cardiac enzymelevels (Laueretal.
1997).
2) To compare disease severity as judged by duration of ventilation,
inotrope use and mortality in infants ventilated for RSV positive
lower respiratory tract infection with and without elevated
transaminaselevels.
3) To investigate for concomitant infection with common hepatitis
viruses and respiratory viruses, which have been associated with
hepatitis.
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3.2.3 Patients:
In a prospective observational study consecutive children ventilated with
severe RSV bronchiolitis, confirmed on RSV antigen testing,
immunofluorescence and/or culture, during the annual RSV winter epidemic
between October 2001 and March 2002 were enrolled. The local Research
and Ethics Committee of Royal Liverpool Children’s Hospital NHS Trust
(Institutional Research Ethics Review Board) had waived the needfor informed
consentby parents or guardians of children included in the study.
3.2.4 Measurements:
3.2.4.1 Virology:
RSV antigen was detected following standard methods with an antigen ELISA
in nasopharyngeal and endotracheal secretions. This was followed bycell
culture of the secretions using standard virological techniques at the Public
Health Laboratory (Aintree, Liverpool, UK) to improve sensitivity of detection of
RSV. Foradditional detail see 2.3.2.1. Further virology studies in children with
elevated transaminaselevels were conducted at the Virology laboratory of the
Public Health Laboratory Services at University Hospital Aintree and at the
PCR laboratories at Manchester Children’s Hospital NHS Trust. Common
paediatric hepatitic viruses were sought, as well other respiratory viruses we
had found to cause a severe bronchiolitic picture with extra-pulmonary clinical
impact. Hepatitis A virus IgG and IgM levels, HbsAg, HbcAntibodies, Hepatitis
C virus and Epstein Barr virus antibodies were measured by standard ELISA-
methods. Detection of adenovirus, influenza A and B-, parainfluenza-l, II, and
Ill viruses was by tissue culture systems using HEP-2- and rhesus monkey
kidney- as well as MRC-5- (embryonic human lung) cells. Cytomegalovirus
DNAwasdetermined by PCR with the Tagman™ System by Roche™.
3.2.4.2 Biochemistry
All study participants had, as part of the daily routine biochemical profile, ALT
and ASTlevels determined. ALT levels were considered to be elevated if
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above 36 IU/I and ASTlevels if they were above 58 IU/I (Hicks and Soldin
1995). Cardiac troponin was utilised to differentiate between hepatic or
cardiac origin of elevated transaminases. Cardiac troponin T has been shown
to be a more sensitive marker of myocyte injury in myocarditis than
conventional cardiac enzyme levels (Lauer et al. 1997). Cardiac troponin
(cTnT) levels were measured when ASTlevels were higher than ALT levels. A
ratio of ALT/AST <1 was considered to be indicative of possible myocardial
involvement and a ratio of 21 was considered to beindicative of hepatitis as
described previously (Kanda et al 1995). Transaminase levels were measured
by photometric analysis and cTnT levels were measured with a standard
chemoluminescence assay (Elecys™) at the laboratories for Clinical Chemistry
at the Royal Liverpool Children’s Hospital - Alder Hey. Cardiac TnT levels
were consideredto be elevated if >10pg/ml.
3.2.4.3 Analytic Methods:
Data on age, gestational age at birth, history of Neonatal Intensive Care Unit
admission, history of chronic lung disease or congenital heart disease,
duration of symptoms before admission, duration of ventilation, inotrope use,
death attributable to respiratory syncytial virus infection, Paediatric index of
mortality (PIM) scores, transaminase and cTnT levels and results of viral
studies arranged werecollected with a standardized data collection form. The
Paediatric Index of mortality and resulting predicted probability of death were
calculated from variables extracted on admission (Shann et al. 1997). They
comprised of specified diagnosis on admission (yes/no), elective admission
(yes/no), mechanical ventilation (yes/no), systolic blood pressure (mmHg),
base excessin arterial or capillary blood (mmol/l), ratio FiO2/PaOz (mmHg"")
and pupils fixed to light (yes/no).
Statistical data analysis was performed with Excel for Word for Windows
(Office 2000™) and Epi info version 6.04b (produced by The Division of
Surveillance and Epidemiology, Epidemiology Program Office, Centre for
Disease Control, Atlanta, USA). For comparison of categorical data chi-
square tests with Yates correction and Fisher exact tests were used. For
continuous data the two sample Student t-test was used after logarithmic
- 43 -
transformation of data if skewnessof data was detected. Differences with a p-
value of < 0.05 were considered to be statistically significant. All p-values
were two-tailed. Multivariate analysis was performed using logistic regression
analysis.
3.3 Results
During the study period 54 children with RSV bronchiolitis were admitted to
PICU and 48 of them were enrolled in our study. Reasons for the 6 excluded
from analysis were: PICU discharge before investigations could be organised,
n = 3; PICU discharge before RSV detected on tissue culture (RSV
antigen/ELISA negative patients), n = 2; ventilation due to upper airways
abnormality/obstruction and not due to RSV infection, n = 1. Elevated
transaminase levels (ALT and/or AST) were found in 22 (46%). Demographic
and clinical characteristics of patients with and without elevated transaminase
levels are shownin Table 3.1.
Thirteen out of 15 (86%) patients with congenital heart disease (CHD) and 9
out of 33 (27%) patients without CHD had elevated transaminase levels
(p<0.01). The types of cardiac lesions in the 15 children in the study with CHD
were: ventricular septal defects (7); transposition of the great arteries (2);
tetralogy of Fallots (2); double outlet right ventricle (2); hypoplastic left ventricle
(2); truncus arteriosus (1); coarctation of the aorta (1); persistent ductus
arteriosus (1); anomalous pulmonary venous drainage (1). Eleven of the 15
children with CHD had had complete or partial correction of their underlying
cardiac lesion before entry into the study. Six of the 15 children with CHD
were cyanotic at the time of PICU admission, and 4 were in cardiac failure
Clinically.
The ALT/AST ratio was 2 1 in 6 (27%) patients. ALT/AST ratio was <1 in 16
patients (73%). Of patients with ALT/AST ratio < 1, 62% were patients with
congenital heart disease. The proportion of patients with CHD amongst
patients with predominantly elevated AST levels wasnotstatistically significant
different from the proportion of patients without CHD (p = 0.65). Time course
of ALT levels in patients with elevated levelsis illustrated in Figure 3.1. Two
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outliers had ALT levels which peaked at 3676 and 1490 IU/I on days 5 and 6
after admission respectively. Both patients died, however elevated ALT did
not necessarily correlate with poor outcome. In Figure 3.2, AST levels of
patients with and without CHD were compared. AST levels in patients with
CHD weresignificantly higher than in patients without CHD on day 2 and 3
after admission.
Cardiac troponin T levels were elevated in 6 (50%) out of the 12 of patients
with an ALT/AST ratio <1. In 4 of such patients a cTnT level was not
performed. The elevation of cTnT levels at its peak was to a median of
610pg/ml(range 160 to 2720pg/ml). All patients with elevated cTnTlevels had
underlying CHD. Three out of the 6 patients who died and 5 out of the 11
patients on inotropes had elevated cTnTlevels. All patients that died, andall
but one patient with inotrope requirements, had underlying CHD.
Virological studies revealed a simultaneous infection with a second virus in
only one patient — Influenza A infection was detected in nasopharyngeal
secretions, with no evidence of recent infection with any of the other viruses
investigated.
Multiple logistic regression analysis utilizing transaminase levels as the
dependentvariable and entering CHD, inotrope use, and death as covariates
with backward stepwise (likelihood ratio) regression, revealed that CHD
emerged as the only factor with a significant (p < 0.01) change in -2log
likelihood on removal from the modelat the last step.
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Table 3.1: Demographic and clinical characteristics of patients ventilated with
RSV bronchiolitis with and without elevated transaminase levels.
 
 
  
Patients with elevated Patients with normal p-value
transaminaselevels transaminase levels
(n = 22) (n = 26)
Age on admission (months) 2.0 (1.0;6.5)? 1.5 (0.7;7.0) 0.61°
Gestational age at birth (months) 36.3 (5.1)° 38.4 (2.4) 0.157
Duration of symptoms before 2.7(2.4)° 3.3 (2.4) 0.38°
admission (days)
History of Neonatal Intensive Care 7 6 0.72'
Chronic lung disease of prematurity 3 1 0.32°
Congenital heart disease (CHD) 13 2 <0.019
Predicted probability of death in %, 9.3 (8.1;10.5)" 8.3 (7.1;9.4) 0.71°
according to PIM model
Duration of ventilation (days) in all 10.6 (9.4:11.7)? 3.5 (2.8:4.2) <0.01°
patients
Duration of ventilation (days)in 7.9 (6.7; 9.1)* 3.5 (2.8;4.2) <0.01°
patients without CHD
Patients requiring inotropes (n = 11) 9 2 <0.019
Numberof deaths in each group 6 (27%) 0 (0%) <0.019   
“ median (IQR)
> two samplet-test for unequal variance after logarithmic transformation of data
“arithmetic mean (SD)
“two samplet-test for unequal variance
*“ two sample t-test
‘chi-square test with Yates correction
® Fishers exact test with twotailed p-values* geometric mean (95% Cl).
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Figure 3.1: Alanine aminotransferase (ALT) levels in all patients ventilated
with RSV bronchiolitis with elevated ALT-levels (n = 16).
286 261250 -
200 | —-2<0.01 p<0.01 p=0.09 pr0.56
150 -
100 -   AST-levelsinIU/I 50 - 
12 3 4 5 6 7 8 9 10 11 12
Days since admission
Figure 3.2: AST levels in children with —— (n = 15) and without- - - (n = 33)
congenital heart disease ventilated with RSV bronchiolitis (geometric means and
95% Cl; p-values are from two tailed, two sample t-test for unequal variance after
logio-transformation of data).
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3.4 Discussion
Hepatic transaminase levels were elevated in 46% (22 out of 48) of children
ventilated with severe RSV bronchiolitis. There are several possible
explanations for this finding. Virus-induced hepatitis, ischaemic hepatitis or
hypoxic hepatitis were possible causes in patients with elevated hepatic
transaminase and normal cTnT levels. None of the medication used on the
PICU was hepatotoxic and a previous study (Eisenhut and Thorburn 2002)
demonstrated that there was no association between medications used and
hepatitis in children ventilated for severe RSV bronchiolitis. The lack of
infection with either known hepatitis viruses or respiratory viruses known to
cause hepatitis may suggest that RSV itself caused the hepatitis. Conclusive
proof of hepatic RSV infection would require a liver biopsy and this is
inappropriate on ethical grounds.
RSV has beenisolated from both liver tissue and the myocardium previously
(Nadal et al. 1990; Fishaut, Tubergen and McIntosh 1980). A case report of
hepatopulmonary syndrome in viral hepatitis caused by hepatitis A virus
suggested that a link between hypoxia (due to intrapulmonary shunting) and
hepatitis, even without fulminant hepatic failure (Regev et al. 2001). A
previous retrospective study in our PICU (Eisenhut and Thorburn 2002)
indicated that there was no evidence of hypoxic events before admission being
associated with elevated transaminase levels. In another study, hypoxic
hepatitis has only been seenin severe hypoxia (arterial PO2 < 6.kPa) (Henrion
et al. 1999). Hypoxic hepatitis as an explanation was unlikely. In the present
study the patients’ oxygen levels were continuously monitored and hypoxia
wasavoided.
The elevated transaminase levels in the majority of patients with underlying
congenital heart disease (CHD) may have been on accountof right ventricular
failure causing ischaemic hepatitis due to hepatic venous congestion. This
hypothesis is supported by a previously reported cohort study of adult patients
with ischaemic hepatitis who had right ventricular failure as an underlying
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cause in 94% of cases (Seeto, Fenn and Rockey 2000). Elevated ASTlevels
have previously been reported in children with systemic venous congestion
due to congenital heart disease (Mace, Borkat and Liebman 1985). Pulmonary
hypertension, which is a well-described phenomenonin ventilated children with
RSV bronchiolitis with CHD, may also have played a role (Moler et al. 1992;
Khongphatthanayothinet al. 1999).
Elevated cTnT levels in patients with CHD may mean that cardiac failure,
which has been described as a cause of elevated cTnT levels (Missov and
Mair 1999), was exacerbated by severe RSV bronchiolitis. This could explain
the significantly higher ASTlevels in patients with CHD compared to patients
without CHD on the second andthird day after admission (see Figure 3.2). At
this time the strain to the right ventricle from pulmonary hypertension due to a
peakin ventilation requirements may have been particularly severe. Another
explanation for elevated cTnT levels may be RSV-associated myocarditis,
which has been reported previously (Thomas et al. 1997; Huang, Bigos and
Levine 1998).
In our study predicted probability of death calculated from PIM scores was not
significantly higher in patients with elevated transaminase levels as compared
to patients without elevated transaminase levels during course of disease.
This may have been due to the fact that the PIM is calculated from data
extracted on admission when eventual disease severity has not yet evolved.
PIM is also an ‘all-comers’ score and not designed for specific diseases.
Underlying congenital heart disease rather than the pathophysiology
underlying transaminase level elevation may have accounted for the excess
mortality in the group with elevated transaminase levels. In adults elevated
transaminase levels have beenidentified as predictors of increased mortality in
chronic cardiac failure and severe bacterial pneumonia requiring mechanical
ventilation (Dahmash and Chowdhury 1994; Batin et al. 1995). Underlying
CHD leading to right ventricular failure due to pulmonary hypertension, may
have contributed to excess mortality and inotrope requirements in patients with
CHD. Right ventricular failure associated with more severe pulmonary disease
and leading to prolonged ventilation requirements, may also have been the
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cause of temporarily elevated transaminaselevels in patients without CHD.
Interpretation of the results is limited by the lack of a control group of similar
children with severe RSV-negative bronchiolitis. Without such a comparable
groupit is difficult to assess whether the effects observed are a consequence
of RSVinfection or due to the severity of their disease per se. Future studies
would be strengthened by a RSV-negative control group.
Whether hepatic transaminase level elevation, the magnitude of this elevation
or cardiac troponin T levels in the first 3 days after PICU admission could be a
useful predictor of mortality in children ventilated with severe RSV disease
would require a specific larger, long-term prospective study in children with and
without CHD.
3.5 Conclusions
Transaminase level elevation was commonin children in our PICU ventilated
with RSV bronchiolitis. There was no evidence that other commonviral
infections caused this phenomenon.
Disease severity as judged by duration of ventilation, inotrope use and
mortality was greaterin children with elevated transaminaselevels (Table 3.1).
The greater severity of disease as judged by duration of ventilation was
independent of the presence of CHD.
The elevated transaminase levels may have been a reflection of myocardial
failure and/or ischaemic hepatitis secondary to myocardialfailure.
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4 Myocardial damage and disease
severity in children with severe RSV
bronchiolitis.
4.1 Introduction
Myocardial involvement during RSV bronchiolitis wasfirst reported in 1972 in a
case offatal interstitial myocarditis in a child (Puchkov and Minkovich 1972).
The reported degree of cardiac involvement during infection with this virus
ranged from no detectable electrical or functional abnormality, focal
involvement of the conducting system, supraventricular- and ventricular
arrhythmias to global myocardial involvement with electrical and mechanical
dysfunction (Giles and Gohd 1976; Menahem and Uren 1985; Menahem 1991;
Hutchinson et al. 1994; Thomaset al. 1997; Huang, Bigos and Levine 1998).
Cardiac arrhthmias have also been reported during RSV infection in patients
with structurally normal hearts and were not associated with hypoxia or beta
agonist therapy (Armstrong and Menahem 1993; Donnerstein et al. 1994;
Thomaset al. 1997; Playfor and Khader 2005).
Cardiovascular compromise in the form of hypotension without cardiac
arrhythmias has also been described and has been associated with evidence
of myocardial damageas evident from elevated cardiac troponin | and levels.
An observational study of 218 infants admitted to a children’s hospital with
RSV bronchiolitis described 7 infants with features of shock (Njoku and
Kliegman 1993). Elevated cardiac troponin levels have also been foundin 35
— 54 % of infants ventilated on PICU with RSV bronchiolitis (Checchia et al.
2000). Additionally, elevated cardiac troponin | levels have also been found in
children with RSV infection not requiring mechanical ventilation (Moynihan et
al. 2003). The degree of cardiovascular support reported has ranged from
administration of fluid boluses to inotropic support (Checchia et al. 2000; Kim
and Frankel 1997; Moynihanet al. 2003).
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RSV has beenisolated from myocardial tissue in immunodeficient individuals
(Fishaut, Tubergen and McIntosh 1980). A previous retrospective study on the
prevalence of hepatitis associated with RSV-disease revealed that 13% of
children admitted to our PICU with RSV bronchiolitis had significantly elevated
aspartate aminotransferase (AST) levels (Eisenhut and Thorburn 2002). The
elevated AST levels were suggestive of being of myocardial origin. All infants
who had only elevated AST-levels died. Myocardial involvement may have
contributed to these deaths from severe RSV disease.
Troponin is an inhibitory protein complex forming part of the contractile
apparatus of all striated muscle, including cardiac muscle. Specific forms of
the troponin subunits T, | and C exist in the various different muscle types.
Cardiac troponin T (cTnT) is a myocardio-specific 37-kDa protein that is
responsible for the binding of the myocardial troponin complex to tropomyosin.
Cardiac TnT is a more sensitive and specific marker of myocardial damage
than conventional cardiac enzyme levels (Immer et al. 1997; Lauer et al.
1997). Cardiac-specific troponins T and | have become established as the
gold standard biochemical marler for myocardial necrosis and damage
(Bhayana and Henderson 1995, Hetland and Dickstein 1998). Measurements
of cTnT levels were therefore used to determine the prevalence of myocardial
involvement (damageorinjury) in infants admitted to PICU with severe RSV
bronchiolitis. The relationship of cTnT levels to the clinical characteristics of
the study patients, their myocardial abnormalities, indicators of disease
severity and outcomewasinvestigated.
4.2 Patients and Methods
4.2.1 Setting
20-bed regional multidisciplinary tertiary paediatric intensive care unit (PICU)in
university-affiliated children’s hospital.
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4.2.2 Objectives
1. To determine the prevalence of myocardial involvement (damage, injury
or strain) in severe RSV bronchiolitis as evident from elevated cardiac
Troponin T (cTnT)levels.
2. To assess the nature of the myocardial involvement as manifested in
electrocardiographic and echocardiographic abnormalities.
3. To compare severity of disease with and without myocardial
involvement as evident from duration of ventilation, inotrope
requirements and death.
4.2.3 Patients
Infants, both with and without congenital heart disease, admitted to the PICU
during the winter season October 2002 to March 2003 with RSV bronchiolitis
detected by RSVantigen in respiratory secretions (see 2.3.2.1 for details) were
includedin this prospective observational cohort study.
Written and informed consent by parents or guardians wasobtained.
The Liverpool Children’s Research Ethics Committee approvedthe study.
Exclusion criterion: Any infant that acquired their RSV in PICU (i.e.
nosocomial RSV infection).
4.2.4 Measurements
4.2.4.1 Biochemistry:
Cardiac TnT levels were measured within 48 hours of PICU admission with a
one-step monoclonal sandwich immunoassay (Roche Diagnostics Ltd) in the
Departmentof Clinical Biochemistry at the Royal Liverpool Children’s Hospital.
Cardiac TnT levels were considered to be elevated if detectable (>10pg/ml). If
cTnT levels were found to be elevated they were repeated until they became
undetectable or until arterial access waslost or routine blood sampling ceased.
Additionally see 2.3.2.3 for further details.
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4.2.4.2 Cardiac:
Pulse wave Doppler echocardiographic assessment(using Vivid 5 orVivid 7,
General Electric Healthcare, Milwaukee, USA) was performed within the 48 —
72 hours of PICU admission by a Paediatric Cardiologist in enrolled patients -
measurements included: left ventricular end diastolic and systolic dimension,
and left ventricular fractional shortening. Measurements were repeated three
times per patient and average values calculated. Two cardiologists reviewed
and analysed the recordings independently. The average of their calculated
values wasutilized.
Electrocardiography (ECG) monitoring was routinely undertaken throughout
the admission. Abnormalities on ECG monitoring were registered and formally
recorded for cardiology analysis.
4.2.5 Analytic Methods:
Data were collected on included patients with a data extraction sheet,
comprising of: age, gestational age at birth, year of admission, Paediatric
Index of Mortality (PIM) score (Shann et al. 1997) on admission, history of
chronic lung disease, congenital heart disease, history of neonatal intensive
care, duration of symptoms before admission, duration of ventilation, inotrope
use and its duration, death, cTnT levels, ECG- and echocardiographicfindings.
Statistical analysis was performed with SPSS version 10.0 and Epi Info version
6.04b (CDC Atlanta). A result was consideredstatistically significant if p <0.05.
4.3 Results
34 RSV-positive children were included in the study. Twelve children (35%)
had elevated cTnT levels. The levels measured within 2 days of admission had
a median (IQR) of 50 pg/ml (37.5 — 67.5pg/ml). Cardiac TnT levels decreased
to undetectable levels at a median of 4 days after admission. In one patient
with a haemodynamically significant ventricular septal defect the cTnT levels
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reached a peak of 591pg/ml and were 40pg/ml! when last measured 11 days
after admission.
Data on baseline characteristics, clinical course and outcome are summarized
in Table 4.1. Infants with elevated cTnT levels were generally younger than
those with undetectable levels. Analysis of components of the PIM score
revealed that there was no significant difference between patients with and
without cTnT elevation with regards to FiO2, PaOz, ratio of FiO2/PaO2 and base
excess on admission (p > 0.05). The mean (SD) systolic blood pressure (BP)
was 73 (21) mmHgin children with and 95 (20) mmHg without elevated cTnT
(p = 0.01). Four children in the group with elevated cTnT and nonein the
group with undetectable cTnT (p = 0.01) were found to be hypotensive with a
BP more than 2 SD below the mean for age and sex (Task Force on Blood
Pressure Control in Children 1987). None of these 4 infants had
cardiopulmonary resuscitation or a hypoxic insult before admission. The
duration of the hypotensive episode on admission had a median of 14.5 hours
and management included repeated boluses of crystalloid and colloid fluids.
Fractional shortening on echocardiograms performed at a median (IQR) of 3
days (2.5 — 4 days) after admission had a mean (SD) of 35% (8%) in subjects
with elevated and 35% (6%) in patients with undetectable cTnT levels (p =
0.94).
Asymptomatic arrhythmias (one patient with supraventricular tachycardia and
another with ventricular extrasystoles) on ECG were found in 2 cases with
elevated cTnT levels and none of the patients with normal cTnT levels (p =
0.12).
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Table 4.1: Demographics,clinical characteristics and course, and outcome
of patients with RSV bronchiolitis with and without elevated cardiac troponin
(cTnT)levels.
 
 
     
cTnT elevated cTnT undetectable p-value
(n=12) (n=22)
Male/female ratio 3.0 3.4 0.74°
Median age (IQR) in months 1.4 (0.7-2.0) 4.0 (1.7-6.6) 0.04°
Mean(SD)gestational age atbirth 34.4 (3.7) 35.6 (5.1) 0.44°
History of neonatal intensive care 4 6 0.717
History of chronic lung disease 0 3 0.53°
History of congenital heart disease 1 7 0.217
Mean (SD) duration of symptoms before 3.4 (2.3) 4.1 (2.9) 0.50°
admission in days
Mean (SD) predicted mortality according 15.8 (4.3) 10.8 (2.1) 0.02°
to PIM score on admission (%)
Mean(SD) duration of ventilation in days 7.3 (8.0) 7.8 (6.7) 0.86°
High frequencyventilation used 0 3 0.25°
Inotrope use 0 1 1.0°
Death 0 1 1:0"
* Fishers exact test
° Mann WhitneyU test
° Student’s t-test.
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4.4 Discussion
This study was the first to provide data on the prevalence of myocardial
involvement in RSV lung disease. Myocardial involvement (injury or strain)
was common and occurred in patients with structurally normal heart. It
resolved in most caseswithin 4 days of admission. This makes myocarditis, in
which a more persistent cTnT elevation would be expected, unlikely to be a
cause. Cardiovascular function appeared to be transiently impaired in patients
with elevated cTnT on admission as reflected by a low blood pressureat that
time. Subsequent echocardiograms found no evidence of a persistent
reduction in myocardial contractility. In previous reports cTnT elevation was
found to be commonin patients on PICU with systemic inflammatory response
syndrome and it has been suggestedthat cytokines like tumour necrosis factor
(TNF) are toxic to myocardial myocytes (Girior and Stromberg 2000). TNF
release by the respiratory tract is a feature of the acute phase of RSV positive
bronchiolitis (Matsuda et al. 1995). Cardiac TnT level elevation has been
reported in patients with pulmonary disease - in preterm infants ventilated for
respiratory distress syndrome and in two adults with chronic obstructive lung
disease and lobar pneumonia (Trevisanuto et al. 2000; Weinberg, Cukierman
and Chajek-Shaul 2002). Acute pulmonary hypertension associated with
pulmonary embolism in adults without coronary artery disease is a well
described cause of cInT elevation and is thought to be due to myocardial
ischemia (Giannitsis et al. 2000; Konstantinides et al. 2002). A prospective
echocardiography study on infants with acute bronchiolitis found that features
of pulmonary hypertension like pansystolic tricuspid regurgitation with high
peak systolic velocity across the tricuspid valve were common and detectable
in 75% of patients ventilated with acute bronchiolitis (Sreeram, Watson and
Hunter 1991). The echocardiographic assessmentin this specific study did not
check for signs of pulmonary hypertension.
Elevated cTInT could be a reflection of the strain on the right ventricle
associated with pulmonary hypertension associated with the poor gas
exchange and lung compliance and hyperinflation of the lungs in the initial
phase after admission to PICU. A reduction of myocardial strain by optimising
oxygenation and reducing respiratory effort by mechanical ventilation and
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sedation may have accounted for the rapid decline of cTnT levels. Cardiac
TnT elevation can be cause or effect of hypotension. Healthy coronary
arteries in infants make them less prone to myocardial ischaemia secondary to
hypotension compared to adults. Henceit is more likely that the hypotension
was consequence or associated with the myocardial insult causing the cTnT
elevation. Systolic hypotension is a feature found in acute pulmonary
hypertension (Giannitsis et al. 2000).
Although the patients with elevated cTnT levels were youngerthan those with
undetectable cTnT levels, it is improbable that the cTnT elevation wasrelated
to a perinatal asphyxiating event, which has previously been described as
being associated with elevated cTnT levels (Trevisanuto et al. 1998). Most
patients with elevated cTnT levels were older than 3 weeks and cTnT has a
half life in serum of 2 hours (Katus et al. 1991). Cardiac TnT has a short half
life in serum of 2 hours (Katus et al. 1991), and therefore diminishes rapidly
following an acute insult (e.g. perinatal asphyxia). Most of the study patients
with elevated cTnT levels were older than 3 weeks. All the patients, both with
and without elevated cTnT levels, had similar gestational ages at birth and
histories of neonatal intensive care (Table 4.1). Cardiac TnT concentrations
have previously not been found to be correlated to gestational age (Panteghini
et al. 1997). Perhaps a younger myocardium copes less well with strain from
severe parenchymallung disease.
4.5 Conclusions
Raised cardiac troponin levels are commonin infants with structurally normal
hearts and severe RSV lung disease. This data may help to explain the
increased morbidity and mortality associated with RSV bronchiolitis in children
with significant congenital heart disease (Fixler 1996). Myocardial injury or
strain, which, according to this data, occursin infants with a structurally normal
heart with severe RSV lung disease, may cause a heart already understrain
from a structural abnormality to fail. However, whether the raised cTnT levels
are specific to severe RSV lung disease per se or rather related to severe
infective parenchymal lung disease in general remains to be determined.
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5 Reducedright ventricular function in
infants without congenital heart disease
with severe RSV bronchiolitis.
5.1 Introduction
An extrapulmonary impact from RSV infection is well recognised (Eisenhut
2006). Thefirst report of clinically symptomatic myocardial involvement during
RSV bronchiolitis was that of a case of fatal interstitial myocarditis in 1972
(Puchkov and Minchovich 1972). The degree of cardiac involvement during
RSV infection reported has ranged from electrical/conduction abnormalities
(arrhythmias) to global myocardial involvement with mechanical dysfunction
(Giles and Gohd 1976; Menahem and Uren 1985; Armstrong and Menahem
1993; Donnerstein et al. 1994; Thomaset al. 1997; Huang, Bigos and Levine
1998; Checchia et al. 2000; Eisenhut et al. 2004; Playfor and Khader 2005).
Previous studies investigating hypotension and inotrope requirements in
infants ventilated with RSV bronchiolitis (Checchia et al. 2000; Eisenhutet al.
2004) demonstrated associated myocardial damage as evident from elevated
cardiac troponin levels. Echocardiographic assessment of left ventricular
ejection fraction revealed no difference between patients with and without
elevated cardiac troponin T (cTnT) levels (Eisenhut et al. 2004) indicating no
evidence of global or left ventricular failure. Findings suggested that right
ventricular failure was the cause of elevated cTnT levels. Right ventricular
strain resulting in ischaemic hepatitis due to hepatic venous congestion was
also deemed to be a causative factor in studies that identified elevated
transaminase levels in ventilated infants with RSV bronchiolitis, with the
elevated transaminase levels being significantly more commonin children with
congenital heart disease (Eisenhut and Thorburn 2002; Eisenhut, Thorburn
and Ahmed 2004). The above-mentioned studies (Checchia et al. 2000;
Eisenhut and Thorburn 2002; Eisenhut et al. 2004; Eisenhut, Thorburn and
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Ahmed 2004) therefore generated the following hypothesis: Right ventricular
failure is associated with myocardial damage and causes ischaemic hepatitis
in infants ventilated with RSV bronchiolitis.
5.2 Patients and Methods
5.2.1 Setting:
20-bed regional multidisciplinary tertiary paediatric intensive care unit (PICU)in
university-affiliated children’s hospital.
5.2.2 Objectives:
1. To establish whether severe RSV bronchiolitis is associated with
reduced right ventricular function in infants without congenital heart
disease.
2. To investigate the cause of right ventricular impairment by analysis of
the relationship to left ventricular and atrial volumes and severity of
respiratory disease.
3. To investigate whether reduced right ventricular function is associated
with myocardial damageorstrain.
4. To investigate whether reduced right ventricular function is associated
with elevated transaminaselevels.
5.2.3 Patients:
In a prospective observational study consecutive infants under 12 months of
age and ventilated with severe RSV bronchiolitis, confirmed on RSV antigen
testing, immunofluorescence and/or culture, were enrolled after informed
written consent by parents or carers. The study was approvedbythe Liverpool
Children’s Research Ethics Review Committee.
Exclusion criteria: Any child that acquired their RSV in PICU (i.e. nosocomial
RSV infection). Children with evidence of congenital heart disease were
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excluded in order to avoid underlying myocardial disease confounding
interpretation of data.
5.2.4 Measurements:
5.2.4.1 Virology
Nasopharyngeal aspirates were tested by the Directigen™ RSV test [Becton
Dickinson microbiology systems, Maryland, USA]. These are in vitro
immunochromatographic assays for the rapid and qualitative detection of RSV
antigen directly from nasopharyngeal specimens. Samples negative for RSV
using the rapid antigen tests were cultured using standard virological
techniques at the Health Protection Agency (Aintree, Liverpool, Uk).
Immunofluorescence was performed using standard virological techniques at
the Health Protection Agency.
5.2.4.2 Biochemistry:
Cardiac troponin T (cTnT) levels were determined, as a marker of myocardial
damage (17lmmeret al 1997), on the day of echocardiographic assessment
with a one-step monoclonal sandwich immunoassay (Roche Diagnostics Ltd)
in the Department of Clinical Biochemistry at the Royal Liverpool Children’s
Hospital. Elevated levels were defined as values of >10pg/ml. Urea and
creatinine levels, transaminase levels (alanine and aspartate aminotransferase
levels), and C-reactive protein (CRP) levels were determined daily. Normal
ranges for urea was 2.3 - 6.4 mmol/l and for creatinine 24 - 52 umol/l. Normal
ranges for alanine aminotransferase was 9-36 IU/I and for aspartate
aminotransferase 15-58 IU/I (Hicks and Soldin 1995). An elevated C-reactive
protein level wasdefined as a level of > 10mg/I.
5.2.4.3 Cardiac:
Pulse wave Doppler echocardiographic assessment (using Vivid 5 or Vivid 7,
General Electric Healthcare, Milwaukee, USA) was performed by a Paediatric
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Cardiologist (SA, SN) on admission in all enrolled patients - measurements
included: pulmonary valve ejection time, tricuspid valve closure time, left
ventricular end diastolic and systolic dimension and left ventricular fractional
shortening. Measurements were repeated three times per patient and average
values calculated. The two cardiologists (SA, SN) reviewed and analysed the
recordings independently. The average of their calculated values wasutilized.
The right ventricular Tei index was calculated as described previously (Tei et
al. 1996) from tricuspid valve closure time (time interval between cessation and
onsetoftricuspid inflow) (a) and pulmonary valve ejection time (b) following the
formula: Right ventricular Tei index = a-b/b. This is a reliable and reproducible
technique as demonstrated in a previous study that revealed inter-observer
andintra-observer coefficients of variation of 3.3 and 4.5% respectively (Teiet
al. 1996). An elevated Tei index indicating reduced right ventricular function
was defined as an index of more than 2 standard deviations (SD) above the
meanfor children (across all age groups and both genders) of 0.24 (SD 0.04)
(Ishii et al. 2000).
Electrocardiography (ECG) monitoring was routinely undertaken throughout
the admission with any abnormalities leading to formal tracing and analysis.
5.2.5 Analytic Methods:
Data were collected on a standardised data collection form including: age,
gender, ventilation and oxygenation indices (Peters et al. 1998), duration of
mechanical ventilation, calculation of the right ventricular Tei index, left
ventricular fractional shortening and dimensions, cardiac troponin T levels,
transaminase and C-reactive protein levels during stay on the PICU. Non-
parametric data analysis using median and range, Mann-Whitney test for
comparison of continuous data, and Fishers’ exact test for categorical data
were used because of small and unequal sample size. A p-value of <0.05 was
considered to indicate statistical significance of difference. All p-values were
two tailed. Software used for analysis was SSPS version 15.0 and Epi-Info
version 6.04 (CDC,Atlanta).
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5.3 Results
Thirty four ventilated infants with confirmed RSV bronchiolitis and no
underlying congenital heart disease were enrolled over two RSV seasons
(2003 — 2005). Median age was 1.4 months [range 0.4 — 11.7] and median
length of ventilation 5 days [range 2 — 10].
Echocardiography was performed within 24 hours of PICU admission in 79%
(27/34) of the cases and within 48 hours for the remainder. Seven (20%)
infants had an elevated right ventricular Tei index indicating significantly
reduced right ventricular function - median Tei index 0.46 [range 0.33 — 0.92].
The group with a normal Tei index had a median of 0.19 [range -0.17 — 0.31]
(p < 0.01). Age, gender,left ventricular function including fractional shortening,
left ventricular end diastolic and systolic diameters, left atrial diameter and
admission systolic blood pressure were not different comparing patients with
and without right ventricular dysfunction (Table 5.1). None of the patients in
this study required inotropes. Tricuspid regurgitation was found in eight
patients (24%) - 2/7 with an elevated Tei index [calculated pulmonary artery
pressure range 25 — 35mmHg] and 6/27 [calculated pulmonary artery pressure
range 25 — 35mmHg] with a normal Tei index (p = 0.8). Three patients (3/7)
with elevated and eleven with normal Tei index (11/27) had a detectable
cardiac troponin T level (p = 1.0). Cardiac troponin T (cTnT) was therefore
raised in 14 (40%) of the 34 ventilated children with RSV bronchiolitis - median
measurement 30 ng/I [range 10 — 140]. There was no difference in age of
patients with (median 0.9 months, range 0.4 — 11.7) and without elevated cTnT
levels (median 1.45 months, range 0.4 — 6.4) (p = 0.32). There was no
difference in left ventricular (fractional shortening) and right ventricular function
(Tei index) in infants with elevated cTnT (median fractional shortening 32%
[range 21 — 39] and median Tei index 0.22 [range -0.17 — 0.55]) and without
elevated cTnT (median fractional shortening 32% [range 16 — 45] and median
Tei index 0.22 [range 0.14 — 0.92]) levels (p = 0.70 and p = 0.75 respectively).
No arrhythmias or other ECG abnormalities were observed in either group.
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Table 5.1: Echocardiographic data in children ventilated with respiratory
syncytial virus infection with and without right ventricular dysfunction as
demonstrated by an elevated or ‘normal’ Tei-index (Teiet al. 1996).
 
 
     
Elevated Tei index Normal Tei index p-value*
(n=7) (n=27)
Gender(male) 4 17 1.0
Age (months, median, [range]) 1.1 [0.4-3.3] 1.5 [0.4-11.7] 0.56
Left ventricularfractional 32.6 [22-45] 32.1 [16-42] 0.45
shortening (%, median, range)
Left ventricular end diastolic 1.8 [1.4-2.1] 1.8 [1.4-2.6] 0.45
diameter (cm, median, range)
Left ventricular end systolic 1.1 [1.0-1.3] 1.3 [0.9-1.8] 0.06
diameter
(cm, median, range)
Left atrial diameter 0.83 [0.57-1.0] 0.90 [0.61-1.47] 0.27
(cm, median, range)
Admission systolic blood pressure 65 [62-86] 75 [42-120] 0.18
(mmHg,median, range)
* Mann-Whitneytest
Alanine aminotransferase levels were elevated in 3/7 and aspartate
aminotransferase levels in 2/7 patients with elevated Tei index and in 12/27
patients each with normalTei index (p = 0.21 and 0.67 respectively)
Highest transaminase and C-reactive protein levels, highest ventilation and
oxygenation indices, as well as duration of mechanical ventilation, were not
different betweenpatients with and without elevated Tei index (Table 5.2).
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Table 5.2: Clinical and laboratory parameters in children ventilated with
respiratory syncytial virus infection with and without right ventricular
dysfunction as demonstrated by an elevated or ‘normal’ Tei-index (Tei et al.
 
 
  
1996).
Elevated Tei index NormalTei index p-value
(n=7) (n=27)
Admission ventilation index (median, 27.2 [21.0-34.4] 23.4 [16.9-29.3] 0.77*
range)
Admission oxygenation index 6.0 [4.1-9.5] 5.9 [4.8-11.4] 0.60*
(median, range)
Highest ventilation index (median, 28.1 [24.2-65.2] 27.8 [14.9-80.2] 0.43*
range)
Highest oxygenation index (median, 8.1 [3.7-18.6] 5.9 [1.5-19.5] 0.59*
range)
Duration of mechanical ventilation 5.0 [4.0-7.0] 5.0 [2.0-10.0] 0.62*
(days, median, range)
Elevated cardiac troponin T level 3 11 1.007
>10 ng/l)
Highest ALT 35 [21-379] 28 [13.0-339] 0.21*
(IU/l, median, range)?
Highest AST 54 [25-103] 46 [25-126] 0.78*
(IU/I, median, range)?
Highest C-reactive protein level 26 [8-142] 41 [7-179] 0.58*
(mg/l, median, range)?    
* Mann-Whitneytest, 1 Fisher’s exacttest
4 Highest level during stay on the Paediatric Intensive Care Unit
ALT = alanine aminotransferase level
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AST = aspartate aminotransferase level
 
5.4 Discussion
Significantly reduced right ventricular function was found in 20% of infants
without congenital heart disease ventilated for RSV bronchiolitis. This reduced
right ventricular function was not related to the severity of respiratory disease.
This finding in infants with severe RSV disease is contrary to an earlier study
of 10 infants with RSV disease whichdid not find an increased right ventricular
ejection time and right ventricular systolic time intervals in patients with
moderate to severe compared to patients with mild disease (Pahl and Gidding
1988). Unlike the present study the authors concluded that RSV bronchiolitis
was not associated with a significant depression of cardiac performance (Pahl
and Gidding 1988).
This study is the first employing a standardised right ventricular performance
index in infants with RSV disease and the largest containing data on right
ventricular performance in severe RSV infection requiring ventilation published
so far. The Tei index was utilized as it is non-invasive, uncomplicated,
reproducible, and not significantly influenced by heart rate, right ventricular
pressure, the ventricular dilatation or, importantly, tricuspid regurgitation (Teiet
al. 1996; Ishii et al. 2000). Because the index is essentially a time ratio it is not
affected by ventricular geometry and is useful in assessment of global right
ventricular function in children with their complex right ventricular shape (Eiden
et al 1998; Tsutsumi et al. 1999; Ishii et al. 2000). The index has been shown
to correlate well with clinical symptoms of right ventricular failure and overall
survival (Eiden et al 1998; Tsutsumi et al. 1999; Ishii et al. 2000; Burgess,
Bright-Thomas and Ray 2002). A normal range in healthy children has been
established (Tei et al. 1996; Ishii et al. 2000).
As with prior studies, raised cardiac troponin levels (cTnT) were found
commonly in children with RSV infection — present study 41% of cases;
Checchiaet al. 54.5% (Checchia et al. 2000); Moynihan et al. 40% (Moynihan
et al. 2003); Eisenhut et al. 35% (Eisenhut et al. 2004). In an earlier study in
our PICU, cardiovascular function appeared to be transiently impaired in
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children with elevated cTnT on admission as reflected by a low blood pressure
at that time (Eisenhut et al. 2004). Echocardiographic assessment ofleft
ventricular function found no evidence of reduction in myocardial contractility,
but right ventricular function was not specifically assessed (Eisenhut et al.
2004). In this study, despite raised cardiac troponin levels, any global orleft
ventricular dysfunction clinically or on echocardiography could not be
demonstrated. Contrary to the primary hypothesis, raised cardiac troponin /
myocardial damage wasnot related to right ventricular dysfunction. A feature
further dispelling the hypothesis was the finding of a normal cTnT level in a
child with severe right ventricular dysfunction according to the categorisation of
Eidenet al (Eiden et al. 1998).
The original hypothesis was further eroded by the finding that transaminase
levels were not higher in patients with right ventricular dysfunction. It does not
support the concept of right ventricular strain resulting in hepatic venous
congestion leading to elevated transaminase levels in ventilated infants with
RSV bronchiolitis. It is conceivable that children with RSV bronchiolitis and
congenital heart disease, excluded from this study, may have more severe and
chronic right ventricular failure leading to transaminase level elevation from
hepatic venous congestion and ischaemic hepatitis (Eisenhut and Thorburn
2002). The inflammatory response to RSV reflected in CRP levels was not
more marked in patients with right ventricular dysfunction. Potentially cardio-
depressant inflammatory markers (e.g. tumour necrosis factor, interleukin-6,
etc.) were not measured and future studies are required to assess their
correlation with right ventricular dysfunction in children with RSV bronchiolitis.
Echocardiographic determination of pulmonary artery pressures in a normal
heart is usually reliant on tricuspid regurgitation to generate Doppler-derived
measurements to compare to systemic arterial pressure. Tricuspid
regurgitation was not a commonfinding in our study population and therefore
other indirect measurements of pulmonary artery pressure (e.g. left ventricular
andleft atrial dimensions) wereutilized. Left ventricular and atrial dimensions,
which are reduced in significant pulmonary hypertension (Patel et al. 1980)
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were not different comparing patients with and without right ventricular
dysfunction in the reported study. Additionally, there was no evidence of
volume overload, which causes a reduction of left ventricular ejection fraction
(EF) (Patel et al. 1980), as fractional shortening was notdifferent in patients
with and without right ventricular dysfunction. Tei index has been shown to
reflect right ventricular failure in adult patients with primary pulmonary
hypertension (Tei et al. 1996; Yeo et al. 1998). In children with an atrioseptal
defect (ASD) without pulmonary hypertension, the Tei index was normal(Ishii
et al. 2000). Despite suspicions, significant pulmonary hypertension, which
has been associated with severe RSV bronchiolitis in previous studies
(Sreeram, Watson and Hunter 1990; Fitzgerald et al. 2001), could not be
clearly demonstrate as a cause of right ventricular dysfunction. Without
tricuspid regurgitation, all that can be reported with any confidenceis that the
pulmonary artery pressures were not systemic or suprasystemic, but not
whether the pulmonary artery pressures were higher than normal.
Although right ventricular dysfunction has been clearly demonstrated in the
study group, the causefor the right ventricular dysfunction is less forthcoming.
| suspect that the small sample size, especially in the group with an elevated
Tei index, has limited the ability to expose trends or aetiology in this patient
group. Ventilation with a high positive end expiratory pressure strategy has
previously been associated with right ventricular strain (Dhainaut and Brunet
1990), but that was not a concerted approachin this study group and therefore
unlikely to have differentiated the two subgroups. Even though right
ventricular preload can be influenced by the degree of lung expansion or
overinflation, this was not different in the two groups as reflected by similar
ventilation and oxygenation indices. A limitation of this study is the lack of a
comparative non-RSV infected group to help differentiate whether it is RSV
itself that causes right ventricular impairment. The immunological process
triggered by the cellular immune response against RSV may causecollateral
immune-mediated damage to myocardial tissue and hepatocytes (Eisenhut
2006). Direct invasion of the myocardium and liver has been identified and
may cause myocarditis or hepatitis (Eisenhut 2006). Howevera raised cardiac
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troponin would be expected with RSV myocarditis. RSV-induced hepatitis as a
possible cause for raised transaminases wasinvestigated in previous studies
in which no other known hepatitis viruses or respiratory viruses known to
cause hepatitis was found in a similar patient group (Eisenhut and Thorburn
2002; Eisenhut, Thorburn and Ahmed 2004). liver biopsy looking for hepatic
RSV infection would makeor disprove such a diagnosis, but is inappropriate
on ethical grounds. Future larger studies need to corroborate the findings of
this study particularly with simultaneous measurement of pulmonary artery
pressures to verify whether pulmonary artery hypertension impacted on right
ventricular function / dysfunction. Once causative factors of reduced right
ventricular function are identified the next step would be to assess the
influence of these factors in infants with congenital heart disease infected with
RSV, as this subgroup have increased morbidity and mortality from severe
RSV disease (Howard et al. 2000; Holmanet al. 2003; Panickar et al. 2005).
5.5 Conclusions
Right ventricular dysfunction is not uncommonin severe RSV disease, but the
degree of dysfunction is not related to the levels of respiratory support or
biochemical markers of inflammation.
Myocardial and hepatocellular damage occurs in infants ventilated with RSV
bronchiolitis with normalright and left ventricular function.
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6 Pulmonary bacterial co-infection in
children with severe RSV bronchiolitis.
6.1 Introduction
Respiratory syncytial virus (RSV) is the most important viral cause for lower
respiratory infection in infants and young children throughout the world
(Howard et al. 2000). It is one of the commonest causes of respiratory tract
infection leading to respiratory failure. It has been estimated that in each year
600,000 deaths occur world-wide that are directly or indirectly attributable to
RSV (Howard et al 2000). Factors that increase susceptibility to the virus
include chronological age less than 6 weeks, bronchopulmonary dysplasia,
congenital heart disease, prematurity, and immunodeficiency (MacDonald et
al. 1982; Navas et al. 1992; Langley et al. 1997a; Buckingham et al. 2001).
Although the mortality rate for those hospitalized may be as low as 1 — 3%, the
mortality rate increases in those with severe bronchiolitis requiring intensive
care management . (MacDonald et al. 1982; Navas et al. 1992; Langleyetal.
1997at+b; Buckingham et al. 2001; Thorburn et al. 2004). In developed
countries about 2% of infants and children admitted to hospital with RSV
require assisted ventilation (Behrendt et al. 1998). RSV bronchiolitis is a
commoncause for admission to a PICU in the winter season (Behrendtetal
1998; Buckingham et al. 2001; Thorburn et al. 2004).
The pharmacological management of RSV bronchiolitis, other than the use of
supplementary oxygen, has long been debated (Simoes 1999; Harrisonetal.
2001). In particular, many advocate against the routine use of antibiotics in
bronchiolitis on account of a reported low incidence of concurrent or secondary
bacterial infections in RSV patients (Friis et al. 1984; Hall et al. 1988; Korppi et
al. 1989: Todd 1990; Kuppermannet al. 1997; Purcell and Fergie 2002; Titus
and Wright 2003; Bloomfield et al. 2004; Levine et al. 2004). However, these
studies focused on extrapulmonary bacterial co-infection and included only
limited numbers of children with severe respiratory compromise/failure.
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Physiologically the lower airways are normally sterile. Nevertheless, the
relationship of bacterial co-infection with viral respiratory disease has been
recognised previously, with an escalating incidence with increasing severity of
respiratory illness (Hament et al. 1999). Three retrospective studies
investigated the occurrence of bacterial co-infection in children with severe
RSV infection requiring PICU admission and found the incidence of pulmonary
bacterial co-infection to vary between 17.5% - 44% (Duttweiler, Nadal and Frey
2004; Randolph, Reder and Englund 2004; Kneyberet al. 2005).
In this study the incidence of pulmonary bacterial co-infection using
established quantitative microbiology (American Thoracic Society 2005) in
patients with severe RSV bronchiolitis on admission to a tertiary PICU was
prospectively investigated and the impact of the bacterial co-infection on
morbidity and mortality evaluated.
6.2 Patients and Methods
6.2.1 Setting:
20-bed regional multidisciplinary tertiary paediatric intensive care unit (PICU)in
university-affiliated children’s hospital.
6.2.2 Objectives:
1. To determine the incidence of pulmonary bacterial co-infection in
patients requiring PICU for severe RSV bronchiolitis.
2. To study the impact of the co-infection on morbidity, including length of
ventilation and inflammation, and mortality.
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6.2.3 Patients:
All children with severe RSV bronchiolitis, confirmed on RSV antigen testing
and/or culture, requiring PICU and on whom lower airway secretions were
obtained on admission were studied prospectively during 3 consecutive RSV
seasons (winter seasons) between 2002 and 2005.
The Liverpool Children’s Research Ethics Committee waived the need for
formal ethical approval as the studyfell into the realms ofclinical audit.
Exclusion criteria: Nosocomial cases of RSV infection in the PICU.
6.2.4 Respiratory support:
Intubation was performed by our PICU retrieval team at the referring hospital,
in our accident & emergency (A&E) department, or in one of the hospital wards
prior to PICU admission. Alternatively, the anaesthetic team of the referring
hospital intubated some of the patients preceding the arrival of our PICU
retrieval team. It is policy that all children who require intensive care and
ventilatory support are movedto the regional PICU.
The timing of extubation was judged clinically and not influenced by bronco-
alveolar lavage (BAL) results.
6.2.5 Microbiologic sampling:
Diagnostic samples of nasopharyngealaspirates (for RSV detection) and lower
airway secretions (for bacterial culture) through endotrachealtube using sterile
precautions (de Blic et al. 2000) were taken on admission and processed
immediately in the laboratory. Prior to routine bronchial toilet a sterile suction
catheter was passed down the endotracheal tube. Two 1ml/kg aliquots of
sterile 0.9% saline were instilled through the suction catheter, immediately
followed by aspiration with constant pressure into a mucus trap. Samples
were collected by specialist respiratory physiotherapists or PICU staff
members. BAL was performed immediately after endotracheal intubation in
children intubated in our hospital and onarrival in the PICU - generally within
three hours of endotracheal intubation for those retrieved from other hospitals.
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All children within the region are only ventilated in the regional PICU, so are
rapidly transferred to the PICU.
Surveillance samples of throat and rectum were obtained on admission and
then twice weekly, in keeping with the routine surveillance practice in our unit.
6.2.6 Measurements:
6.2.6.1 Virology:
Nasopharyngeal aspirates were tested by the Directigen™ RSV test [Becton
Dickinson microbiology systems, Maryland, USA]. This is an in vitro enzyme
immunoassay [ELISA] membranetest for the rapid and qualitative detection of
RSV antigen directly from nasopharyngeal specimens.All samples negative for
RSV using the ELISA membranetest were cultured using standard virological
techniques at the Public Health Laboratory. See 2.3.2.1 for further details.
6.2.6.2 Bacterial/Yeast
Diagnostic or clinical samples were processed immediately in a qualitative and
semi-quantitative way using standard microbiological methods.Forall types of
samples, macroscopically distinct colonies were isolated in pure culture.
Broncho-alveolar lavages were centrifuged at 1200xg for 10 minutes. All but
0.5ml of the supernatant was removed and the centrifuged deposit re-
suspended in the remaining fluid. A sterile calibrated loop was used to plate
out 0.01ml of the BAL sample. Thereafter the agar plates were incubated.
Less than 10 colonies on the agar plate equated to <10° CFU/ml; between 10-
100 colonies equated to 10°-10* CFU/ml; >100 colonies to >10* CFU/ml; and
>1000 colonies to > 10° CFU/ml of BAL. Chocolate, MacConkey, mannitol
salt, and blood agars were usedfor bacterial isolation; and Sabuoraud agarfor
fungalisolation.
Standard methodsforidentification, typing, and sensitivity patterns were used
for all micro-organisms (Brook 1979, Baselski and Wunderlink 1994, Standards
Unit HPA UK 2009).
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6.2.6.3 Chestradiology
Chest Xray appearance was not utilized to diagnose bacterial co-infection as
chest Xray changes are not pathognomonic of secondary bacterial or viral
infections (Friis et al 1990; Hamentet al. 1999).
6.2.7 Antibiotic policies
Patients with signs of infection received intravenous cefotaxime (150
mg/kg/day 4 times daily for up to 7 days) asfirst line therapy for 48 hours
whilst awaiting culture results. Clinical status on presentation governed
whether supplementary intravenous cover with an aminoglycoside, gentamicin
(7.5 mg/kg/day 3 times daily for up to 7 days) was added. Antibiotics were
rationalized once culture and sensitivity results becameavailable.
6.2.8 Definitions:
Bacteria positive - The presence of micro-organisms in the lower airways
which is normally sterile.
Co-infection - Infection is a microbiologically proven, clinical diagnosis of
inflammation, local and/or generalized. In this study clinical signs were
unreliable as all patients had bronchiolitis, so microbiological definitions were
utilized. Bacterial co-infection required bacteria colony counts >10° CFU/mlof
diagnostic sample for each single species obtained from lower airway
secretions and, on a semi-quantitative scale of + = few (<50 X 10°/L), ++ =
moderate (>100 X 10°/L) and +++ = many leucocytes (>1000 X 10°/L), the
presence of at least a moderate [++] number of leucocytes (A’Court etal.
1993; Sarginson et al. 2001; van Saene, Damjanovic and Alcock 2001).
Low bacterial growth - Diagnostic samples from lower airway secretions
which yielded <10° CFU/mlof diagnostic sample and only a few [+] leucocytes.
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6.2.9 Analytic Methods:
Data were collected prospectively. Prediction of mortality using paediatric
index of mortality (PIM) was obtained on the patient’s first contact with the
PICU team (Shann et al 1997). Results were expressed as a percentage of
the total study population; median and inter-quartile ranges (IQR) were used to
describe the demographic distributions.
Continuous data was analyzed using the Wilcoxon-Mann-Whitney (W-M-VW)
test. Categorical data was analyzed using Fisher’s exact or McNemar’stest.
Correlation was assessed using Spearman’s rank test (two-tailed).
Multivariate analysis was performed using linear and logistic regression
analysis.
Statistical calculations were performed with the Statistical Program for Social
Science release 11.0.0 (SPSS 11, Chicago, IL). A p value < 0.05 was
consideredstatistically significant.
6.3 Results
A total of 181 children were admitted to the PICU with RSV positive
bronchiolitis during the three consecutive RSV seasons (2002 — 2005). The
indication for PICU admission for these children was ventilatory/respiratory
support (respiratory failure (172) and/or life-threatening apnoeas (9)). All
patients were mechanically ventilated for a median of 5.0 days [IQR 3.0 — 7.3].
Median age was 1.6 months[IQR 0.5 — 4.6]. 103 were boys and 78 girls. 165
children were enrolled in the study — an admission bronco-alveolar lavage
(BAL) sample wasnotavailable in 16 patients (8.8%).
Table 6.1 shows the demographics, inflammatory marker values, antibiotic
history and mortality of the RSV-positive critically ill children in the subgroups:
RSVonly, bacterial co-infection, low bacterial growth and bacteria positive (co-
infection + low bacterial growth). Admission white cell count, neutrophil count
and CRP did not differentiate between the groups, and neither did these
indices during PICU days 1 — 5.
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Although all patients were admitted primarily for respiratory disease, 43%
(71/165) of them had other co-morbidities — congenital heart disease 37,
chronic lung disease 8, immunodeficiencies 4, abnormality of large airways 5,
congenital heart disease and abnormality of large airways 8, congenital heart
disease and chronic lung disease 4, neuromuscular disease 7. Co-morbidity
did not increase the risk of positive bacterial cultures (odds ratio = 0.77, 95%
Cl 0.55 to 1.09).
Overall 45% (74/165) received antibiotics prior to PICU admission(i.e. started
by the referring hospital or ward), most often cefotaxime or ceftriaxone. The
breakdown between the subgroups is shown in Table 6.1. Receipt of
antibiotics prior to PICU admission did not affect PIM (W-M-W test p = 0.6) and
LOV (W-M-W test p = 0.2). All patients, bar eight, were continued or
commencedonantibiotics in the PICU — usually cefotaxime. Antibiotics were
continued for a median of 5 days [IQR: 3 — 6 days]. The empiric use of
antibiotics was at the discretion of the attending consultant. Gender, age
groups, PIM, co-morbidity, receipt of prior antibiotics, time on antibiotics prior
to intubation, admission oxygen and ventilation index were not predictive of
positive bacterial cultures by uni- or multivariate analysis (all p-values > 0.16).
The organisms that were isolated from lower airway secretions obtained on
admission are shownin Table 6.2.
All those with positive endotracheal bacteriology, had the same organisms
isolated on admission surveillance swabs. Community organisms accounted
for 83% (81/98) of the bacteria cultured.
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Table 6.1: Patient characteristics according to broncho-alveolar culture result
— median[interquartile range].
 
 
 
      
RSV only Bacterial Low bacterial Bacteria
co-infection growth positive(> 10° CFU/ml) (< 10° CFU/ml) (Co-infection + low
bacterial growth)
Number(total 165) and 95 36 34 70
percentageof total number 57.6% 21.8% 20.6% 42.4%
Origin 48/29/18 11/17/8 14/11/9 25/28/17
(Retrieved/intra-hospital/A&E)
Age (months) 1.4 1.3 3.5 1.8
[0.4 — 3.9] [0.7 -— 2.5] [1.2 - 10] [0.9 - 4.6]p = 0.8" p=0.04" p=0.9%
Paediatric Index of Mortality (PIM) 0.08 0.09 0.08 0.08
[0.03 — 0.12] [0.04 — 0.14] [0.06 — 0.12] [0.05 — 0.13]p =0.6* p=0.5' p=0.6"
Length ofventilation (days) 4 6 6 6
[3 - 7] [4-8] [5 — 9] [4 - 8]p <0.01* p<o.o1t p< 0.017
Admission OxygenIndex (Ol) 8 6 9 7
in the PICU [5 -— 12] [4 - 9] [6 — 12] [4-11]p =0.2* p=0.6' p=0.7*
Admission Ventilation Index (VI) 26 27 26 27
in the PICU [18 — 39] [16 — 44] [20 — 32] [19 — 39]p= 0.9* p=o.2t p= 0.8"
White Cell Count (X 10° cells/!) 9.8 10.6 11.5 11.3
on PICU admission [7.2 — 13.7] [7.1 — 13.5] [6.9 — 14.7] [7.1 — 13.8]pass p=o0.6' p= 0.4"
Neutrophil count (X 10° cells/I) 5.2 7.1 5.8 6.2
on PICU admission [2.9 — 7.6] [3.9 — 10.3] [3 — 10.3] [3.6 — 10.3]p=0.1" p=0.9' p=0.2"
C-reactive protein / CRP (mg/l) 14 14 21 18
on PICU admission [4 — 45] [5 — 52] [4 — 46] [4 — 49]p =0.9* p=o.9" 0.9*
Antibiotics prior to PICU 48% 36% 44% 40%admission p = 0.08*
Time on prior antibiotics (days) 1 1 1 1
[1-2] [1 — 3] [1 - 3] [1 - 3]Mortality: 8 2 2 4
(RSV-related deaths) (3) (1) (1) (2)
Percentage with co-morbidities® 40% 61% 41% 51% ;
p=0.6
CFU/ml= colony forming units of a single bacterial species per ml of diagnostic sample
Retrieved
Intra-hospital
= patients retrieved from other hospitals
= patients admitted from wards with our hospital
A&E = patients admitted directly from the Accident & Emergency department
*RSV-only vs. Bacterial co-infection * RSV-only vs. Low bacteria growth
+ RSV-onlyvs. All those positive for bacteria (bacterial co-infection + low bacteria growth)
Wilcoxon-Mann-Whitney test used, exceptfor prior antibiotics and co-morbidities - McNemar’stest.
§ Co-morbidities = congenital heart, chronic lung disease, abnormality of large airways,
immunodeficiencies, neuromuscular disease
Ol = mean airways pressure (MAP)x FiO2/PaO2
VI = respiratory rate x PaCOz x peak inspiratory pressure / 1000
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Table 6.2: The 98 bacterial isolates obtained on admission to PICU from the
lowerairwayin 70 children with severe RSV bronchiolitis.
 
 
Co-infection Low bacterial growth
(> 10° CFU/ml) (< 10° CFU/ml)
Community organisms~*””
H. influenzae 17 11
S. aureus 10 12
M. catarrhalis 8 10
S. pneumoniae 6 6
S. pyogenes 1
Abnormal organisms**”° 1
P. aeruginosa 2
B. pertussis
K. pneumoniae
E. coli
E. cloacae and C. freundii =
fC
O
O
C
O
S
R
K
—_
—
P. mirabilis
S. agalactiae
N. meningitidis
MRSA     
23 patients had multiple organisms (18 had two, 5 had three bacteria) - Community organisms
were involved in 91% of these cases, compared to 77% ofsingle isolates. (Fisher's exact p = 0.2)
167% (10/15) had chronic illnesses
There were twelve deaths (6.6%), of which 5 appeared to be RSV-related
(2.8%) as the patients were still RSV positive when they died. Two were
oncology patients (leukaemics on chemotherapy) that died from RSV
pneumonitis on day 1 and 16 respectively. Neither had proven bacterial co-
infection and both received broad spectrum empiric antibiotic therapy.
Other associated causes included singles cases of: hypoplastic right heart
coupled with cystic fibrosis (on day 8), Bordetella pertussis co-infection with
hypoxaemic respiratory failure requiring extracorporeal membrane oxygenation
(ECMO)(on day 26), and a child with a congenital myopathy (on day 8). The
remaining 7 deaths occurred 6 — 31 days after admission subsequent to the
RSV cultures becoming negative. Causes of these RSV ‘un-related’ deaths
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included: complex congenital heart disease 3, multiple congenital anomalies 2,
congenital myopathy1, anoxic brain injury 1.
Positive bacterial cultures did not predict death (odds ratio = 1.3, 95% Cl 0.57
to 2.95), but co-morbidity did (odds ratio = 0.51, 95% Cl 0.37 to 0.7).
6.4 Discussion
This observational study over 3 consecutive RSV seasons evaluating bacterial
pulmonary co-infection found that 42% of children admitted for severe RSV
infection harboured bacterial pathogensin their lower airways. Thesecritically
ill children run a serious risk of developing bacterial pneumonia (Hamentetal.
1999; Liberati et al. 2004; Liberati et al. 2006).
BAL samples were collected very soon after intubation so significant growth
densities of bacteria reflect pathogens in the normally sterile lower airways.
The high number of colony forming units makes it highly unlikely that the
micro-organisms isolated were ‘pushed down’ the trachea onintubation. It is
acknowledged that the number of leukocytes in lower airways secretions will
also be influenced by RSV infection and therefore bacterial growth was
primarily utilised. The microbiological criteria were strict and avoided
potentially confounding clinical factors. This microbiological approach is
supported by recent literature concerning ventilator-associated pneumonia
(VAP) (Gauvin et al. 2002; Gauvin et al. 2003). On the other hand, it must be
appreciated that the study group was very different from this VAP group, as
they had ‘virgin’, iatrogenically uncontaminated lower airways. Certainly the
group defined as co-infection had substantial bacterial growth densities far too
soon after intubation to have been oropharyngealflora transported there by the
endotracheal tube. If anything, the strict microbiological criteria probably
underestimated the number co-infected by categorizing many of them as low
bacterial growth. It should be appreciated that differentiating the groups into
co-infected and low bacterial growth may be somewhatartificial as the lower
respiratory tract should be free from bacteria.
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The term “co-infection” was used, as, at the time of PICU admission, these
infections could either be secondary or concurrent. It would not be easy to
detect the ‘chicken’ from the ‘egg’ as far as which wasprimary, the RSV or the
bacteria, although a viral infection destroying cilia is in general required for a
bacterial co-infection (Hamentet al. 1999). The true co-infection rate is likely
to be higher than the 22% rate detected, as 45% of the cases received
antibiotics prior to PICU admission. These antecedent antibiotics may have
converted some of the “co-infection” patients into the “low bacterial growth”
group,or even prevented bacterial growth altogether.
Previous studies have looked at bloodstream, otitis media or urinary tract
infections in children with bronchiolitis, very few of whom had severe RSV
bronchiolitis requiring intensive care (Friis et al. 1984; Hall et al. 1988; Korppi
et al. 1989; Todd 1990; Kuppermannet al. 1997; Purcell and Fergie 2002;
Titus and Wright 2003; Bloomfield et al 2004). These studies generally found
a very low incidence of secondary serious bacterial infection (1.2%) (Hall et al.
1988) or bacteraemia (0.6%) (Bloomfield et al. 2004) in their hospitalized RSV
patients. Because these studies did not specifically concentrate on those with
severe bronchiolitis, it is difficult to extrapolate their results to this population.
Duttweiler et al retrospectively studied 127 infants admitted to intensive care
for RSV bronchiolitis and found that 25 (44%) of the 57 ventilated and
endotracheally sampled infants had “concomitant bacteria pneumonia”
(Duttweiler, Nadal and Frey 2004). Similarly, the retrospective study of
Kneyber et al (82 PICU admissions with 65 or 79% ventilated) found that 9
(33%) of the 24 children on whom admission endotracheal aspirates were
performed had positive bacterial culture (Kneyber et al. 2005). Randolph et
al retrospectively examined 165 previously healthy infants admitted to the
intensive care unit over a 12-year period with laboratory-confirmed RSV
infection (63 or 38% required mechanical ventilation). They found that 17.5%
— 38% of the 63 intubated infants had “probable” or “possible” bacterial
pneumonia (Randolph, Reder and Englund 2004). The incidence of bacterial
-80-
pulmonary infection in these retrospective PICU reports is in keeping with that
of this prospective study in whichall bronchiolitic admissions wereincluded.
Fifty-one percent of the patients with bacteria in their airways and 40% of the
RSV-only children had co-morbidities - congenital heart disease, chronic lung
disease, large airway abnormality, immunodeficiency, neuromuscular disease.
This is in keeping with well-recognised risk factors associated with more
severe RSV disease (MacDonald et al. 1982; Langley et al. 1997; Hall 2001;
Bloomfield et al. 2004; Thorburn et al. 2004). Co-morbidities did not account
for differences in length of ventilation amongst the study groups, but did
contribute towards mortality. The high percentage with co-morbidities is most
probably also influenced by our centre being the regional paediatric cardiac
referral centre, thereby resulting in children with congenital heart disease and
bronchiolitis being more likely to be referred to our PICU for intensive care
management.
There were fewer deaths in the bacteria-positive group than in those with RSV
only. However, whenadjusted for those children who had recovered from their
RSV infection only to demise later from RSV-unrelated causes, both groups
had similar mortalities (2.9% vs. 3.2%). Paediatric Index of Mortality (PIM) is a
pointof first contact score that is used to assess the risk of death while in the
PICU (Shann et al. 1997). The PIM scores for all the groups were similar,
suggesting that all groups had matching severity of illness on admission to the
PICU. Yet those with positive bacterial cultures required ventilatory support for
longer than those with RSV only. Kneyberet al found likewise (Kneyberetal.
2005). Although length of ventilation was significantly different between the
groups,other respiratory support and inflammation indices did not differentiate
between them (Table 6.1). Perhaps the general inflammatory response once
triggered by RSV is not so refined as to be further enhanced by concomitant
bacterial infection. Others have also found inflammatory markers unhelpful in
differentiating bacterial infection in this group of patients (Toikka et al. 2000;
Resch, Gusenleitner and Muller 2003; Kneyber et al 2005). Unfortunately, in
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this study no early clinical measurements which would identify those RSV
patients with bacterial co-infection could be identified.
Receipt of and length of time onprior antibiotics did not predispose to bacterial
co-infection. Moreover, many of the RSV children had had only a dayorless
(often a single doseclose to intubation) of antibiotics. The fact that nearly all
the RSV positive children received antibiotics in our PICU limited any
interpretation on the impact of antibiotics on their outcome. All those patients
with positive bacteriology in their endotracheal secretions had the same
organisms isolated on admission surveillance swabs, indicating primary
endogenous infection (van Saene, Stoutenbeek and Torres 1992). This
reinforces the pathogenesis of lower airways infections in that potential
pathogens are carried first in the nasopharynx and then there is migration
down the trachea into the lower airways (van Uffelen, van Saene and
Lowenberg 1984: van Saene, Stoutenbeek and Torres 1992). The organisms
isolated on admission were generally normal community organisms because
the majority of the patients were in good health prior to RSV infection and
PICU admission (A’Court et al. 1993; Friis et al. 1990). In contrast,
Pseudomonas aeruginosa was the most common of the abnormal bacteria
(Table 6.2). All these patients were carriers of abnormal organismsin their
throats, and in most the common denominatorfor their abnormal carriage was
chronicillness (Gilman et al. 1982; van Saene, Stoutenbeek and Torres 1992).
Interestingly, Streptococcus pneumoniae was isolated from relatively few
patients. This could be the result of prior antibiotic use (Sirvent et al. 1997).
Although the majority of LRTI in children are viral in aetiology, mixed viral-
bacterial infections are seen in up to a quarter of hospitalized children (Korppi
2003; Michelow et al. 2004). Additionally there is the risk of developing
bacterial superinfection with viral LTRI (Hament et al. 1999). These issues
have played a role in the World Health Organization’s recommendations for
the treatment of community-acquired pneumonia to include empirical
antibiotics (Korppi 2003; World Health Organisation 2005). Concerns that
using antibiotics (in our PICU’s case cefotaxime) pre-emptively in this group of
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critically ill children would breed antibiotic resistance have been shown to be
unfoundedin a four-year study (Sarginson et al. 2004). The assessmentof the
influence of antibiotics on children with severe bronchiolitis would require a
prospective randomized controltrial.
6.5 Conclusions
Up to 40% of patients admitted with severe RSV bronchiolitis were infected
with bacteria in their lower airways.
Co-morbidity, namely congenital heart disease, chronic lung disease, large
airway abnormality, immunodeficiency, neuromuscular disease, predispose to
more severe RSV disease.
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7 Mortality rate in children admitted to
PICU with RSV infection.
7.1. Introduction
World-wide each year 600,000 deaths occur that are directly or indirectly
attributable to respiratory syncytial virus (RSV) (Howard et al. 2000). It has
been estimated that in children under one year of age nearly 50 deaths per
year in the UK (Fleming, Pannell and Cross 2005) and over 200 deathsin the
USA (Thompsonetal. 2003) are attributable to RSV. RSV has been found to
be the most commonviral cause of death in children below 5 years of age and
especially those less than 1 year old (Thompsonet al. 2003). The estimated
paediatric all-cause RSV mortality rates were 8.4 (UK) and 5.4 (USA) per 100
000 population in the less than one year old age group, and decreased
substantially with increasing age (Thompsonet al. 2003; Fleming, Pannell and
Cross 2005). However, whenrestricted to respiratory causes only the UK rate
fell to 2.9 deaths per 100 000 population in the less than one year old age
group (Fleming, Pannell and Cross 2005). Epidemiological studies have
demonstrated that the bronchiolitis-related mortality rate has remained low and
stable in the USA, and has declined in the UK over the past two decades
(Holmanet al. 2003; Panickar et al. 2005).
It is recognised that a considerable proportion of children who die from
bronchiolitis have serious underlying conditions / co-morbidity, such as cardiac
and central nervous system anomalies, chromosomal abnormalities and
immunodeficiencies (Holman et al. 2003; Panickar et al. 2005). However,
these pre-existing conditions are often not effectively identified as contributing
factors in epidemiological studies which rely on national statistics coding (Shay
et al. 1999; Shay et al. 2001; Holman et al. 2003; Thompson etal. 2003;
Fleming, Pannell and Cross 2005; Panickaret al. 2005; Jansen et al. 2007).
The reported mortality rate for those hospitalised may be as low as 1 — 3%, but
the mortality rate increases in those with severe bronchiolitis requiring
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intensive care management (MacDonald et al. 1982; Navas et al. 1992;
Langley et al. 1997; Thorburn et al. 2004).
In order to determine the mortality rate and risk factors for death in children
with severe RSV infection, a study of all children admitted for paediatric
intensive care over an eight year period (i.e. 8 RSV seasons) was performed.
7.2 Patients ans Methods
7.2.1 Setting:
20-bed regional multidisciplinary tertiary paediatric intensive care unit (PICU)in
university-affiliated children’s hospital.
7.2.2 Objectives:
1. To determine the mortality rate in children with severe RSVinfection.
2. To determine the risk factors for death in children with severe RSV
infection.
7.2.3 Patients:
All children with RSV bronchiolitis, confirmed on RSV antigen testing,
immunofluorescence and/or culture that required PICU admission between
June 1999 and May 2007(i.e. encompassing eight consecutive RSV seasons
— October to March) werestudied.
The data were collected prospectively during the last six RSV / winter seasons
(October 2001 onwards) andretrospectively for the first two seasons. PICU
admission wasutilised as the marker of severity of disease. The study was
approved by the Royal Liverpool Children’s Hospital’s Clinical Audit
Department - a subgroup of the Research and Clinical Development
Directorate.
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7.2.4 Respiratory support:
It is national policy that all children who require intensive care and mechanical
respiratory support are transferred to the regional PICU. Al forms of
mechanical ventilation (conventional and high frequency) and continuous
positive airways pressure (CPAP) support are carried out on the PICU. Muscle
relaxants are not routinely used. Non-invasive CPAP support is usually
performed on our 14-bed high dependency unit (HDU) which is separate from
the PICU. More recently some of the regional secondary-level hospitals have
been performing non-invasive CPAP support within their paediatric
HDU/wards.
Children requiring extracorporeal life support (ECLS) / extracorporeal
membrane oxygenation (ECMO) are transferred to one of four national
centres.
7.2.5 Microbiologic sampling:
Diagnostic samples of nasopharyngeal aspirates (for RSV detection) and lower
airway secretions (for bacterial culture and viral detection) were taken on
admission to PICU and thereafter when clinically indicated. From January
2002 onwards RSVsurveillance samples were taken on all children during the
RSV season (October — March) on admission and twice a week while on PICU.
Samples were collected by specialist respiratory physiotherapists or PICU staff
members. Additionally see 2.3.1.
7.2.6 Measurements:
7.2.6.1 Virology:
Nasopharyngeal aspirates were tested by the Directigen™ RSV test [Becton
Dickinson microbiology systems, Maryland, USA] (1999 — 2004) or NOW™
RSV test [Binax Inc., Maine, USA] (2005 — 2009). These are in vitro
immunochromatographic assays for the rapid and qualitative detection of RSV
antigen directly from nasopharyngeal specimens. Additionally see 2.3.2.1.
Samples negative for RSV using the rapid antigen tests were cultured using
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Rmix shell vial culture techniques at the Public Health Laboratory (Aintree,
Liverpool, UK).
Immunofluorescence for RSV was performed using SimulFluor™ reagents
(Chemicon/Millipore, Massachusetts, USA) at the Public Health Laboratory.
7.2.6.2 Bacterial/Yeast:
Diagnostic or clinical samples were processed immediately in a qualitative and
semi-quantitative way using standard microbiological methods. Standard
methods for identification, typing, and sensitivity patterns were used for all
micro-organisms (Brook 1979). Additionally see 2.3.2.2.
7.2.7 Antimicrobial policy:
The empiric use of antibiotics in children with severe bronchiolitis was at the
discretion of the attending consultant. Patients with signs of infection received
intravenous cefotaxime (50 mg/kg/dose 4 times daily) asfirst line therapy for
48 hours whilst awaiting culture results. Clinical status on presentation
governed whether supplementary intravenous cover with an aminoglycoside,
gentamicin (7 mg/kg/day - single daily dose) was added. Antibiotics were
rationalised or stopped onceculture and sensitivity results became available.
Ribavirin therapy is only considered in immunocompromisedchildren.
7.2.8 Definitions:
Nosocomial RSV infection — when a child admitted to the PICU was RSV
negative or from whom no samples were taken asthey did not exhibit signs of
bronchiolitis, and who then became RSVpositive five or more days after the
admission (Hall et al. 1978; Raymond and Aujard 2000; Thorburn et al. 2004).
RSV-attributable deaths — Deaths were considered directly attributable to
RSV if the patients were still RSV positive when they died or when the RSV
infection contributed to the adverse clinical course leading to death (Simonet
al. 2008; von Renesseetal. 2009).
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7.2.9 Analytic Methods:
Results were expressed as a percentageof the total study population; median
and inter-quartile ranges (IQR) were used to describe the demographic
distributions. Prediction of mortality using paediatric index of mortality (PIM)
was obtained onthe patient’s first contact with the PICU team (Shannetal.
1997). Standardised mortality ratio (SMR) is the ratio of actual deaths
compared to the numberpredicted (in this study derived from PIM score).
Continuous data were analysed using the Wilcoxon-Mann-Whitney (W-M-W)
test. Categorical data were analysed using Fisher’s exact or McNemar’stest.
Multivariate analysis was performed using linear and logistic regression
analysis.
Statistical calculations were performed with the Statistical Program for Social
Science release 11.0.0 (SPSS 11, Chicago, IL). A p value < 0.05 was
consideredstatistically significant. Relative Risk (RR) with 95% confidence
intervals (95% Cl) calculations was performed with Confidence Interval
Analysis software (CIA 2.1.2) from Statistics with Confidence, editors: DG
Altman, D Machin, TN Bryant, MJ Gardner; BMJ Books, London (2000).
7.3 Results
During the study period 406 RSV-positive patients were admitted to PICU.
The patient numbers and deaths for each RSV season are shown on Table
7.1. The causesof death of the 35 RSV-positive children that died are shown
in Table 7.2. Overall PICU RSV mortality was 8.6% with a standardised
mortality ratio (SMR) of 0.76. During the study period 2009 RSV-positive
patients were admitted to the children’s hospital, giving a hospital RSV
mortality rate of 1.7%. Of the deaths 18 were directly RSV-attributable as the
patients were still RSV positive when they died. The remaining 17 children
died from non-pneumonitis causes after becoming RSV negative on antigen
testing and viral culture, giving a PICU RSV-attributable mortality of 4.4% and
a hospital RSV-attributable mortality of 0.9%. RSV infection did not appear on
the death certificate in 13 of the 35 deaths (37%).
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Table 7.1: RSV-positive children admitted to PICU: 1999 — 2007.
 
RSV season Number Deaths (%)
1999 - 2000 28 1 (4%)
2000 - 2001 39 7 (18%)
2001 - 2002 54 8 (15%)
2002 - 2003 50 3 (6%)
2003 - 2004 94 9 (10%)
2004 - 2005 55 4 (7%)
2005 - 2006 37 3 (8%)
2006 - 2007 49 0 (0%)   
Table 7.2: Causes of Deaths in patients with severe RSV infection: (n = 35).
RSV Pneumonitis* 5
Acute RSVbronchiolitis worsening the underlying cardiac condition* 5
Acute Respiratory failure on a background of Chronic Lung Disease* 4
Died on Extracorporeallife support / ECMO* (CHD3; underlying lung disease 1) 4
Sepsis" 6
Withdrawal’ (multiple anomalies 2; severe complex CHD 1; severe myopathy 1) 5
Heart failure’ (complex CHD 2) 2
Cardiorespiratory Arrest’ (complex CHD + severe tracheomalacia 2) 2
Hypoxic Ischaemic Encephalopathy" 1
Chestinfection on underlying Chronic Lung Disease* 1  
* deaths while RSV positive
T later deaths once RSV negative
CHD = congenital heart disease
ECMO= extracorporeal membrane oxygenation
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Patient demographics of those admitted to PICU are shown in Table 7.3.
Mechanical ventilation was required in 96.5% of the children and non-invasive
respiratory support only in 3.5%. Clinical characteristics of in the children
admitted to PICU are shownin Table 7.4. Analysis of oxygen and ventilation
indices (Peters et al. 1998), even though measured, was not undertaken as
the high incidences of pre-existing cardiac anomalies and chronic lung disease
in both groups would confound interpretation. Pre-existing diseases
(chromosomal abnormalities, cardiac lesions, neuromuscular disorders,
chronic lung disease, large airway abnormality, immunodeficiency) was
present in 187 children (46%) on admission to PICU. Of these children with
pre-existing disease, 142 (76%) were admitted primarily for RSV disease and
the remainder were post-operative (cardiac and general surgery), neurology,
chronic respiratory, or sepsis.
Table 7.3: Patient demographics for children admitted to PICU with severe
RSVinfection: 1999 — 2007.
 
 
Deaths Survivors
(ni 35} (n = 374)
Median lQR Median IQR p-value*
Age
(months) 5.1 [2.4 - 13.6] 2.5 [1.2 - 9] < 0.05
Paediatric
Index of
Mortality’’ 0.13 [0.07 - 0.31] 0.09 [0.04 - 0.14] < 0.05
Length of
PICU stay(days) 16.5 [8 - 31] 5 [4-9] < 0.05
Days RSV
positive 7 [3 - 11] 3 [2 - 5] < 0.05
* Wilcoxon-Mann-Whitneytest
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All of the RSV deaths had pre-existing medical conditions / co-morbidity —
chromosomal abnormalities 29%, cardiac lesions 27%, neuromuscular 15%,
chronic lung disease 12%, large airway abnormality 9%, immunodeficiency
9%. Nineteen children (56%) had pre-existing disease in two or more organ
systems and carried a significantly higher risk of death (Table 7.4).
There was an interaction effect between pre-existing disease, nosocomial /
hospital-acquired RSV infection and mortality (McNemar’s test p < 0.001).
Children with pre-existing disease and nosocomial / acquired RSV infection
stayed in PICU longer (W-M-W test p < 0.001) and were older (p < 0.05). Pre-
existing disease and nosocomial / hospital-acquired RSV infection were
predictive of death by uni- and multivariate analysis (all p-values < 0.05), but
age, gender, previous prematurity, bacterial co-infection and inter-hospital
transfer did not add to their prognostic value. Children that died while RSV-
positive and those that died later once RSV-negative were similar in age, age
group, pre-existing disease (including cardiac and multiple organ system
involvement), gender, bacterial co-infection, previous prematurity and inter-
hospital transfer (Fisher's exact test all p-values > 0.3). However, the latter
group had a longer length of PICU stay - median [IQR]: 31 days [22 - 58] vs.
11 days [8 - 17] (W-M-W test p < 0.05).
Data onthe prior receipt of prophylactic monoclonal RSV antibody therapy has
not been reported as it was only introduced into clinical practice late in the
study period and therefore any impact would be difficult to ascertain at this
stage. Three children received ribavirin (all were immunocompromised
following chemotherapy). Surfactant therapy wasutilised in two children with
severe pneumonitis.
Five children received ECLS/ECMO,of which the four that died all had pre-
existing disease, but not the survivor. One child that died on ECLS/ECMO had
RSV andpertussis dualinfection.
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Table 7.4: Clinical characteristics in children admitted to PICU with severe
RSV infection: 1999 — 2007.
 
 
Deaths
(n = 35)
Pre-existing disease 100%
2 or more
pre-existing diseases 54%
Cardiac anomaly 68%
HPBFcardiac 65%
Nosocomialinfection 18%
Ex-Pretermer 9%
Under6 weeksold 17%
Under1 year of age 71%
Gender (male) 56%
Bacterial co-infection 24%
Inter-hospital transfer 32%
Survivors
(n = 371)
41%
12%
23%
64%
6%
19%
35%
78%
55%
36%
52%
RR
2.36
4.38
2.98
1.01
2.89
0.46
0.48
0.91
1.02
0.66
0.61
[95% Cl]
[2.02 - 2.76]
[2.92 - 6.58]
[2.16 - 4.12]
[0.71 — 1.44]
[1.26 - 6.6]
[0.15 - 1.39]
[0.23 - 1.02]
[0.72 - 1.13]
[0.75 - 1.4]
[0.35 - 1.24]
[0.37 - 1.01]
RR = Relative Risk (Death vs. Survival) 95% Cl = 95% ConfidenceIntervals
Pre-existing disease = chromosomal abnormalities, cardiac lesions, neuromuscular disorders,
chronic lung disease, large airway abnormality, immunodeficiency.
HPBFcardiac = cardiac lesions with high pulmonary blood flow (e.g. septal and atrioventricular
canaldefects)
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7.4 Discussion
This observational cohort study over 8 consecutive RSV seasons found that
only children that had pre-existing disease / co-morbidity died from severe
RSV infection, i.e. prior good health protected against death. PICU admission
wasutilised as a marker of severe RSV diseasein this study which differs from
many other studies that defined hospitalisation as reflecting severe RSV
disease (Navas et al. 1992; Langley et al. 1997; Howard et al. 2000;
Buckingham et al. 2001; Holman et al. 2003; Purcell and Fergie 2004). Having
focused on a higherrisk group than manyof the previous reports, this study
uniquely compared therisk factors in those that died with the survivors within
this subgroup with severe RSV disease.
Even thoughthis hospital-based data does not necessarily reflect incidencesin
the general community which are better reflected in epidemiological /
population-based studies, it does reflect risk factors pertinent to RSV infection
in the general paediatric population. The assessments and estimates from
epidemiological studies are derived from data obtained from diagnosis-based
coding categories retrieved from National Surveillance organizations (e.g.
Center for Disease Control and Prevention in USA and Health Protection
Agency in UK). They therefore suffer from the acknowledged limitation of
reliance on specific codes (e.g. for respiratory, circulation deaths) which may
not cover all RSV-associated pathologies (Shay et al. 1999; Shay et al. 2001;
Holmanet al. 2003; Thompsonet al. 2003; Fleming, Pannell and Cross 2005;
Panickaret al. 2005; Jansen et al. 2007). This would have been the case in a
number of the deaths in our study population as their deaths occurred after
becoming RSV negative and were not necessarily directly RSV-
related/attributable (Table 7.1). The detrimental role or destabilising effect that
the RSV infection played in the clinical course of these casesis difficult to
assess accurately as the cause of death wasoften extra-pulmonary. Certainly
death certificates did not report the recent RSV infection in nearly 40% of the
deaths and this failure would contribute to the RSV influence being missedin
epidemiological studies. This may have been a factor in the conclusions of
Shay et al. that the majority of RS\V-attributable deaths did not occurin
- 93 -
children at high risk for severe RSV disease which is contrary to our data
(Shay et al. 2001). Their USA study differed in that the study period was
earlier (1979 — 1997) and its epidemiological design relied on cause-specific
International Classification of Deaths 9" revision (ICD-9) codes on death
certificates. Nearly all the children in the present study that died had well-
recognised risk factors for severe RSV disease (MacDonald et al. 1982; Navas
et al. 1992; Langley et al. 1997; Handforth, Friedland and Sharland 2000;
Buckinghamet al. 2001; Purcell and Fergie 2004; Lopez et al. 2007).
In our institution RSV deaths in PICU reflect the total hospital deaths from RSV
asit is highly unlikely that any children with severe RSV disease would not be
admitted to PICU and more than 85% of hospital deaths occur in PICU. The
hospital RSV mortality rate is similar to other studies (Navas et al. 1992;
Langley et al. 1997; Handforth, Friedland and Sharland 2000; Buckingham et
al. 2001; Holman et al. 2003; Purcell and Fergie 2004; Smyth and Openshaw
2006), even taking into account that our children’s hospital is a regional referral
centre, thereby collecting cases with severeillness. Additionally, our centre is
the regional paediatric cardiac referral centre, resulting in children with
congenital heart disease and bronchiolitis being more likely to be referred to
our PICUfor intensive care management. It is therefore not surprising that one
third of deaths in this RSV patient group were in children that were retrieved /
transferred from other base hospitals. As found in other studies the numberof
deaths from RSV each yearvaried widely (Shay et al. 2001; Thompsonetal.
2003; Fleming, Pannell and Cross 2005). Typing of the RSV strain is not
performedin our institution, so we are unable to speculate as to whether the
strain influenced mortality overall or season on season.
The mostsignificant risk factor for death was pre-existing disease, of which a
cardiac anomaly held a particularly high risk. Interestingly, contrary to what
one might have presumed, cardiac lesions with high pulmonary blood flows
(e.g. endocardial cushion defects, ventriculoseptal defects, truncus arteriosus,
etc.) did not stand out from the rest as predisposing to mortality. Congenital
heart disease being a significant risk factor for severe disease and deathis in
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keeping with previous reports (MacDonald et al. 1982; Navas et al. 1992:
Handforth, Friedland and Sharland 2000; Buckingham et al. 2001; Holmanet
al. 2003; Panickar et al. 2005). [Earlier studies have identified previous
prematurity as a risk factor for hospital admission and death (Hall 1977; Navas
et al. 1992; Buckingham et al. 2001; Holman et al. 2003, Purcell and Fergie
2004; Lopez et al. 2007; Simon et al. 2007). Howeverin our study population,
when compared to the survivors with severe RSV disease, it was not an
additional risk factor for death. Perhaps in this patient group previous
prematurity predisposes to severe disease (morbidity), whereas other pre-
existing conditions govern mortality. Having said this, caution should be
exercised as the sample size may underpower the confidence of
interpretations. The pre-existing disease most probably has bearing on the
finding that, as a group, those that died were older and stayed in PICU longer.
Pre-existing disease may confoundthe relationship between nosocomial RSV
infection and death. Children with more complex underlying conditions stay in
hospital and on PICU longer and thereby have protracted exposureto potential
cross infection. This is borne out by the longer length of stay in the group of
RSV deaths with its high incidence of both pre-existing disease and
nosocomial RSV infection. Previous studies have described an increased
incidence of nosocomial RSV infection in children with congenital heart
disease, chronic lung disease and immunodeficiency (Hall, Douglas and
Geiman 1975; Hall et al. 1986; Buckingham et al. 2001; Purcell and Fergie
2004; Thorburn et al. 2004; Smyth and Openshaw 2006). It highlights not only
their vulnerability to nosocomial infection, but also its potential devastating
impact on these children. Perhaps this subgroupof patients should beisolated
(in a cubicle) and reverse barrier-nursed during the RSV season to minimise
nosocomialinfection, acknowledging that it may further stretch already strained
isolation spaces.
The prolonged days of RSV positivity in the group of RSV deaths may also
relate to the high incidence of pre-existing diseases. It has been recognised
that patients with underlying conditions may excrete virus / RSV for longer
- 95 -
periods (Hall et al. 1986; Hall 2001; Thorburn et al 2004). So,in addition to
susceptibility to nosocomial infection, once infected they constitute a prolonged
sourcefor potential cross infection within the unit. RSV prophylaxis (expensive
monoclonal antibody therapy) or an eagerly-awaited vaccine (still under
development) may offer some protection from RSVinfection in the community
for this vulnerable group of children with pre-existing disease.
7.5 Conclusions
Pre-existing disease / co-morbidity, in particular multiple pre-existing diseases
and cardiac anomaly,is associated with a significantly higher risk of death from
severe RSVinfection.
Nosocomial / hospital-acquired RSV infection is an additional majorrisk factor
for death in children with severe RSV infection.
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8 Nosocomial (acquired) RSV infection in
ventilated critically tll children — a ten
year perspective.
8.1 Introduction
Respiratory syncytial virus (RSV) infection of the lower respiratory tract is one
of the commonest causes of respiratory failure in children throughout the
world. Annually RSV-related hospitalisations account for 20 000 admissionsin
the UK, 26 000 in Germany, and 90 000 in the USA (Handforth, Friedland and
Sharland 2000; Deshpandeet al. 2003; Simon et al. 2008). RSV infection is
not innocuous with an estimated 600 000 deaths worldwide directly or
indirectly attributable to RSV each year (Howard et al. 2000).
RSV epidemics occur at predictable annualintervals during the winter months
in moderate climates (Hall 2001). During this time the hospital admissions for
RSVinfection are greatly increased and cross-infection (nosocomial infection)
of inpatients occur. RSV infection accounts for nearly 10% of all admissions
to paediatric intensive care units throughout the UK. During the winter patients
with RSV may constitute the largest patient group on PICU’s around the
country (O’Donnell and Darowski 2006). RSVis a highly contagious virus and
the mode of nosocomial spread is by close or direct contact with large droplets
(fomites) of infected secretions or body fluids (Hall et al. 1981; Hall and
Douglas 1981; Hall 2000; Hall 2001). Following direct inoculation of the
nasopharynx or eyes, the incubation period is usually 2 - 5 days (Hall and
Douglas 1981; Simoes 1999; Hall 2001). Nosocomial infections are a
significant complication of hospital care in children and impact on morbidity,
costs and mortality (EPINE Working Group 1992; Macartney et al 2000;
Raymond and Aujard 2000). 5.5 — 72% of inpatients with RSV infection were
found to have acquired their RSV infection in hospital. Most reports relate to
children in wards or babies in neonatal units (Hall et al. 1978; Isaacs et al.
1991; Madge et al. 1992; Doherty et al. 1998; Karanfil et al. 1999; Mlinargic-
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Galinovic and Varda-Brkic 2000; Cox, Roa and Brandon-Cox 2001; Simon et
al. 2008).
Comorbidities/underlying conditions, including congenital heart disease,
chronic lung disease, chromosomal anomalies, airways abnormalities,
immunodeficiency, neuromuscular impairment — are well recognised risk
factors for hospitalisation and severe disease in RSVinfection (Buchingham et
al. 2001; Hall 2001; Holman et al. 2003; Panickar et al. 2005; Smyth and
Openshaw 2006; Jansen et al. 2007). Due to the potential influence that
underlying conditions may play comorbidity scores are often utilised to adjust
for case-mix when studying nosocomialinfections. In adult study populations
comorbidity indices / scores such as the Charlson score, the Karofsky index,
and the McCabeand Jacksonclassification have been shownto correlate with
risk of nosocomial infections in prevalence surveys (Sax and Pittet 2002). The
Charlson score has been adapted for use in a general paediatric population
(Muhlemenet al. 2004).
The incidence of nosocomial RSV infection in our regional tertiary referral
PICU overa ten year period was investigated, and its impact on morbidity and
mortality studied.
8.2 Patients and Methods
8.2.1 Setting:
Observational cohort study in a 20-bed regional multidisciplinary tertiary PICU,
which includes 8 isolation cubicles, in university-affiliated children’s hospital
with an annual PICU admission rate of 1100 children.
8.2.2 Objectives:
1. To determine the incidence of nosocomial (PICU-acquired and hospital-
acquired) RSVinfection in PICU over a ten-year period
2. To determine the impact of nosocomial infection with RSV on mortality
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3. To determine the impact of nosocomial infection with RSV on morbidity
as determined by duration of ventilation and length of PICU stay.
8.2.3 Patients:
All ventilated children with RSV infection, confirmed on RSV antigen testing,
immunofluorescence and/or culture, admitted to PICU between June 1999 and
May 2009 (i.e. encompassing ten consecutive RSV seasons — October to
March) were studied. Data were collected prospectively during the last eight
RSV / winter seasons (October 2001 onwards) and retrospectively for the first
two seasons with all the same data points being available as for the
prospective data. The study was approvedbythe Clinical Audit Department —
a division of the Directorate of Research and Clinical Development at the
RoyalLiverpool Children’s Hospital NHS Trust.
8.2.4 Sampling:
Diagnostic samples of respiratory tract secretions were taken on admission to
PICU and thereafter whenclinically indicated. From January 2002 onwards
RSV surveillance samples were taken onall children during the RSV season
(October — March) on admission and twice a week while on PICU. RSV
positive children were sampled more regularly to identify wnen they became
negative, as 3 consecutive RSV antigen negative tests would allow ‘release’
from an isolation cubicle.
8.2.5 Measurements:
8.2.5.1 Laboratory procedures: RSV wasidentified on respiratory tract
samples at the Health Protection Agency Laboratory (Aintree, Liverpool, UK)
using Rmix shell vial culture techniques, and immunofluorescence for RSV
using SimulFluor™ reagents (Chemicon/Millipore, Massachusetts, USA), orin-
house by immunochromatographic assays: Directigen™ RSV test [Becton
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Dickinson microbiology systems, Maryland, USA] (1999 — 2004) or NOwW™
RSV test [Binax Inc., Maine, USA] (2005 — 2009). Additionally see 2.3.2.1.
8.2.6 Definitions
Community-acquired RSV infection - Children with RSV_ bronchiolitis
confirmed on RSV antigen testing, immunofluorescence or viral culture from
respiratory tract secretions on admission to hospital.
Hospital ward-acquired RSV infection - Children who were RSV negative (or
from whom no samples were taken as they had nosigns of bronchiolitis) on
admission to hospital and who then became RSVpositive five or more days
after admission to hospital (Hall et al. 1978; Raymond and Aujard 2000;
Thorburn et al. 2004).
PICU-acquired RSV infection - Children who were RSV negative (or from
whom no samples were taken as they had no signs of bronchiolitis) on
admission to PICU and who then became RSVpositive five or more days after
admission to PICU (Hall et al. 1978; Raymond and Aujard 2000; Thorburn et
al. 2004).
RSV-attributable deaths — Deaths were considered directly attributable to
RSVif the patients were still RSV positive when they died or when the RSV
infection contributed to the adverseclinical course leading to death (Simonet
al. 2008; von Renesseetal. 2009).
8.2.7 Infection Control Policy
The RSV infection control policy is based on the prevention of transmission via
hands of carers and equipment. The six main manoeuvresare isolation, hand
hygiene, protective clothing, care of equipment, surveillance, and minimising
risk of cross-infection.
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. Isolation — all known or suspected RSV-positive children are nursed in
isolation cubicles. ‘Release’ from an isolation cubicle is allowed
following negative RSV antigen tests on 3 consecutive days.
. Strict hand hygiene — hand washing before and after contact with each
patient.
. Protective clothing — single use gloves when handling blood and body
fluids + single use plastic aprons are worn whenin the cubicle and
thrown out onexit.
. Equipment — the environment is cleaned daily with a chlorine-release
agent. The bed frame is cleaned before arranging clean linen.
Mattresses andpillow covers are thoroughly inspected for signs of wear
and tear; if damaged they are disposed of and replaced. If there is no
damage butis fouled, they are cleaned with detergent solution. The
room is disinfected after discharge.
_ Surveillance — RSV ELISA tests (nasopharyngeal aspirates, broncho-
alveolar lavages or tracheal aspirates) on admission to the PICU or
developmentof any respiratory symptoms, and twice weekly during the
RSV season.
_ Minimise cross-infection — on each shift, an assigned PICU residentwill
look after the RSV-positive patients and not be allocated any cardiac,
chronic lung disease or immunosuppressedpatients.
Monoclonal RSV antibody therapyis not utilised to control RSV cross-infection
in inpatients in our children’s hospital.
8.2.8 Controlling for confounders: Matched Controls and multivariate
analysis.
To counter the confounding factor of comorbidity, controls from the community-
acquired RSV group were matched for comorbidity with individuals in the
nosocomial (PICU-acquired) RSV group. In order to match similar type and
number of underlying conditions/comorbidity within the nosocomial and
community-acquired RSV patients, a new score based on an adapted version
of the Charlson score (Charlson et al. 1987; Sax and Pittet 2002) was created
- 101 -
taking into account established risk factors for severe RSV disease (Table 8.1)
(Buchingham etal. 2001; Hall 2001; Holman et al. 2003; Panickar et al. 2005;
Smyth and Openshaw 2006; Jansen et al. 2007). The priority for matching
was comorbidity index score, with special attention taken to match the major
comorbidities (those scoring 2 points) with the same comorbidities in the
matched community-acquired RSV individuals. To avoid selection bias all
eligible matching community-acquired RSV patients were included.
Table 8.1: Scores of the Comorbidity Index for patients with RSV infection —
adapted from the Charlson score (Charlson et al. 1987).
* haemodynamically-significant congenital cardiac anomaly
> home oxygen requirement
 
Illness or Condition Score
Congenital Heart Disease *
Chronic Lung Disease ”
Large Airways Abnormality ©
Immunodeficiency (congenital or acquired)
Chromosomalabnormality
Neuromuscular condition
=
DM
BO
NM
NY
NY
YM
ND
Ex-pretermer°
Other pre-existingillness(es) ° 1
 
Total Sum offulfilled criteria
° any anatomical or dynamic abnormality from laryngeal inlet to main bronchi
* born before 36 weeksgestation
© metabolic, hepatic, gut, renal, asthma
To investigate whether PICU-acquired and hospital ward-acquired RSV
infection is independently associated with mortality or morbidity a multivariate
analysis which identified independent factors associated with morbidity and
mortality in patients ventilated with RSV infection was conducted.
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8.2.9 Analytic Methods:
Results were expressed as a percentage of the total study population; median
and inter-quartile ranges (IQR) were used to describe the demographic
distributions. Prediction of mortality using pediatric index of mortality (PIM)
was obtained on the patient’s first contact with the PICU team (Shannetal.
1997). Standardized mortality ratio (SMR) is the ratio of actual deaths
compared to the number predicted (in this study derived from PIM score).
Continuous data was analyzed using the Wilcoxon-Mann-Whitney (W-M-W)
test. Categorical data was analysed using Fisher’s exact or Chi-squaretest.
For multivariate analysis, simultaneous multiple regression analysis was used.
To investigate an association of mortality and morbidity as reflected in duration
of ventilation and stay on PICU to PICU-acquired and hospital ward-acquired
RSV infection simultaneous multiple regression analysis entering age, gender,
gestational age, history of prematurity, PIM as an indicator of disease severity
on admission and co-morbidities like congenital hear disease, chronic lung
disease, immunodeficiency, neuromuscular disorders, chromosomal
abnormalities and airway abnormalities as independent and mortality, length of
stay, length of stay after RSV infection and length of ventilation as dependent
variables was performed. Categorical variables were assigned dummy
variables in the regression analysis. A t-statistic of >2 or <-2 was considered
indicative of a significant predictive power for prediction of the dependent
variable.
Statistical calculations were performed with the Statistical Program for Social
Science release 13.0 (SPSS 13, Chicago, IL). A p value < 0.05 was
considered statistically significant. Relative Risk (RR) with 95% confidence
intervals (95% Cl) calculations were performed with Confidence Interval
Analysis software (CIA 2.1.2) from Statistics with Confidence, editors: DG
Altman, D Machin, TN Bryant, MJ Gardner; BMJ Books, London (2000).
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8.3 Results
During the ten-year study period 491 RSV-positive patients were ventilated on
PICU. Forty children acquired their RSV infection following admission to PICU
(8.1% of all RSV infection on PICU) and 38 (7.8%) following admission to a
hospital ward. Of the 491 RSV-positive ventilated patients, 232 (47%) had
been transferred into our regional PICU from other hospitals. During the study
period there were 2557 RSV-positive patients admitted to our children’s
hospital. The patient numbers and deaths for both the community-acquired,
PICU- and hospital ward-acquired (nosocomial) RSV infection groups for each
RSV season are shown on Table 8.2.
Overall PICU RSV mortality was 8.6% with a standardised mortality ratio
(SMR) of 0.78. Number of deaths in the nosocomial group that acquired RSV
infection in PICU was 10 (25%) (RR 4.3, 95%Cl 2.2 — 8.3) and 8 (21%) that
acquired RSVinfection in a hospital ward prior to PICU admission (RR 3.6,
95%Cl 1.8 — 7.5), compared to 24 (6%) in those with community-acquired RSV
infection. The SMRfor the PICU-acquired group was 2.02, the hospital ward-
acquired group 1.48, and community-acquired group 0.56. Ten of the deathsin
children with nosocomial (PICU- and hospital ward-acquired) RSV infection
were directly related to RSV giving a RSV-attributable mortality of 12.5% in the
nosocomial RSV infection group compared to 4% (n = 15) in the community-
acquired RSV group (RR 2.8, 95%Cl 1.2 — 7.1).
Patient demographics and clinical characteristics of those admitted to PICU
are shownin Table 8.3 and Table 8.4.
Mechanical ventilation was required in 95.3% of the children and non-invasive
respiratory support in 4.7%.
Length of PICU admission following becoming RSV positive has also been
included as total length of PICU admission would be confounded by the time
period required to qualify as nosocomial / acquired RSVinfection.
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: Percentage (%) of total PICU admission with RSV infection
- 105 -
Table 8.2: RSV-positive children admitted to PICU: 1999 - 2009.
RSV season Number Deaths
1999 — 2000 28
Community-acquired 25 1
Hospital ward-acquired 1 (4%) 0
PICU-acquired > 7%)" 0
2000 — 2001 39
Community-acquired 36 7Hospital ward-acquired 2 (5%) 0
PICU-acquired 1 (3%)" 0
2001 — 2002 54
Communhity-acquired 37 4Hospital ward-acquired 5 (9%). S
PICU-acquired 42 (22%)" 1
2002 — 2003 50
Community-acquired 37 2Hospital ward-acquired 6 (12%) 0
PICU-acquired y 14%)" 1
2003 — 2004 94
Communhity-acquired 80 6Hospital ward-acquired 7 (7%) 2
PICU-acquired 7 (7%)* 1
2004 — 2005 55
Community-acquired 42 2Hospital ward-acquired 7 (13%) 0
PICU-acquired 7 (13%)" 2
2005 — 2006 37
Community-acquired 35 2Hospital ward-acquired 1 (3%), 0
PICU-acquired 1 (3%)" 1
2006 — 2007 49
Community-acquired 47 0Hospital ward-acquired 2 (4%). 0
PICU-acquired 0 (0%)" 0
2007 — 2008 35
Community-acquired 30 1Hospital ward-acquired 4 (11%) 3
PICU-acquired 1 (3%)" 1
2008 — 2009 50
Community-acquired 45 2Hospital ward-acquired 3 (6%). 0
PICU-acquired 2 (4%)" 0
Table 8.3: Patient demographics for children ventilated on PICU (1999 - 2009)
with community-acquired RSV infection, PICU- and hospital ward-acquired
RSVinfection, and controls matched for comorbidity — Median [IQR].
 
Community- PICU- Hospital ward-
acquired acquired acquired Controls *(n = 413) (n = 40) (n = 38) (n = 103)
Age (months) 2.6 [1.2 - 8.9] 8.1 [1.9 - 27.4] 5.1 [2.2 - 14.2] 6.5 [2.8 - 19.3]
p<0.01" p=0.02" p=0.48*
p = 0.24 *
Paediatric Index 0.08[.04-.13]  0.07[.04-.12] 0.09 [.04-.16] 0.08 [04 -.14]
of Mortality (21) p=0.63" p=0.18" p= 0.56"
p=0.36-
Comorbidity 1 [0-2] 2 11-3] 2 [2-4] Matched forIndex score p<0.01" p<0.01" comorbidity
p=0.35
Length of 5 [8.5 -8] 18 [10 - 38] 7 [6-11] 8 [4-12]
ventilation p<0.01° p<0.01° p<0.01°
(days) p<0.01
Length of PICU 5 [4-9] 20 [11.5 - 39] 7 [5 -11.5] 8 [5-12]
stay (days) p<0.01" p= 0.02" p<0.01*
p < 0.01 *
PostRSVlength 5 [4-85] 13 [6 - 28] 6 [4-11] 7 [5-11]
of PICU stay p<0.01° p=0.07" p<0.01°seeys) p= 0.04"
Days RSV 3 [2-5] 3 [1-4] 3.5 [1-5] 3 [1-6]
positive p=0.66" p=0.72" p=0.79*
p = 0.81
 
Community-acquired = RSV positive on admission to PICU
PICU-acquired = RSV infection acquired (nosocomial) after admission to PICU
Hospital ward-acquired = RSV infection acquired (nosocomial) after admission to hospital
* Controls from community-acquired RSV group matched for comorbidity to PICU-acquired RSV patients
t Wilcoxon-Mann-Whitney test - community-acquired RSV vs. hospital- or PICU-acquired RSV infection
* Wilcoxon-Mann-Whitneytest - controls vs. PICU-acquired RSV infection
* Wilcoxon-Mann-Whitneytest - PICU-acquired RSV infection vs. hospital-acquired RSV
2 Length of PICU stayafter testing positive for RSV
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Table 8.4: Clinical characteristics in children ventilated on PICU with
community-acquired RSV
_
infection, PICU- and hospital ward-acquired
(nosocomial) RSV infection (1999 - 2009).
 
 
Community- PICU- Hospital ward-
acquired acquired acquired(n = 413) (n = 40) (n = 38)
Death 24 (6%) 10 (25%) 8 (21%)
RSV-attributable death ° 15 (4%) 5 (13%) 5 (13%)
Gender (male) 226 (55%) 17 (43%) 25 (66%)
Ex-preterm infant ° 101 (24%) 5 (13%) 10 (26%)
Less than 6 weeksof age 148 (36%) 9 (23%) 6 (16%)
Congenital Heart Disease © 86 (16%) 19 (48%) 21 (55%)
Chronic lung disease © 37 (9%) 8 (20%) 9 (24%)
Large airway abnormality © 23 (6%) 5 (13%) 6 (16%)
Immunodeficiency 9 (2%) 4 (10%) 2 (5%)
Chromosomalabnormality 25 (6%) 3 (8%) 2 (5%)
Neuromuscular impairment 40 (10%) 6 (15%) 4 (10%)
Otherpre-existingillness(es) 9 34 (8%) 11 (28%) 17 (45%)
 
Community-acquired = RSV positive on admission to PICU
PICU-acquired = RSV infection acquired (nosocomial) after admission to PICU
Hospital ward-acquired = RSVinfection acquired (nosocomial) after admissionto hospital
2 still RSV positive at death
b born before 36 weeksgestation
© haemodynamically-significant congenital cardiac anomaly, e.g. atrioventriculoseptal defect, Tetralogy of
Fallot, hypoplastic left ventricle, truncus arteriosus,etc.
d .home oxygen requirement
e . . 3 . . 3 .any anatomical or dynamic abnormality from laryngeal inlet to main bronchi, e.g. tracheomalacia,
bronchomalacia, laryngeal web,etc.
f congenital or acquired, e.g. chemotherapy immunosuppression, Di George syndrome,etc.
g metabolic, hepatic, gut, renal, asthma
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Comparing the first 5 RSV seasons (1999 — 2004) with the second 5 seasons
(2004 — 2009), the incidence of PICU-acquired RSV infections decreased -
29/265 (10.9%) vs. 11/226 (4.9%) (Chi-square p = 0.022; RR 2.2, 95%Cl 1.1 —
4.4). During these two time periods the age (W-M-W test p=0.17) and
comorbidity index scores (p=0.95) were similar. During these two time periods
overall RS\V-attributable deaths - 28/265 (10.6%) vs. 14/226 (6.2%) (Chi-
square p=0.11, RR 1.71, 95%CI 0.92 — 3.16), and PICU-acquired RSV-
attributable deaths - 6/265(2.2%) vs. 4/226 (1.7%) (Fisher's exact test p=0.76,
RR 1.28 (95% Cl 0.37-4.5) were not different. However the duration of
ventilation (medians 6.0 vs. 4.5 days, W-M-W p<0.001) and length of PICU
stay (medians 6.5 vs. 5.0 days, p=0.002) were significantly decreased.
To counter the confounding interaction between comorbidity and mortality,
children with comorbidities in the PlCU-acquired RSV group (n=34) were
matched with controls from the community-acquired RSV group (n=103) -
Table 8.3. Compared to the comorbidity-matched community-acquired RSV
children, age (W-M-W test p=0.48) and PIM (p=0.56) were similar, but deaths
(10/34 vs. 17/103 in matched controls) were higher (Chi-square test p=0.04),
and post-RSV length of stay and duration of ventilation was longer (W-M-W
tests p<0.01) in the PICU-acquired RSV group.
The strength and independence of the predictive power of patient
characteristics for parameters reflecting morbidity (duration of ventilation and
length of stay on PICU) and mortality were analysed using simultaneous
multivariate regression analysis (Table 8.5). The strongest predictor for death
were congenital heart disease (t-statistic=5.1and immunodeficiency(t-statistic
=5.4). The strongest predictor for duration of ventilation and length of stay on
PICU were PICU-acquired RSV infection with a t-statistic of 7.6 and 8.0
respectively. When the simultaneous multivariate regression analysis was
repeated for length of stay on PICU afterfirst detection of respiratory syncytial
virus to allow for influence of nosocomial RSV infection itself and time until
nosocomial infection was detected on length of stay significant predictors of
this parameterwith a t-statistic >2 and p<0.05 were in order of magnitudeoft-
statistic airway abnormality (t=5.0), PlCU-acquired RSV infection (t =4.6),
chronic lung disease (t=3.0), and neuromuscular disease (t=2.3).
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Table 8.5: Factors associated with morbidity (duration of ventilation and length
of stay on PICU) and mortality in children ventilated on PICU with RSV
infection on simultaneous multivariate regression analysis (n=491).
 
 
           
Duration of Lengthof stay Death
ventilation on PICU
Beta t-statistic p-value Beta t-statistic p-value Beta t-statistic p-value
Age 0.002 0.039 0.969 0.026 0.636 0.52 0.081 -1.89 0.059
Gender(male) 0.018 -0.483 0.629 0.015 -0.39 0.69 0.014 -0.35 0.72
History of. * 0.041 -1.0 0.31 0.045 -1.127 0.26 -0.04 -0.94 0.347prematurity
Paediatric Indexof Mortality "=" 0.033 0.8 0.39 0.041 1.07 0.28 0.061 1.52 0.128
Hospital-acquiredRSVinfection 0.025} -0.61 0.54 0.043] 9.8-1.0 0.29 0.031 0.73 0.46
PICU-acquiredRSVinfection 0.337 7.65 <0.01 0.349 8.0 <0.01 0.017 0.37 0.70
Congenital heart5 + 0.133 2.7 <0.01 0.119 2.5 0.01 0.261 5.2 <0.01disease
Chronic lung. + 0.127 3.0 <0.01 0.134 3.2 <0.01 0.093 2.13 0.03disease
Large airway § 0.247 6.1 <0.01 0.237 5.9 <0.01 0.016 0.4 0.70abnormality
immuno- ° 0.082 2.07 0.038 0.068 1.7 0.08 0.223 5.37 <0.01deficiency
Chromosomalabnormality 0.031 -0.748 0.45 -0.02 -0.38 0.70 0.096 2.24 0.025
Neuromuscularimpairment 0.07 1.73 0.083 0.079 1.95 0.051 0.133 3.1 <0.01
Other wage ** 0.024 0.57 0.56 0.025 0.60 0.54 0.128 2.9 <0.01co-morbidities
* born before 36 weeksgestation
: haemodynamically-significant congenital cardiac anomaly
+ :home oxygen requirement
8
e . . . .congenital or acquired immunodeficiency
KOK metabolic, hepatic, gut, renal, asthma
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any anatomical or dynamic abnormality from laryngealinlet to main bronchi
 
8.4 Discussion
The majorfindingsof this study of nosocomial RSV infection on PICU are that
8% of the children ventilated in our PICU with RSVinfection acquired it on the
PICU and another 8% had acquired RSV in a hospital ward. These children
had a higher mortality rate, stayed longer on PICU once RSV positive, and
were more likely to have an underlying condition/comorbidity than those
admitted with community-acquired RSVinfection.
There is very little literature on nosocomial RSVinfection in PICU (Thorburn et
al. 2004; Simonet al. 2008; von Renesseet al. 2009). This study differs from
epidemiology-based studies in that it investigates a specific subgroup with
severe RSV disease (i.e. requiring ventilation). However, the ten-year
incidence of PICU-acquired RSVinfection (8%) is close to the 11% ofall PICU
admissions and the 8% hospital ward-acquired incidence close to the 6%ofall
inpatients with RSV infection reported in a multi-centred German study (1999 —
2005) (Simonet al. 2008; von Renesseet al. 2009), and the 6% of an earlier
inpatient multi-centred Canadian study (1994 - 1996) (Langleyetal. 1997a).
A quarter of the children that acquired their RSV infection on PICU died. This
finding confirms the reported increased mortality in children with nosocomial
RSVinfection (Langley et al. 1997a; Simonet al. 2008). The‘attributable’ RSV
mortality (12.5%) in our nosocomial groupis similar to that in a recent German
study (15%) in mechanically ventilated children (von Renesse et al. 2009).
Owing to the detrimentalrole or destabilising effect that RSV infection plays in
the clinical course of thesecritically ill childrenit is difficult to differentiate true
RS\V-attributable deaths from the deaths where it has playedlittle or no part.
Multivariate analysis demonstrated that although there was a tendency toward
nosocomial RSV infection being associated with death, the major influence
was byits association with comorbidity. However, when compared to RSV
controls matched for comorbidity, those with nosocomial (PICU-acquired and
hospital ward-acquired) RSV infection had significantly increased mortality
rates. The most important element therefore in diminishing these deaths is to
eradicate nosocomial spread.
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It is recognised that underlying chronic conditions / comorbidity can influence
both predisposition to nosocomial infections and length of hospital admission
(EPINE Working Group 1992; Macartney et al. 2000; Raymond and Aujard
2000; Sax and Pittet 2002; Muhleman et al. 2004). However, in this study,
patients with nosocomial RSV infection had a longer duration of mechanical
ventilation and length of stay on PICU which wasindependently significant on
multivariate analysis and when compared to a control group matched for
comorbidity. This effect could not be explained by increased disease severity
on admission because the risk of mortality score (PIM) was not different
between groups. The longer duration of mechanical ventilation and length of
stay on PICU would suggest that acquiring RSV infection at a time when the
children are sicker(i.e. sick enough to be on PICU) has an additive effect on
severity of overall disease. This additive effect is supported by the raised SMR
in the nosocomial RSV group, suggesting that they fared worse than their
admission risk of death would have predicted. Additionally, chronic injury to
lung tissues secondary to the prior mechanical ventilation may predispose to a
prolonged disease course upon acquisition of RSV infection.
RSV positivity is tracked in our PICU as there are a limited numberofisolation
cubicles (8 only), so once RSV negative (3 consecutive negative RSV antigen
tests) the patients are moved out onto the open PICUfloor. It is interesting
that although other studies have described prolonged viral shedding in children
with nosocomial RSV this was not found in the present study, even with a high
level of comorbidity in the nosocomial RSV group and sickerpatients (requiring
PICU care as compared to general inpatients) than previous studies (Hall,
Douglas and Geimen 1975; Hall et al. 1978; Viera et al. 2003; Simon etal.
2008). Perhaps this is because extended shedding of RSV is found in children
with immunodeficiency and there were not many immunodeficient patients (15
of 491) in the present study population (Hall, Douglas and Geiman 1975; Hall
1977; Hall et al. 1986; Wendt et al. 1995; Hall 2001; Madhi et al. 2001).
Seeing that the mode of nosocomial spread is by close or direct contact with
large droplets (fomites) of infected secretions the thrust of our nosocomial
prevention strategies has been meticulous hand hygiene, barrier precautions
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and education. This strategy appears to have been effective. Following a
nosocomial RSV outbreak in PICU (2001/2002) there was reinforcement of
strict infection control measures. This produced a steady improvementin the
subsequent RSV seasons(bar a brief relapse) downto consistently low (0 —
4%) nosocomialinfection rates (Table 8.2). This decrease in the incidence of
nosocomial RSV infection is highlighted when comparing the first 5 RSV
seasons with the second half of the study period. Co-morbidity and mortality
were similar, but duration of ventilation and length of PICU stay significantly
diminished in the second 5 seasons (both p-values<0.01). Taking into account
that nosocomial RSV infection was the strongest predictor of these parameters
on multivariate analysis, it is not unexpected that a reduction in nosocomial
RSVinfections had the potential to reduce duration of ventilation and length of
PICUstayin this population. These reductions impact on patient health, PICU
bed availability and hospital costs. Staffing levels, number of isolation
cubicles, and the transmission factorof visiting teams / house staff had been
consistent throughout this 10 year period, so this improvement was most likely
the product of persistent reinforcement of basic infection control measures,
ongoing education and RSVsurveillance.
The lack of a comparable group without RSV infection maylimit interpretation
in that it may be difficult to differentiate whether the clinical impact is
specifically related to acquiring RSV infection or a phenomenon of nosocomial
infection in general. The significant predictive power of nosocomial RSV
infection on duration of PICU stay persisted whenonly time of stay from first
isolation of RSV wasincluded in the calculation. This rules out that an increase
in risk of infection with longer duration of prior hospitalisation generated the
relationship of prolonged ventilation and PICU stay and nosocomial RSV
infection.
Vaccination of at-risk children would be the ideal answerto prevention, but no
effective RSV vaccine is presently available (Hall 2001; Smyth and Openshaw
2006). Prophylaxis with humanised monoclonal RSV antibody in high-risk
patients has been shown to decrease the risk of subsequent hospitalisation
with RSV (PREVENT Study Group 1997; American Academy of Pediatrics
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1998; Impact-RSV Study Group 1998; Hall 2001; Smyth and Openshaw 2006).
Even though our at-risk patients are already hospitalised, some reports (largely
case series) have suggested using monoclonal RSV antibody therapy to
combat intra-hospital spread of nosocomial RSV (Cox, Rao and Brandon-Cox
2001; Heerens, Marshall and Bose 2002; Abadessoet al. 2004; Halasaetal.
2005). Seeing that children with significant comorbidity are at greatest risk of
death from nosocomial RSV infection, there is a strong argument for treating
this group with monoclonal RSV antibody prophylaxis on admission to hospital
during the RSV season. Currently this monoclonal RSV antibody strategy has
not been utilised in our PICU as our recent rate of nosocomial RSV infection
(as shownin this study) has been low.
8.5 Conclusions
PICU-acquired RSV infection accounted for 8% of the children ventilated for
RSV infection on our PICU over a period of ten winter seasons.
Mortality is increased in nosocomial (both PICU- and hospital ward-acquired)
RSV infection, but principally by its association with pre-existing conditions /
comorbidity.
Nosocomial (PICU- and hospital ward-acquired) RSV infection was the
strongest predictor of duration of ventilation and length of stay in children on
PICU.
Persistent reinforcement of basic infection control measures, ongoing
education and RSV surveillance lead to a decrease in the rate of PICU-
acquired RSVinfection.
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9 Conclusion
This thesis describes a series of studies into the clinical impact that severe
RSVinfection has oncriticallyill children. The aims of this thesis were:
1) To determine the relationship between hepatic transaminase levels and
disease severity, and the aetiology of the elevated transaminase levels in
children with severe RSV disease;
2) To determine the prevalence of myocardial involvement andits relationship
with disease severity in children with severe RSV bronchiolitis;
3) To investigate whether severe RSV bronchiolitis is associated with reduced
right ventricular function in infants without congenital heart disease, and to
determine whether reduced right ventricular function is associated with
myocardial damage,elevated transaminase levels, and disease severity;
4) To determine the incidence of pulmonary bacterial co-infection and its
impact on mortality and morbidity in children with severe RSV bronchiolitis;
5) To determine the mortality rate and the risk factors for death in children
admitted to PICU with RSV infection;
6) To determine the incidence of nosocomial (acquired) RSV infection in
critically ill children, and the impact of nosocomial RSV infection on mortality
and morbidity.
9.14 Summary of conclusionsfrom the studies
1) Transaminaselevel elevation was commonin children with severe RSV
bronchiolitis. There was no evidence that other commonviral infections
caused this phenomenon. Disease severity, as judged by duration of
ventilation, inotrope use and mortality, was greater in children with elevated
transaminase levels. Disease severity as judged by duration of ventilation was
independent of the presence of CHD. The elevated transaminase levels may
have been a reflection of myocardial failure and/or ischaemic hepatitis
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secondary to myocardialfailure.
2) Myocardial damage orinjury is common in infants with structurally
normal hearts and severe RSV lung disease. This may help to explain the
increased morbidity and mortality associated with RSV bronchiolitis in children
with significant congenital heart disease. Myocardial strain or necrosis may
cause a heart already understrain from a structural cardiac abnormality to fail.
3) Right ventricular dysfunction is not uncommonin severe RSV disease,
but the degree of dysfunction is not related to the levels of respiratory support
or biochemical markers of inflammation. Myocardial and hepatocellular
damage can occurin infants with severe RSV bronchiolitis with normal right
andleft ventricular function.
4) Up to 40% of patients admitted with severe RSV bronchiolitis were
infected with bacteria in their lower airways. Co-morbidity, namely congenital
heart disease, chronic lung disease, large airway abnormality,
immunodeficiency, neuromuscular disease, predispose to more severe RSV
disease.
5) Pre-existing disease / co-morbidity, in particular multiple pre-existing
diseases and cardiac anomaly,is associated with a significantly higherrisk of
death from severe RSV disease. Prior good health appears to protect against
death from severe RSV disease.
6) PICU-acquired (nosocomial) RSV infection accounted for 8% of the
children ventilated for RSV infection on our PICU over a period of ten winter
seasons. Mortality is increased in nosocomial RSVinfection, but principally by
its association with pre-existing conditions / comorbidity. Nosocomial RSV
infection was the strongest predictor of duration of ventilation and length of
stay in children on PICU. Persistent reinforcement of basic infection control
measures, ongoing education and RSV surveillance lead to a decreasein the
rate of nosocomial RSVinfection.
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9.2 Future Research
9.2.1 RSV Hepatitis?
There was no evidence in mystudies that co-infection with other commonviral
infections resulted in more severe respiratory disease and caused the elevated
transaminaselevels / hepatitis. The lack of infection with either known hepatitis
viruses or respiratory viruses known to cause hepatitis may imply that RSV
itself caused the hepatitis. There is a single case report of RSV alone being
isolated from liver tissue in a 7-month old infant with bronchiolitis and
extrahepatic biliary atresia (Nadal et al. 1990). Conclusive proof of hepatic
RSV infection would require a liver biopsy. Understandably this would be
inappropriate in live patients on ethical grounds, but following parental consent
could be performed on the children that die from (or with) severe RSV
infection. Clinical and biochemical data could be correlated with the histology
and viral PCR results to assess whether the entity of RSV hepatitis (i.e. RSV
infection of hepatocytes) exists.
9.2.2 RSV myocarditis?
Myocardial damage or injury is commonin infants with structurally normal
hearts and severe RSV lung disease. RSV has been isolated from myocardial
tissue in immunodeficient individuals (Fishaut, Tubergen and Mclntosh 1980).
As with RSV hepatitis, conclusive proof of RSV myocarditis would require
sampling the heart muscle. Once again this would be inappropriate in live
patients on ethical grounds, but following parental consent could be performed
on children that die from (or with) severe RSV infection. Histology and/orviral
proof or disproof of RSV myocarditis could be sought.
9.2.3 Additional markers of myocardial damageorstrain?
Prior studies (including from this thesis) have reported raised cardiac troponin
levels (cTnT) in 35 - 54.5% of children with RSV infection (Checchia etal.
2000; Moynihanet al. 2003, Eisenhut et al. 2004). | found elevations in cTnT
to be transient and echocardiographic assessment of left ventricular function
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failed to demonstrate evidence of reduction in myocardial contractility. It raises
the possibility that using cardiac troponin alone may be overestimating the true
incidence of myocardial involvement in children with RSV infection, although
the patients presented in the studies in this thesis all have severe RSV
infection as reflected by the need for PICU treatment. Perhaps utilising
additional biochemical markers of myocardial insufficiency (e.g. BNP, GP-BB,
H-FABP) may confirm these findings or establish different patterns of
myocardial involvement.
Brain natriuretic peptide or B-type natriuretic peptide (BNP) is a 32 aminoacid
polypeptide secreted by the ventricles of the heart in response to excessive
stretching of cardiomyocytes. The plasma concentrations of both BNP and
NT-proBNP (the amino terminal segment of BNP’s prohormone)are increased
in patients with asymptomatic or symptomatic left and right ventricular
dysfunction. In children with congestive heart failure, BNP and NT-proBNP
levels correlate with functional capacity (Kempet al. 2004; Doust et al. 2005).
BNP candifferentiate cardiac from pulmonary causesin infants with respiratory
distress (Nir and Nasser 2005).
Glycogen phosphorylase (GP) catalyses the breakdown of glycogen in the
sarcoplasmic reticulum. One ofit’s isoenzymes, BB, is found in brain and
heart. GP-BBis released from the sarcoplasmic reticulum into the cytoplasm,
and theninto the circulation through the damaged cell membrane. It has been
reported to be a useful marker of myocardial damage (Kempet al. 2004).
Heart fatty acid binding protein (H-FABP), a 132 aminoacid polypeptide, is
released rapidly from the myocardium into the bloodstream after ischaemic
injury. It also appears rapidly in urine, and the urinary concentration correlates
with the severity of the myocardial injury (Kempetal. 2004). The presenceof
these cytosolic proteins in the plasma of patients implies that cell membrane
permeability may be compromised in congestive heart failure and myocardial
strain (Kempet al. 2004; Doustet al. 2005; Nir and Nasser 2005).
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9.2.4 Myocardial depressant factors?
Myocardial dysfunction is well described in sepsis with negatively inotropic
factors, so-called myocardial depressant factors, being proposed as a
mechanism. Certain cytokines (e.g. IL-6, TNFa, IL-1) have been reported to
mediate myocardial depression (Giroir and Stromberg 2000; Pathan et al.
2004). The antiviral and cell-mediated immune reaction to RSV infection is
primarily coordinated by RSV-infected respiratory epithelial cells and by
alveolar macrophages. Therespiratory epithelial cells release cytokines (TNF,
interferons, interleukins) and chemokines. These cytokines and chemokines
may enter the systemic circulation and impact on myocytes (Openshaw ,
Culley and Olszewska 2001; Tripp 2004; Openshaw 2005; Tripp, Oshansky
and Alvarez 2005). Echocardiographic assessment of myocardial function,
measurement of biochemical markers of myocardial damage orstrain (e.g.
cTnT, BNP,etc.), combined with clinical parameters could be correlated with
known‘myocardial depressant’ cytokine levels in patients with RSV infection to
ascertain whether increased serum ‘myocardial depressant’ cytokine levels are
associated with severe disease and/or myocardial dysfunction. Recent
multiplexed DNA micro-array techniques make testing of a numberof targeted
cytokines easier and less costly.
9.2.5 Right ventricular dysfunction?
Significantly reduced right ventricular function was found in 20% of infants
without congenital heart disease ventilated for RSV bronchiolitis. To
differentiate whether it is RSV per se that causes right ventricular impairment
or severe lung disease secondarily impacting on the ventricular function, a
study comparing a control group with non-RSV severe lung disease with a
study group with severe RSV bronchiolitis is indicated.
9.2.6 Bacterial co-infection in severe RSV bronchiolitis?
My study over 3 consecutive RSV seasons evaluating bacterial pulmonary co-
infection found that 42% of children admitted for severe RSV infection
harboured bacterial pathogens in their lower airways and 22% had strong
- 118 -
microbiological evidence ofbacterial co-infection. | found inflammatory markers
(CRP + WCC)to be unhelpful in differentiating bacterial infection in this group
of patient with severe RSV bronchiolitis, as have other investigators (Toikka et
al. 2000; Resch, Gusenleitner and Miller 2003; Kneyberet al 2005). Perhaps
utilising such a subgroup with diagnosed bacterial co-infection would be an
ideal study group to investigate the value/efficacy of reportedly more bacterial-
specific inflammatory markers (e.g. procalcitonin, TREM-1/triggering receptor
expressed on myeloid cells, IL-6) (Gibot et al 2004; van Rossum,
Wulkan,Oudesluys-Murphy 2004).
9.2.7 Influence of antibiotics on children with severe bronchiolitis?
My study over 3 consecutive RSV seasonsevaluating bacterial pulmonary co-
infection found that receipt of and length of time on prior antibiotics did not
predispose to bacterial co-infection. Nearly all the RSV positive children
received antibiotics in our PICU, limiting any interpretation on the impact of
antibiotics on their outcome. Up to 40% of patients admitted with severe RSV
bronchiolitis were infected with bacteria in their lower airways and those with
bacterial co-infection were ventilated for longer than those with RSV alone.
Perhaps the use of prophylactic antibiotic on admission to PICU may be
beneficial in this group of patients with severe RSV bronchiolitis. The
assessmentofthe influence of antibiotics on children with severe bronchiolitis
would require a prospective randomized controltrial.
9.2.8 Chronic excretion / persistent shedders of RSV?
RSV positivity is tracked in our PICU as there are a limited numberofisolation
cubicles (8 only), so once RSV negative (3 consecutive negative RSV antigen
tests) the patients are moved out onto the open PICU floor. RSV is usually
shed for 4 — 6 days, but shedding can range from 3 — 27 days (Hall, Douglas
and Geiman 1975: Hall et al. 1976; Hall et al. 1977; Hall et al. 1978). The
duration of viral shedding can correlate with severity ofillness. Neonates may
shed RSVfor longerperiods of time than olderpatients. During an outbreak of
nosocomial RSV infection on our PICU (2001/2002) a second smaller peakin
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nosocomial RSV infections (February 2002) was noted, the source was
surmised to be patients who were persistent shedders of RSV. Two chronic
PICU patients were identified who had tested negative on consecutive RSV
ELISA tests, thereby being allowed out of their isolation cubicle into the ‘open’
unit, only to once again test RSV ELISApositive later. Quality of sample (i.e.
poor quantity of nasal secretions obtained) can influence the sensitivity of RSV
ELISA tests. The quality of the RSV ELISA test in detecting low
concentrations of virus may also play a role. The ELISA tests are generally 80
— 90% sensitive and specific when compared to immunofluorescence and viral
culture (Smyth and Openshaw 2006). In critically ill children, viral shedding
can fluctuate (Hall et al. 1977). Both of the suspected persistent shedders had
congenital heart disease along with other co-morbidity, and both had been
ventilated for more than 3 weeks(i.e. seriously ill children). The suspicion is
that this subgroup of RSV-positive patients (chronic with comorbidities) may
predispose to subclinical persistent shedding / chronic excretion of the virus.
To conclusively establish this hypothesis these persistent shedders would
need to firstly be identified and then tracked throughout their entire stay in
PICU (and evenin hospital). In real terms this would require that all samples
on all RSV-positive patients sent for RSV testing be kept so that any patient
that subsequently tests positive again can be identified. Once identified, their
samples can be typed (to confirm ‘re-activation’ of the same virus) and PCR
analysis performed to measureviral loads.
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9.3. Conclusion of thesis
The studies reported in this thesis have documented marked pulmonary and
extrapulmonary clinical implications for children with severe RSV disease.
RSVinfection is not innocuous and causessignificant morbidity and mortality
worldwide every year. Notall children are equal whenit comesto infection by
RSV as those with underlying chronic conditions/comorbidity carry an
additional risk of severe disease, nosocomial infection and death.
This thesis has demonstrated that an extrapulmonary (myocardial and
hepatocellular in particular) impact from severe RSV bronchiolitis is common.
These extrapulmonary effects appear to be indirect, being secondary to
parenchymal lung disease and its causative respiratory compromise or
consequential of prowling inflammatory mediators, rather than direct RSV
effects (i.e. site-specific RSV infection of that tissue). Although host genetic
factors manipulate the patient's immune-augmented response, acquired
(comorbidity) factors govern and compromise their reserve at both pulmonary
and distant extrapulmonary sites.
Investigating the clinical inter-relationship between the pulmonary and
extrapulmonary systems and highlighting how they impact on morbidity and
mortality improves both theinsight into and the managementof these children
with severe RSVinfection.
Although the basic sentiments of Reynolds and Cook in 1963 — “Oxygen is
vitally important in bronchiolitis and there is little evidence that any other treatmentis
useful’ (Reynolds and Cook 1963)
—
still ring true, our understanding of RSV
disease, its impact on multiple organ systems and its treatment options has
progressed overtime.
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